Document:

Distributor Agreement

 Exhibit 10.24 
  
 [CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION.]

  

			
	

	 	

  
 Effective Date:
January 27, 2003 
  
 DISTRIBUTOR AGREEMENT 

 
 between 
  
 Xenogen Corporation 
  
 860 Atlantic Avenue 
  
 Alameda, CA 94501 
  
 and 
  
 SC BioSciences Corporation 
  
 Izumi Shiba-Daimon Bldg. 3F 2-2-11, Shiba-Daimon 
  
 Minato-ku, Tokyo, 105-0012 Japan 
  
  
  
  
  
  
  
  
  
  
  
  
  

 Xenogen Confidential & Proprietary 

 GENERAL TERMS 
  
 This Distributor Agreement, including these General Terms, the attached Exhibits and each additional executed and effective
Terms of Sale (collectively, the “Agreement”), is entered into as of the Effective Date set forth above by and between Xenogen Corporation, a corporation incorporated in Delaware (“Xenogen”) and SC BioSciences
Corporation (the “Distributor”) (each of Xenogen and Distributor a “Party,” and collectively the “Parties”). 
  

WHEREAS, Xenogen owns or Controls the IVISTM Imaging System (as defined below), certain bioluminescent cells or organisms, and the Xenogen Imaging Technology (as defined below); 
  
 WHEREAS, Distributor wishes to be appointed as a distributor of
Xenogen products and Xenogen is willing to grant such appointment on the terms and conditions contained herein; 
  
 NOW THEREFORE, in consideration of the mutual promises and covenants herein, the Parties hereby agree as follows: 
  
 1. Definitions 
  
 1.1 The Parties agree and acknowledge that all references in
this Agreement to the “purchase” or “sale” of Licensed Products mean and refer to a sale in the case of hardware for Xenogen Imaging Systems and accessories; a license in the case of Software; a license to use and practice
Xenogen Imaging Technology; and a bailment without transfer of title in the case of BiowareTM and LPTATM animal models. 
  
 1.2 The capitalized terms in this Agreement shall have the meanings ascribed to them in this Agreement, including without limitation the terms set forth in Exhibit A (“Definitions”). 
  
 2. Appointment 
  
 2.1 Distributor Appointment. Subject to the terms and
conditions of this Agreement, Xenogen appoints Distributor as its distributor of Licensed Products in the Territory and grants to Distributor a non-transferable, limited right to market and sell Licensed Products in the Territory to Local Customers
in the Territory in the Field pursuant to written End User Agreements in the form specified in Exhibits Band C-1 through C-4. The foregoing appointment and right is exclusive with respect to Instrumentation, Software and BiowareTM and non-exclusive with respect to LPTATM animal models. In addition, Distributor may also
distribute Documentation to Local Customers in connection with their use of the Licensed Products. 
  
 2.2 Right to Purchase for Own Account. Distributor may also purchase Licensed Products on its own account for its own internal
business use, and the Parties agree that such internal use includes use of Licensed Products for demonstration, training, and education purposes. All such internal purchases for Distributor’s own account shall be subject to the terms and
conditions of this Agreement generally, as well as Article 4 specifically, and Distributor hereby agrees to be bound by such for any such Licensed Products purchased hereunder. 

 2.3 Scope. The appointment set forth in Section 2.1 is exclusive with respect to
Local Customers in the Territory. Xenogen expressly reserves the right to market and sell Licensed Products or other of its products and services to non-Local Customers in the Territory, either directly or indirectly. The range of Xenogen products
and services that Distributor has the right to market, distribute and sell hereunder are identified in Exhibit B, attached hereto. 
  
 2.4 Territory Expansion. Distributor has the right to negotiate to expand the scope of the Territory on a country-by-country basis
in Asia (“Expansion Option”). Distributor may do so by providing Xenogen with written notice of its intent to exercise its Expansion Option and identification of the desired countries, and the Parties thereafter will conduct good
faith negotiations regarding the potential expansion of the Territory. Notwithstanding the foregoing, for each new market (i.e. Taiwan, Korea, etc.) entered into by Distributor pursuant to its Expansion Option, Distributor will commit to an initial
Licensed Product placement consisting of five (5) Initial Systems in a specified timeframe to be agreed to by both Parties, but not to exceed six (6) months after the date on which Distributor’s Territory is expanded. 
  
 2.5 Independent Contractors. The relationship of the
Parties is that of independent contractors. Nothing in this Agreement may be construed to make either Party the agent or partner of the other. Neither Party may legally bind the other in any manner. Xenogen and Distributor agree that no obligations
will be owed one to the other, or to third parties, based in any way on the law of partnership or joint ventures or similar legal theories. 
  
 2.6 Exclusivity. Xenogen will not appoint another third party to distribute Licensed Products in the Territory to Local Customers
as long as Distributor maintains its exclusive rights as provided in this Agreement. Distributor will not, directly or indirectly through an affiliate: (i) market or sell in the Territory any product intended to produce, detect or record
bioluminescence within mammals other than the Licensed Products; (ii) directly solicit sales, promote, market or sell Licensed Products outside the Territory; (iii) solicit or accept orders from persons or entities located outside the Territory; or
(iv) provide Licensed Products to any third party if Distributor or an affiliate knows or has reason to believe, that the Licensed Products provided to such third party have been sold, or are intended for sale, outside of the Territory. Distributor
will not, directly or indirectly through an affiliate, market or sell in the Territory any product intended to produce, detect or record bioluminescence within mammals other than the Licensed Products. 
  
 2.7 Product Dealing Limitations. Other than the
distribution rights explicitly granted in Section 2.1, and the internal use purchase rights set out in Section 2.2, Distributor has no other rights to deal in the Licensed Products, Xenogen Imaging Technology or the Software. Distributor agrees that
it will not promote, market or sell the Licensed Products, directly or indirectly, to third parties located outside the Territory or that Distributor reasonably believes will use Licensed Products outside the Territory, without the written approval
of Xenogen, which Xenogen may give or withhold in its sole and absolute discretion. Xenogen reserves and retains all rights not expressly granted herein, including the right to market and sell the Licensed Products to non- Local Customers in the
Territory by any other means, either directly or through other distributors, partners or third parties and anywhere in the world outside the Territory. 
  

 -2- 

 3. Equity Investment. As partial consideration for the rights and licenses granted herein,
Distributor will invest at least one million dollars (US$1,000,000) in Xenogen’s next round of financing in which it raises at least five million dollars (US$5,000,000) in equity financing, on the terms and conditions applicable to all other
investors in such round and agreed to by Xenogen. 
  
 4.
Licenses 
  
 4.1 Xenogen Imaging
Technology. During the Term and subject to the terms and conditions of this Agreement, Xenogen grants Distributor a non-exclusive, non-transferable, royalty-free license, without the right to sublicense, to use Xenogen Imaging Technology solely
with Imaging Systems for demonstration, training and education purposes in the Field in the Territory. Distributor shall not pledge, lease or rent Distributor’s rights under this Section 4.1 or use, or allow a third party to use, this license
for fee-for-service or contract research. The rights under this license grant may only be exercised if and when Distributor is current on all fees due to Xenogen under this Agreement. 
  
 4.2 Software and Documentation. 
  
 (a) Subject to the terms and conditions of this Agreement, Xenogen hereby grants to Distributor an
exclusive, nontransferable limited license to copy, store and distribute the Software and Documentation in the Territory solely to the extent necessary for Distributor to exercise its rights and fulfill its obligations (including for demonstration,
training and installation purposes) under this Agreement; provided, that: (i) Distributor shall only distribute the Software to End Users that are current on all fees, including without limitation all fees due under Service Contracts; (ii)
Distributor shall only distribute Major Versions and Minor Versions to End Users whose Imaging Systems are covered under Xenogen’s limited warranty for the applicable Imaging System (as described in section 16.5 below) or a current, paid-up
Service Contract; and (iii) the rights under this license grant may only be exercised if and when Distributor is current on all fees due to Xenogen under this Agreement. 
  
 (b) In addition, Xenogen hereby grants to Distributor a non-exclusive, nontransferable license, without the
right to sublicense, to use, store and display the Software and Documentation with the practice of the Xenogen Imaging Technology for demonstration, training, installation and related purposes at the System Sites. Distributor may make copies of the
Software and Documentation as necessary to exercise the rights granted herein, as well as an additional copy for backup purposes. Licenses for additional copies of the Software may be purchased from Xenogen at its then-applicable retail price.

  
 4.3 Software Restrictions. Distributor
shall not pledge, lease, rent, distribute or share Distributor’s rights under 4.2. Distributor shall not alter the Software in any manner whatsoever, and Distributor agrees that it will not, without Xenogen’s prior written consent,
directly or indirectly, modify, make derivative works, or make any additional copies of the Software, except as expressly authorized in this Article 4. Distributor further agrees that it shall not, directly or indirectly, attempt to reverse engineer
or decompile the Software or otherwise derive source code from the Software and shall not allow third parties to do so. Distributor shall not make the Software available to any other third party or provide services to third parties based on the
Distributor without 
  

 -3- 

 Xenogen’s express written consent (including as evidenced by a fully-executed End User Agreement of
appropriate form). Distributor shall not cause or permit any combining of the Software with other computer program materials to form a derivative work without Xenogen’s express written permission, and in the event such permission has been
granted, Distributor shall, upon discontinuance or termination of this license, remove the Software from the derivative work and return it to Xenogen or, at Xenogen’s option, destroy the Software and certify such destruction to Xenogen.

  
 4.4 No Implied Licenses. Only the
licenses granted pursuant to the express terms of Article 4 shall be of any legal force or effect. No other license rights shall be granted or created by implication, estoppel or otherwise. 
  
 4.5 Ownership. The copyrights of the Software and
Documentation are, and shall remain, owned by Xenogen. As between Xenogen and Distributor, title to and ownership of the Software and Documentation, and all copies thereof, as well as any improved, updated, modified or additional parts thereof, and
all copyright, patent, trade secret, trademark and other intellectual property rights embodied in the Initial Systems, shall at all times remain the property of Xenogen. This license conveys only a limited right of use revocable in accordance with
its terms. 
  
 5. Supply of licensed Products

  
 5.1 Quarterly Forecast. On the
Effective Date of this Agreement and thereafter on the first day of each calendar quarter during the Term, Distributor shall provide Xenogen with a twelve (12) month rolling forecast setting forth its estimated requirements for delivery to
Distributor of Licensed Products on a monthly basis, including both its requirements based on its Minimum Sales Commitment pursuant to Section 6.3, and its good faith forecast of reasonable sales above that amount (“Quarterly Forecast”).
Each Quarterly Forecast will be in English and contain content reasonably specified by Xenogen, including forecasted monthly demand for each Licensed Product (beginning with the first day of the next calendar month) and reasonable details of sales
and business prospects. Such Quarterly Forecasts are for planning purposes only, and will not be binding on either Party. Notwithstanding the foregoing, Distributor will use commercially reasonable efforts to make each Quarterly Forecast as accurate
as possible. In the event that Distributor believes that a Quarterly Forecast is materially inaccurate, Distributor shall promptly notify Xenogen and provide Xenogen with a revised Quarterly Forecast. 
  
 5.2 Purchase Orders. Distributor shall submit
Licensed Product orders to Xenogen in writing, substantially in the form of Exhibit D, specifying the specific Licensed Products, quantity desired, End User (including name and address) and a requested delivery date by Xenogen (each, a
“Purchase Order”). Distributor may initiate an order by telephone call, telecopy, e-mail or facsimile, provided that Xenogen receives a confirmation Purchase Order within five (5) days of such order’s initiation. Each Purchase Order
will be deemed to incorporate all of the provisions of this Agreement. Purchase Orders may not contain any additional terms, conditions or other provisions purporting to be legally binding or inconsistent with this Agreement and to the extent they
do, such terms, conditions and provisions will be null, void and deemed stricken from the Purchase Orders unless otherwise agreed upon by the Parties. 
  

 -4- 

 5.3 Order Acknowledgments. Xenogen shall provide written acknowledgment accepting
or rejecting each Purchase Order, including the reasons therefor if rejected, within three (3) business days after receipt of such Purchase Order. All Purchase Orders are subject to acceptance by Xenogen, and Xenogen shall have no liability for
Purchase Orders that it does not accept. No partial acceptance of a Purchase Order shall constitute the acceptance of an entire order, absent Xenogen’s written acceptance of such entire Purchase Order. If a specific Licensed Product requires
execution of an End User Agreement (as identified in Exhibit B), then each Purchase Order shall be accompanied by an executed End User Agreement of appropriate form as identified in Exhibits Band C-1 through C-4. Xenogen will specify the delivery
date or dates for each Purchase Order in the written acceptance that Xenogen provides to Distributor (the “Shipment Date”). Xenogen intends to deliver all accepted Purchase Orders for quantities of Imaging Systems within the annual
Minimum Sales Commitment within thirty (30) days of Purchase Order acceptance. Xenogen further intends to deliver all accepted Purchase Orders for BiowareTM within thirty (30) days as well. Lead-time for LPTATM animal models will be determined on a case-by-case basis. 
  
 5.4 Order Changes. Distributor may not cancel any
Purchase Order within the seven (7) business day period prior to the applicable Shipment Date. Prior to that period, Distributor may cancel a Purchase Order for other than LPTATM animal models only upon payment of a restocking charge of fifteen percent (15%) of the then-current prices set forth in
Exhibit B for the Licensed Product quantity so cancelled. Purchase Orders for other than LPTATM animal models may be rescheduled a single time for a rescheduled shipment date within the same calendar quarter as the original Shipment Date. In addition, if Distributor cancels an
order for LPTATM animal models, Distributor shall
reimburse Xenogen for all direct costs and non-cancelable commitments incurred as a result of such order, including cage costs for such LPTATM animal models, and in the event of animal sacrifice, for the costs of such animals. 
  
 5.5 Shipping and Risk of Loss. Licensed Products delivered hereunder shall be suitably packed for
shipment in Xenogen’s standard shipping cartons, marked for shipment to the destination in the Territory specified by Distributor, and delivered to the carrier agent ex works (Incoterms 2000) Xenogen’s manufacturing facility, at which time
the title and risk of loss shall pass to Distributor. Xenogen will ship Bioware 1M directly to SCB unless requested otherwise. Unless otherwise instructed by Distributor in writing, Xenogen shall select the common carrier. Distributor is to act as
the importer of record, and all freight, insurance, taxes, customs duties and other shipping expenses, as well as expenses for any special packing requested by Distributor and provided by Xenogen, shall be additionally billed to, and paid by,
Distributor pursuant to Sections 8.1 and 8.5. All shipment and freight charges will be deemed correct unless Xenogen receives from Distributor, no later than fifteen (15) days after the date of shipment, a written notice specifying the shipment, the
Purchase Order number and the exact nature of the discrepancy between the order and the shipment in number or type of Licensed Products shipped, or freight or other charges, as the case may be. 
  
 5.6 Product Replacement. Distributor may replace any
licensed Product that fails to materially perform in accordance with Xenogen’s published Specifications and limited warranty (as stated herein) for such licensed Product by complying with Xenogen’s then-current RMA Procedures, a copy of
which is attached hereto as Exhibit E, which may be amended in Xenogen’s sole discretion. Distributor may only replace licensed Products in accordance with the RMA 
  

 -5- 

 Procedures. Any licensed Product returned to Xenogen for replacement by Distributor as permitted under
this Agreement shall be shipped at Distributor’s cost, pre-paid and insured to Xenogen at such location as Xenogen may instruct, using any common carrier and shall be packed in its original packing material. Xenogen may refuse to accept any
licensed Product not properly packed and shipped as herein provided. Biological materials may not be returned. 
  
 5.7 Distribution/Delivery to End Users. Distributor will be responsible for storage of Licensed Products, as well as delivery to,
and installation at, the End User’s desired location. Distributor shall ensure that, when delivered to an End User, Licensed Products shall: (i) be labeled and packaged as delivered to Distributor with all accompanying Documentation and related
materials; (ii) bear all of Xenogen’s and its suppliers’/licensors’ unobstructed/unmasked product and component names, trademarks, logos, patent markings and symbols; (iii) contain such legends and notices as reasonably stipulated by
Xenogen; and (iv) be shipped with Xenogen’s and its suppliers’/ licensors’ terms of use and like agreements, policies, warranty cards and similar documents. 
  
 5.8 Licensed Product Changes. Xenogen reserves the right, in its sole discretion, to discontinue or
to limit its production of any Licensed Product; to allocate, terminate or limit deliveries of any Licensed Product in times of shortage; to alter the design, functions or construction of any Licensed Product or its Specifications; to remove
functionality from or to add additional functionality to the Licensed Products; and upon reasonable notice to Distributor, to change its sales and distribution policies, not inconsistent with the terms of this Agreement. If there are any previously
placed and accepted Purchase Order(s) at the time of such change to the Licensed Product or Specifications, Xenogen shall discuss with the Distributor how to continue to fulfill, or cancel and refund, such Purchase Order(s), as mutually agreed.

  
 5.9 Insurance. During all times in
which Distributor has title or possession of Licensed Products for which Xenogen has not received payment in full, Distributor shall obtain and keep in force comprehensive, general liability insurance with limits at least equal to the total retail
value of all such Licensed Products and naming Xenogen as a loss payee. Distributor shall promptly provide proof of insurance to Xenogen upon request. 
  
 5.10 Security Interest. Xenogen reserves, until full payment has been received, a purchase money security interest in all Licensed
Products delivered to Distributor. Distributor agrees to execute any document appropriate or necessary to perfect the security interest of Xenogen, or in the alternative, Distributor hereby authorizes Xenogen to perfect its security interest by
filing appropriate UCC statements. 
  
 5.11
Luciferin Supply. Upon submission of a written purchase order from Distributor no less than thirty (30) days before the requested delivery date, Xenogen will use commercially reasonable efforts to provide up to one hundred (100) grams of
D-luciferin potassium salt (“D-Luc”) each calendar year, for Distributor’s use in connection with Licensed Products or the Xenogen Imaging Technology in the Territory. Xenogen will make D-Luc available at a transfer price of
*** per gram, subject to any price fluctuations that Xenogen’s supply may experience. Xenogen will ship order quantities of D-Luc hereunder in packages appropriate for air shipment, marked for shipment to the destination point stated in the

  
 *** Confidential treatment requested 
  

 -6- 

 purchase order, and shipped ex works (Incoterms 2000) Xenogen’s shipping point. All such
shipments will be insured and sent via two-day (or similar) service, unless Distributor requests overnight shipment. All freight, insurance and other shipping expenses from the delivery point will be borne by Distributor. Xenogen will invoice
Distributor for such ordered D-Luc quantities upon shipment of the D-Luc ordered by Distributor hereunder. Section 8.2 will govern payment terms for such D-Luc. 
  

6. Marketing 
  
 6.1 Marketing. Distributor shall, at its own expense, use all reasonable and diligent efforts to promote the Licensed Products in
order to achieve maximum sales potential for Licensed Products in the Territory as set by agreed upon volume purchase forecasts, including the following obligations: 
  
 (a) set a reasonable and representative goal and incentive compensation structure for all its sales and
marketing personnel assigned to support the Xenogen Licensed Product line; 
  
 (b) prepare an annual sales and marketing plan to be discussed with Xenogen and mutually agreed-to prior to implementation; 
  
 (c) prepare and distribute promotional materials, subject to Xenogen’s approval, for the Licensed Products in the languages
appropriate for the Territory; 
  
 (d) advertise
Licensed Products at a meaningful level in trade publications within the Territory; 
  
 (e) directly solicit orders for Licensed Products through a field sales organization; 
  
 (f) place the Licensed Products in its catalogues as soon as
possible; 
  
 (g) participate in appropriate
trade shows and conferences at a meaningful level (at least four (4) per calendar year) and feature the Licensed Products at the same; 
  
 (h) provide adequate contact with existing and potential Local Customers within the Territory on a regular basis (at least once per year
in the case of existing Local Customers), consistent with good business practices; 
  
 (i) assist Xenogen in assessing local Customer requirements for the licensed Products, including modifications and improvements thereto,
in terms of quality, design, functional capability, and other features; and 
  
 (j) submit quarterly sales, marketing, and market research information, as reasonably requested by Xenogen, regarding sales performance, competition, pricing, and other changes in the market within the Territory.

  

 -7- 

 6.2 Manner of Marketing. In the marketing and promotion of the Licensed Products,
Distributor shall not make any statements or representations about the Licensed Products that are inconsistent with those made or authorized by Xenogen or its suppliers or licensors or that are capable of being misleading and deceptive. Distributor
may not offer, promise or contract for any Licensed Products for which Distributor does not have the necessary rights or a relationship with Xenogen. Distributor shall represent Xenogen in a manner intended to preserve and enhance the reputation and
goodwill of Xenogen and the Licensed Products. 
  
 6.3 Minimum Sales Commitment. 
  
 (a) Distributor shall meet the specified minimum sales commitment with respect to Imaging Systems during each year of this Agreement as set forth in this Section 6.3 (“Minimum Sales Commitment”). In the event that
Distributor fails to meet its Minimum Sales Commitment for a Licensed Product in any country within the Territory for any calendar year during the term of this Agreement, then Xenogen may unilaterally change Distributor’s appointment under this
Agreement to a non-exclusive basis in such country in the Territory pursuant to Section 13.3; provided that such right shall not be operative in the event that Distributor pays Xenogen, not later than thirty (30) days after the date of
Xenogen’s written notice to Distributor that it is invoking Section 13.3, the amount of ***. Provided further that Xenogen’s right to invoke Section 13.3 or the foregoing shortfall payment provision of this Section 6.3(a) shall not apply
if Distributor’s failure to achieve such Minimum Sales Commitment is due to a failure by Xenogen to supply such Licensed Product as required. In either case the foregoing right of conversion to non-exclusivity shall not be operative and such
shortfall payment shall not be required. 
  
 (b)
Minimum Sales Commitment 
  

			
	 Year 1 (2003)—
	  	four (4) IVIS TM Imaging Systems ***, with no unit purchased in the first half of the calendar year and at least *** in the second half of the calendar year
		
	 Year 2 (2004)—
	  	ten (10) IVIS TM Imaging Systems ***, with at least *** units purchased in the first half of the calendar year and at least *** units purchased in the second half of the calendar year
		
	 Year 3 (2005)—
	  	fourteen (14) IVIS TM Imaging Systems ***, with at least *** units purchased in the first half of

  
 *** Confidential treatment
requested 
  

 -8- 

 the calendar year and *** units purchased in the second half of the calendar year. 
  
 6.4 Xenogen’s Obligations. In support of
Distributor’s marketing obligations under Sections 6.1 and 6.2 above, Xenogen will provide, at its own expense: 
  
 (a) scientific personnel to provide seminars at key scientific conferences and/or customer meetings as reasonably requested by
Distributor, but limited to no more than three (3) trips of reasonable duration to the Territory per calendar year (it being agreed that one such tradeshow / conference visit occurred prior to the Effective Date and shall count against the three (3)
such visits for calendar year 2003); 
  
 (b)
adequate sales and marketing support and direction to the Distributor sales and marketing team as needed; 
  
 (c) sales and marketing personnel for key tradeshow/conferences and/or customer meetings as needed, but limited to no more than three (3)
tradeshow/conferences and three (3) key customer visits per calendar year; 
  
 (d) necessary product updates and/or materials in support of licensed Product line sales; and 
  
 (e) adequate information regarding Licensed Products. 
  
 6.5 Quarterly Sales Report. Within fifteen (15) days after the end of each calendar quarter,
Distributor shall provide Xenogen with quarterly Licensed Product sales and order reports (the “Quarterly Sales Report”) for the period of time since the last Quarterly Sales Report, in an English language format that contains such
quarterly sales and order related information as reasonably specified by Xenogen, including, details of the names, addresses (corporate and Licensed Product installation addresses), contact name & number of End Users, the dates and quantities of
Licensed Products shipped by type in total and to each End User, the serial numbers of such Licensed Products (if applicable) shipped to each End User and Distributor’s Licensed Product inventory status by Licensed Product type. Distributor
shall retain reasonably detailed records of the same. 
  
 6.6 Translation; Localization. Distributor may translate any Documentation and Licensed Product Literature only with Xenogen’s prior written consent, it being understood that Distributor hereby assigns to Xenogen all ownership
rights in and to any such translated versions of the Documentation and Licensed Product Literature. Distributor agrees to, and shall cause its employees, agents and consultants to, execute such documents and to perform such acts as may be reasonably
necessary to perfect and register such assignment in all relevant jurisdictions. Distributor shall not, and shall not cause or permit others to, localize the License Products. 
  
 6.7 Foreign Corrupt Practices Act. In conformity with the United States Foreign Corrupt Practices
Act, Distributor and its employees and agents shall not directly or indirectly make any offer, payment or promise to pay; authorize payment; nor offer a gift, promise to give, or authorize the giving of anything of value for the purpose of
influencing any act or decision of an 
  
 *** Confidential treatment
requested 
  

 -9- 

 official of any government within the Territory or the United States Government (including a decision not
to act) or inducing such a person to use his or her influence to affect any such governmental act or decision in order to assist Xenogen or Distributor in obtaining, retaining or directing any business. 
  
 6.8 Policies and Procedures. Distributor shall abide
by Xenogen’s reasonable Distributor marketing, support and related policies provided to Distributor; provided, however that such policies and procedures shall remain consistent with the provisions hereof and may not purport to unilaterally
amend this Agreement. 
  
 7. Trademarks 

 
 7.1 Trademarks. During the term of this Agreement,
all packaging materials, labels and promotional materials for the licensed Products shall display the Xenogen Marks. In addition, Distributor may, if it so chooses, mark all such materials and labels with “Distributed in [country] exclusively
by SC Biosciences”, it being understood that the Xenogen Mark shall be the more prominently displayed of the two marks. Distributor may only use the Xenogen Marks in the form set form in Appendix 1 to Exhibit A, or as otherwise may be approved
by Xenogen. In the event that any of the Xenogen Marks is not available for use in a specific country in the Territory, then Xenogen and Distributor will mutually agree on a substitute mark to be used in such country. Distributor will display all
proprietary notices required by Xenogen and will comply with all applicable laws and regulations pertaining to the proper use and designation of trademarks in the Territory. 
  
 7.2 License. Xenogen hereby grants to Distributor a non-transferable, nonsublicensable, royalty-free
license to use the Xenogen Marks in the Territory for the term of this Agreement solely in connection with the marketing and promotion of Licensed Products for use and sale within the Field to Local Customers as contemplated in this Agreement.
Xenogen reserves all rights not expressly granted herein. 
  
 7.3 Ownership. Distributor acknowledges that it has no interest in the Xenogen Marks other than the licenses granted under this Agreement, and that Xenogen will remain the sole and exclusive owner of all right,
title and interest in the Xenogen Marks. Distributor agrees that Distributor’s use of the Xenogen Marks and any good will in such Marks resulting from Distributor’s use will inure solely to the benefit of Xenogen and will not create any
right, title or interest for Distributor in the Xenogen Marks. Distributor shall not contest, oppose or challenge Xenogen’s ownership of the Xenogen Marks. Distributor agrees that it will do nothing to impair Xenogen’s ownership or rights
in the Xenogen Marks. Distributor shall not, during the term of this Agreement or thereafter, register, use, or attempt to obtain any right in and to any Xenogen Mark (other than those rights granted herein) or in and to any name, logo or trademark
confusingly similar thereto. Distributor agrees that at no time during or after the term of this Agreement to challenge or assist others to challenge the Xenogen Marks or the registration thereof or attempt to register any trademarks, marks or trade
names confusingly similar to such Xenogen Marks. 
  

 -10- 

 7.4 Infringement. Distributor shall notify Xenogen promptly upon learning of any
actual, alleged, or threatened infringement of a Xenogen Mark in the Territory or of any unfair trade practices, trade dress imitation, passing off of counterfeit goods, or similar offenses. 
  
 7.5 Review and Approval of Promotional Materials.
Distributor’s use of each Xenogen Mark is contingent on Xenogen’s prior approval, at its sole discretion, of a sample of such Mark indicating the form and style and usage intended by Distributor. Distributor shall submit representative
promotional materials, labels, packaging and other materials using any Xenogen Mark (accompanied by an English language version if such materials are not in the English language) to Xenogen for Xenogen’s review and comment prior to their first
use and prior to any subsequent change or addition to such materials. If Xenogen does not object within fifteen (15) business days after receipt of such representative materials by Xenogen, such materials will be deemed approved. Xenogen will not
unreasonably withhold or delay its approval of such materials. Distributor shall not use any Xenogen Mark or other proprietary mark of Xenogen or Xenogen’s suppliers or licensors in a manner that has not been approved by Xenogen. 
  
 8. Price and Payment 
  
 8.1 Price. Distributor’s purchase price for
Licensed Products shall be as set forth in Exhibit B. The difference between Distributor’s purchase price and Distributor’s price to End Users will be Distributor’s sole remuneration for distribution of Licensed Products hereunder.
Freight, shipping, insurance and similar charges are not included in the purchase price shown in Exhibit B and will be added separately to each invoice for payment by Distributor. 
  
 8.2 Payment. Xenogen will issue invoices to Distributor upon delivery of the Licensed Products to
Distributor at Xenogen’s delivery point. Distributor will pay Xenogen, in full, in U.S. Dollars for each delivery hereunder with standard payment terms of net thirty (30) days from date of shipment to the delivery point. For payments due
hereunder other than for Licensed Products, promptly after the Effective Date Distributor and Xenogen agree to meet and further discuss specific payment procedures and mutually agree on such procedures, and other cooperation. All payments under this
Agreement shall be made by check or bank wire transfer in immediately available funds to an account designated by Xenogen. All dollar amounts specified in this Agreement, and all payments made hereunder, are and shall be made in U.S. dollars. Late
payments shall accrue interest at the rate of one and a half percent (1.5%) per month or the highest interest rate allowable by law, whichever is less. Distributor will pay all of Xenogen’s costs and expenses (including reasonable
attorneys’ fees) to enforce and preserve Xenogen’s rights under this Article 8, and in the event that Distributor becomes delinquent in the payment of any sum due hereunder, Xenogen may suspend performance hereunder until such delinquency
is corrected. 
  
 8.3 Currency Conversion.
If any currency conversion shall be required in connection with the calculation of amounts payable hereunder, such conversion shall be made using the buying exchange rate for conversion of the foreign currency into U.S. Dollars, quoted for current
transactions reported in The Wall Street Journal (Eastern Edition) for the last business day of the Reporting Period to which such payment pertains. 
  

 -11- 

 8.4 Price Changes. Xenogen has the right to revise the prices set forth or
referenced in Exhibit B once annually on sixty (60) days written notice by unilateral amendment thereto. For price increases, Distributor has sixty (60) days from the date of such notice to place a Purchase Order for affected Licensed Products at
the current price, and such Licensed Products must be for a delivery date within sixty (60) days thereafter. Purchase Orders previously accepted by Xenogen and requested to deliver within sixty (60) days will be invoiced at the current (unchanged)
prices. The Parties will review Distributor’s percentage discount at the annual review described in Section 9.1 below prior to the start of each new calendar year of the Term and may adjust the discount amount for such year upon mutual
agreement. 
  
 8.5 Taxes. Distributor
shall be responsible for paying any and all local, state, territorial, provincial or federal duties, taxes, excise taxes, goods and services taxes, value added taxes, withholding taxes, ancillary charges and the like owing to any government body or
authority in respect of the transactions anticipated hereunder, except that Xenogen shall be responsible for its own income taxes. The prices/fees listed in this Agreement are exclusive of any government taxes, goods and services taxes, value added
taxes, surcharges, duties or levies and the like. If Xenogen is required to pay any duty, tax, penalty or interest on Distributor’s behalf, then Distributor agrees to promptly reimburse Xenogen for such expenses. Promptly after the Effective
Date, Distributor and Xenogen agree to meet and further discuss tax-related issues in order to minimize any such obligations arising hereunder, and mutually agree on changes in the payment structure of this Agreement, and other cooperation, in order
to accomplish such minimization. 
  
 8.6
Records; Inspection. Distributor shall keep (or cause to be kept) complete, true and accurate books of accounts and records relating to its activities relating to this Agreement for the purpose of determining (a) the amounts payable
hereunder, and (b) compliance with its terms and conditions. Such books and records shall be kept at the principal place of business of the Distributor for at least three (3) years following the end of the calendar quarter to which they pertain.
Such records (and only such records) will be open for inspection during such three (3)-year period by an independent party chosen by Xenogen and reasonably acceptable to Distributor, in order to verify the amounts payable hereunder and compliance
with this Agreement’s terms and conditions. Such inspections may be made no more than once each calendar year, at reasonable times and on reasonable notice and at Xenogen’s expense. However, if such inspection finds an underpayment
exceeding ten percent (10%) of the amounts payable for any period covered by the inspection, Distributor shall bear all costs relating to the inspection and any unpaid amounts, together with interest on such underpaid amounts at the rate set forth
in Section 8.2 above. Xenogen will endeavor to minimize disruption to Distributor by such inspection. 
  
 9. Additional Obligations of Distributor 
  
 9.1 Annual Review. The Parties will meet no later than December 1 of each calendar year to review: sales performance within the
Territory during the calendar year, End User satisfaction, issues, and complaints in the Territory; technical support issues; training; new Licensed Product launches or modifications to existing Licensed Products planned for the subsequent year;
pricing issues within the Territory; Distributor’s marketing plans for the subsequent year; and Minimum Sales Commitment in the Territory for the subsequent year. 
  

 -12- 

 9.2 Modification/Tampering/Reverse Engineering. Unless expressly provided
otherwise in this Agreement, Distributor shall not, and agrees not to, make or authorize any attempt to: (i) access, copy, modify or extract the Software or any other embodiment of the IP contained in the Products; (ii) alter, disassemble, open,
service, maintain, or repair the Licensed Products, or contract with persons other than Xenogen or Xenogen-authorized personnel for any of the foregoing; (iii) Misuse the Licensed Products; (iv) cause improper external stress to the Licensed
Products or otherwise tamper with the Licensed Products or the Licensed Product packaging; (v) repackage or relabel the Licensed Products or bundle the Licensed Products with any additional hardware, software or documentation; (vi) decompile,
reverse engineer, disassemble or otherwise derive the source code from the Software; (vii) modify, enhance, translate, alter, tamper with, upgrade or create derivatives works of the Licensed Products, Software or Documentation; (viii) strip out or
alter any trademark, service mark, copyright, patent, trade secret, ownership or any other proprietary or Intellectual Property notices, legends, warnings, markings or indications on or within any component of the Licensed Products, Software or
Documentation; (ix) remove, cover or obfuscate any Xenogen Marks, labels or other markings; or (x) other than as provided herein, rebrand or label the Licensed Products with any product and component names, trademarks, logos, patent markings and
symbols. 
  
 9.3 Copies. Except as
specifically provided for in this Agreement, Distributor may not copy, replicate, manufacture or duplicate the Licensed Products, Software, training materials or Documentation. 
  
 9.4 Non-Competition. Distributor shall not (directly or indirectly) develop products or software
providing similar functionality as the Licensed Products or Software during the Term of this Agreement and for one (1) year thereafter. 
  
 9.5 Training. Distributor will maintain a trained and certified marketing, sales and technical support (biology and
instrumentation) staff in alignment with Xenogen’s standards. Distributor will conduct training programs for End Users at least once per calendar year. 
  
 9.6 Country Specific Restrictions. Notwithstanding the jurisdictions comprising the Territory, Distributor agrees and acknowledges
that: (i) Distributor may not ship the Licensed Products outside of the Territory unless and until Xenogen has obtained all necessary authorizations from the U.S. government for the applicable foreign jurisdiction and notified Distributor in writing
of same; and (ii) no component of the Licensed Products, Software or Documentation may be distributed or otherwise exported, re-exported or made available into (or to a national or resident of) any country or jurisdiction to which the U.S. has
embargoed such goods; or anyone on the U.S. Treasury Department’s list of Specially Designated Nationals or the U.S. Commerce Department’s Table of Denial Orders; or to any person, country or jurisdiction otherwise prohibited by applicable
law. 
  
 9.7 Patent Enforcement.
Distributor shall notify Xenogen promptly upon learning of any actual, alleged, or threatened claim, suit or proceeding alleging patent infringement and relating to the licensed Products or Xenogen Imaging Technology in the Territory. If the
manufacture, sale or use of any licensed Product in the Territory pursuant to this Agreement results in any claim, suit or proceeding alleging patent infringement against Distributor or Xenogen, Distributor shall promptly notify Xenogen. 

 

 -13- 

 10. End User Agreement 
  
 10.1 End User Agreement. Distributor shall ensure
that Sales Agreements concerning specified Licensed Products (in Exhibit B) sold by Distributor include (or reference) an End User Agreement, in the appropriate form as provided at Exhibits C-1 through C-4 in all Sales Agreements to which
Distributor is a party. Prior to installation of an Imaging System or Xenogen’s delivery hereunder of other Licensed Products, Distributor shall submit two (2) copies of the appropriate End User Agreement executed by the End User to Xenogen for
execution. Xenogen will return one (1) fully-executed copy to Distributor. 
  
 10.2 Changes to End User Agreement. The Parties may agree in writing to amend an End User Agreement in a measured way to fairly address prospective End User concerns therewith while still reasonably protecting
Xenogen’s rights and limiting Xenogen’s liability vis-a-vis such prospective End Users. Alternatively, the Parties may agree in writing, on a case-by-case basis, to amend the End User Agreement for a particularly important prospective
Local Customer to complete that particular sale. Any of the foregoing End User Agreement changes shall first be agreed to in writing between the Parties before submitting such End User Agreement for execution. 
  
 10.3 Xenogen Modifications of End User Agreement. As
Xenogen modifies the End User Agreement as applicable across its customer base, Xenogen shall notify Distributor of changes thereto in writing and, Distributor shall, within thirty (30) days thereafter, use and distribute only the newer version of
the End User Agreement with all subsequently sold Licensed Products identified in Exhibit B as requiring such End User Agreement. 
  
 10.4 End User Breach. Distributor shall promptly notify Xenogen of any material breach of an End User Agreement by any End User
upon Distributor becoming aware of such material breach and shall independently, and to the extent permitted by relevant law, enforce such End User Agreement. Distributor shall work cooperatively with Xenogen in the instances of such material breach
by End User to cooperatively resolve the same and to enforce Xenogen’s and Distributor’s rights thereunder and to minimize each Party’s liability exposure thereunder. 
  
 11. Service and Support 
  
 11.1 Service Contracts. Distributor shall offer, but not compel to purchase, a Service Contract to
each End User who purchases an Imaging System from Distributor. All Service Contracts will be based on the substance of Xenogen’s own support and services agreement (Exhibit F); provided that Distributor may modify such services and contracts
as the Parties agree are reasonably necessary for use in the Territory. Distributor may determine the pricing for such Service Contracts in its sole discretion. 
  
 11.2 Delivery of Post-Sale Service and Support. 
  
 (a) During the period in which they are covered by Xenogen's
limited warranty stated in the applicable End User Agreement, Xenogen will provide post-sales service for the Initial Systems sold to Distributor prior to the Effective Date. During this period, Xenogen will also provide reasonable training of
Distributor service personnel and reasonable technical support to 
  

 -14- 

 Distributor to assist in Distributor's own obligations to its customers as described in Section 12.1 below, and as the
Parties may otherwise mutually agree. 
  
 (b)
Upon completion of the period described in Section 11.2(a) above, Distributor shall be solely responsible for providing post-sales service for the Imaging Systems under all Service Contracts with End Users who purchased the Licensed Products through
Distributor and resolution of all warranty claims made by such End Users, as described in this Section 11.2(b). Distributor agrees and acknowledges that Xenogen will have no obligation to provide direct support of any kind to End Users that purchase
Licensed Products through Distributor. Xenogen will support Distributor for post-sales service and support, including continued training of Distributor service personnel and providing technical support to Distributor to assist in Distributor's own
obligations to its customers, as well as the Parties may otherwise mutually agree. Only employees of Distributor, or its (Xenogen) approved designee, will perform maintenance and repair services made during each Licensed Product's warranty period or
during the term of an applicable Service Contract; provided that Xenogen may send its own delegates to the End User's facility in support of such maintenance and repair services at its own discretion and expense; and further provided that, in the
event Distributor requires Xenogen's presence at an End User's facility in order to perform maintenance or repair services on a Licensed Product, Distributor will reimburse Xenogen for its reasonable expenses incurred in connection therewith. If
Distributor's technical staff is unable to resolve an End User's warranty or service claim by providing the appropriate support or by replacing the relevant Licensed Product or component, Distributor may contact Xenogen for additional technical
support. Only Distributor's technical support personnel may contact Xenogen for such technical support, as the End User may not receive support in this manner. All of Distributor's technical support personnel that will support the Licensed Products
must be trained and certified by Xenogen. 
  
 (c)
In the event Xenogen requests Distributor to provide post-sales support for non-Local Customers in the Territory (as listed in Appendix 1 to Exhibit B), Distributor agrees to do so in a timely manner. In such event, Xenogen will reimburse Xenogen
for its labor costs to provide such support at a rate not to exceed nine hundred twenty-five dollars (US$925) per day, plus reasonable expenses incurred in connection therewith. Xenogen will provide Licensed Product parts for such support by
Distributor at its own expense. 
  
 11.3
Replacement Inventory. Distributor shall maintain an inventory of Instrumentation components and such other products necessary for Distributor to fulfill its obligations under all existing Service Contracts and warranty claims made by End
Users, as further described in this Article 11. To ensure the quality of Licensed Products and preserve the goodwill associated with them, replacement parts for any Instrumentation must be ordered through Xenogen, and Licensed Products may be
maintained and repaired only with Xenogen-approved replacement parts. 
  
 11.4 Software Support. During the Term, Xenogen shall make available to Distributor, at no additional cost, any patches, bug fixes or updates of the Software that Xenogen generally makes available to its
licensees outside the Territory. 
  

 -15- 

 12. Xenogen Assistance 
  
 12.1 Training. Xenogen will provide an initial “kick-off” training session for
Distributor’s employees supporting the marketing/sales, and technical support (biology and instrumentation) efforts. This session includes on site training at Xenogen Corporation in Alameda, CA for not more than three (3) weeks. Beginning in
2003, Xenogen periodically will provide training in the Territory for such Distributor personnel on an agreed-upon schedule, not to exceed an aggregate of fifty-six (56) hours per calendar year. In addition, beginning in 2003, Xenogen will provide
End User on-site advanced training seminars in the Territory up to twice per calendar year. 
  
 12.2 Sales Literature. In addition to the Documentation, Xenogen will provide Distributor with Licensed Product Literature. The
Licensed Product Literature will be written in English only and will be provided to Distributor free of charge in reasonable quantities and subject to the restrictions set forth in Section 6.6. Distributor will bear all cost of reproducing and
adapting such literature for its own use as permitted under this Agreement. 
  
 12.3 Field Service Tool Kit. Xenogen will provide Distributor with one (1) Field Service Tool Kit for Distributor’s use in providing installation, moves, and other post-sales support for Imaging Systems.
Distributor may acquire additional and reasonable quantities of the Field Service Tool Kit from Xenogen at Xenogen’s cost for such Kit. 
  
 13. Term and Termination 
  
 13.1 Term. This Agreement shall commence on the Effective Date and, unless terminated earlier as provided in this Article 13, will
remain in effect for three (3) years after such Date. Thereafter, this Agreement will automatically renew for a single additional term of three (3) years unless, one of the Parties provides the other with at least six (6) months written notice of
its intent not to renew this Agreement. 
  
 13.2
Termination on Material Breach. Either Party may terminate this Agreement upon written notice in the event the other Party has materially breached or defaulted in the performance of any of its obligations hereunder, and if such default is not
corrected within sixty (60) days after the breaching Party receives written notice from the other Party with respect to such default. Notwithstanding the above, in the case of a failure to pay any amount due hereunder the period for cure of any such
default following notice thereof shall be ten (10) days and, unless payment is made within such period, the termination shall become effective at the end of such period. 
  
 13.3 Termination for Distribution Performance. In the event that Distributor desires to cease
distributing Licensed Products for a specific country within the (expanded) Territory or fails to satisfy its Minimum Sales Commitment under this Agreement (either in the Territory in its entirety or in a specific country) during a calendar year,
then Xenogen may convert this Agreement to a non-exclusive basis in such country or in the entire Territory for the remaining Term. 
  
 13.4 Termination on Bankruptcy. Either Party may terminate this Agreement: (i) if the other Party is adjudicated as bankrupt by a
court of competent jurisdiction or consents to the 

 filing of a petition of bankruptcy against it; (ii) if the other Party makes a general assignment for the
benefit of its creditors; or (iii) if a court of competent jurisdiction appoints a receiver, liquidator or trustee in bankruptcy with respect to all or substantially all of a Party’s property or business related to this Agreement. 

 
 13.5 Events Upon Termination/Expiration.

  
 (a) Upon the termination or expiration of
this Agreement, without prejudice to any other of Xenogen’s rights, Distributor shall do all of the following: 
  
 (1) Cease marketing and distributing Licensed Products, except solely as necessary to dispose of its inventory of Instrumentation on hand
as of the effective date of termination or expiration, and may fill any orders for Licensed Products accepted by Xenogen prior to the effective date of termination or expiration, for an aggregate period of six (6) months after such date. Within
thirty (30) days after disposition of such inventory and fulfillment of such orders, Distributor will forward to Xenogen a final report containing the details required by Section 6.5 and pay Xenogen all amounts due under Section 8. 
  
 (2) Except for quantities of BiowareTM sold pursuant to Section 13.5(a)(1) above, destroy all
Licensed Products that consist of biological materials in Distributor’s possession and provide an officer’s certificate attesting to such destruction or delivery. 
  
 (3) At Xenogen’s option, return or destroy all copies of all Xenogen Confidential Information in
Distributor’s possession and provide an officer’s certificate attesting to such destruction or delivery. 
  
 (4) Except as permitted under Section 13.5(a)(1) above, cease distributing any promotional or advertising, labels, or other items bearing
the Xenogen Marks and promptly return to Xenogen, at Distributor’s expense, all such materials and items. 
  
 (5) Except as permitted under Section 13.5(a)(1) above, pay, within thirty (30) days of termination or expiration, all outstanding
amounts, charges, taxes, expenses, costs and the like due to Xenogen hereunder. 
  
 (6) Within thirty (30) days after the effective date of such termination or expiration, and at Xenogen’s sole discretion and
expense, return to Xenogen all Licensed Products (excluding those Licensed Products subject to Sections 13.5(a)(1) or 13.5(a)(2) above) remaining in Distributor’s inventory and provide an officer’s certificate attesting to such delivery as
is satisfactory to Xenogen, acting reasonably. 
  
 (7) Within thirty (30) days after the end of the period described in Section 13.5(a)(1) above, Xenogen will buy back from Distributor (at the transfer price paid) all new and unused Instrumentation remaining in Distributor’s inventory,
at Xenogen’s expense. In addition, in the event of a termination by Xenogen other than under Sections 13.2 through 13.4, the Parties will negotiate in good faith for a mutually agreeable price at which Xenogen will buy back not more than three
(3) Imaging Systems that were used by Distributor solely for demonstration purposes and which are still in good working condition. 

 (b) Following such termination or expiration, and except as expressly stated in this
Section 13.5, Distributor shall have no further right to use the Software and Xenogen Imaging Technology, and all licenses granted by Xenogen to Distributor will terminate. 
  
 13.6 Survival. In addition to any provisions that, by their nature, should survive, the following
Articles and Sections shall survive the termination or expiration of this Agreement: 1, 4.4,4.5, 5.9, 5.10,7.3,8,9.4,9.6,10.4, 11.3, 11.4, 13.5, 13.6, 14, 15,16.7, 17, 18, 19,20, 21.4,21.5,21.9,21.10,21.12 and 21.13. In addition, those Sections
relating to marketing, sales and payments for Instrumentation sold pursuant to Section 13.5(a)(1) shall survive for the period stated in that Section. 
  
 14. Confidential Information 
  
 14.1 Confidential Information. The term “Confidential Information” means any proprietary technical or business
information or data related to, or generated in connection with, the performance of this Agreement and which is provided by one Party (the “Disclosing Party”) to the other Party (the “Receiving Party”) pursuant to this Agreement.
Notwithstanding the foregoing: (i) Software, Documentation, training materials, all confidential, unique and proprietary aspects of Xenogen’s business, affairs, products, services, customer lists and methodologies and all confidential
information of Xenogen’s licensors/suppliers shall be deemed the Confidential Information of Xenogen; and (ii) Quarterly Forecasts and Quarterly Sales Reports and all confidential, unique and proprietary aspects of Distributor’s business,
affairs, products, services, customer lists and methodologies shall be deemed the Confidential Information of Distributor. 
  
 14.2 Obligations. Except as expressly provided herein, the Parties agree that, during the term of this Agreement and for a period
of five (5) years thereafter, the Receiving Party shall keep completely confidential and shall not publish or otherwise disclose to any third party which is not an Affiliate (except under no less stringent obligations of confidentiality and only for
purposes expressly permitted herein) and shall not use for any purpose except for the purposes expressly contemplated by this Agreement any Confidential Information furnished to it by the Disclosing Party pursuant to this Agreement. Confidential
Information, if disclosed in written form must be marked as “Confidential” at the time of disclosure, or if disclosed orally, must be expressly identified as “Confidential” at the time of oral disclosure, and be confirmed as
“Confidential” in a written form that is delivered to the Receiving Party within thirty (30) days of oral disclosure. To the extent it can be established by competent written proof, Confidential Information shall not include information
that: 
  
 (a) is already known to the Receiving
Party, other than under an obligation of confidentiality, at the time of disclosure; 
  
 (b) is generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party;

  
 (c) becomes generally available to the public
or otherwise part of the public domain after its disclosure to the Receiving Party and other than through any act or omission of the Receiving Party in breach of this Agreement; 

 (d) subsequently lawfully disclosed to the Receiving Party by a third party having no
confidentiality obligations with respect thereto; or 
  
 (e) is independently developed by the Receiving Party or its Affiliates without the aid, application or use of the Disclosing Party’s Confidential Information (and such independent development can be properly documented by the
Receiving Party). 
  
 14.3 Permitted Use and
Disclosures. The Receiving Party may disclose the Disclosing Party’s Confidential Information to the extent required by law, rule, regulation, act or order of any governmental authority or agency; provided that Receiving Party promptly
notifies the Disclosing Party of such requirement in order to provide the Disclosing Party an opportunity to seek a protective order or other similar order with respect to such Confidential Information, and thereafter the Receiving Party discloses
only the minimum information required to be disclosed in order to comply, whether or not a protective order or other similar order is obtained by the Disclosing Party. Further, a Party may disclose the existence and terms of this Agreement: (a) to
existing or potential investors or acquirers or merger partners, or to professional advisors (e.g., attorneys, accountants and prospective investment bankers) involved in such activities, for the limited purpose of evaluating such investment or
transaction and under appropriate conditions of confidentiality, only to the extent necessary and with the agreement by these permitted individuals to maintain such Confidential Information in strict confidence; (b) to legal counsel; and (c) in
confidence, in connection with the enforcement of this Agreement or rights under this Agreement. 
  
 14.4 Confidential Terms. Neither Party will issue a press release or otherwise publicize or disclose to any third party the terms
and conditions hereof without the prior written consent of the other Party, except that each Party may disclose such information to its attorneys, advisors or investors on a need to know basis under circumstances that reasonably ensure the
confidentiality thereof, or to the extent required by law (including under applicable federal or state securities laws and regulations). Notwithstanding any other terms of this Agreement, the Parties agree that the existence of this Agreement does
not constitute Confidential Information and may be disclosed without restriction. 
  
 15. No Unauthorized Representations. Except as explicitly provided hereunder, neither Party may make any representation or statement of any kind concerning the other Party, the relationship between the
Parties or the contents of this Agreement, including representations or statements concerning the other Party’s business, affairs, products, services, prices, discounts, fees, whether on a Party’s web site(s), whether written, oral or
otherwise without the prior authorization of the other Party. 
  
 16. Representations & Warranties 
  
 16.1 Representations and Warranties by the Parties. Each of Distributor and Xenogen hereby represents and warrants to the other Party that: 
  
 (a) it is a corporation duly organized and validly existing under the laws of the state or other
jurisdiction of its incorporation; 

 (b) the execution, delivery and performance of this Agreement by such Party has been duly
authorized by all requisite corporate action; 
  
 (c) it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder; 
  
 (d) the execution, delivery and performance by such Party of this Agreement and its compliance with the terms and provisions hereof does
not and will not conflict with or result in a breach of any of the terms and provisions of or constitute a default under (i) a loan agreement, guaranty, financing agreement, agreement affecting a product or other agreement or instrument binding or
affecting it or its property; (ii) the provisions of its corporate charter or other operative documents or bylaws; or (iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which any of its
property is bound; 
  
 (e) this Agreement has
been duly authorized, executed and delivered and constitutes such Party’s legal, valid and binding obligation enforceable against it in accordance with its terms subject, as to enforcement, to bankruptcy, insolvency, reorganization and other
laws of general applicability relating to or affecting creditors’ rights and to the availability of particular remedies under general equity principles; and 
  
 (f) it shall comply with all applicable laws, rules and regulations relating to the performance of its
activities under this Agreement. 
  
 16.2
Governmental Approvals. Distributor represents and warrants that it has obtained all required approvals of government within the Territory in connection with the distribution of licensed Products under this Agreement. 
  
 16.3 Conformity to Documentation. Xenogen represents
and warrants that the Licensed Products will, at the time of delivery to Distributor, conform in all material respects to the applicable performance and functionality stated in the applicable Documentation. 
  
 16.4 No Inconsistent Agreements. Neither Party has in
effect, and after the Effective Date neither Party shall enter into, any oral or written agreement or arrangement that would be inconsistent with its obligations under this Agreement. 
  
 16.5 Limited Warranty. Licensed Products, other than biological materials, will carry Xenogen’s
standard limited warranty for such Licensed Products (in the case of Imaging Systems, twelve (12) months after delivery to and installation at the End User’s location, not to exceed eighteen (18) months after delivery to Distributor (in case
Distributor needs to stock Imaging Systems for more than six (6) months prior to End User delivery, the Parties will discuss the extension of the warranty term on case by case basis); and provided that the Licensed Products have not been used or
operated other than for customary and reasonable inspection/acceptance testing). 
  
 (a) Instrumentation and Software. Xenogen’s standard limited warranty for Imaging Systems is that, during the warranty period
stated in Section 16.5 above: (i) the Instrumentation shall substantially conform to its published specifications existing at the time such Instrumentation is acquired or manufactured by Xenogen; and (ii) the Software will materially 

 perform in conformance with Xenogen’s then-current specifications for such Software. The foregoing
warranty expressly excludes failure to perform due to Misuse of all or any component of the Imaging System, whether Instrumentation or Software. As used in this Agreement, “Misuse” means, without limitation, (i) any use that is
inconsistent with or in contradiction to the instructions provided with the Imaging System, (ii) intentional damage to or misuse of the Imaging System, (iii) damage due to negligence in connection with use of the Imaging System, and (iv) damage
occurring during shipping and after delivery by Xenogen. Xenogen’s sole obligation, and the sole remedy, under this limited warranty is to use reasonable efforts to correct or replace any non-conforming Instrumentation and/or Software at
Xenogen’s expense, including parts, labor and travel expenses related to maintenance and corrective service during the warranty period stated. 
  
 (b) Biological Materials. Xenogen’s standard limited warranties (including limited remedy, exclusions, and limitation of
liability provisions) for biological material Licensed Products are stated in the applicable End User Agreement (see Exhibits C-3 and C-4). 
  
 (c) Physical Media Warranty. Xenogen warrants that each physical copy of the Software delivered by Xenogen hereunder is and will be
free from physical defects in the media that tangibly embodies such copy at the time of delivery (hereinafter the “Physical Media Warranty”), provided, however, that: 
  
 (i) the Physical Media Warranty does not apply to defects discovered more than ten (10) days after the date of delivery of
the copy by Xenogen; 
  
 (ii) the Physical Media Warranty does
not apply to defects arising from acts of non-Xenogen personnel, misuse, theft, vandalism, fire, water, acts of God, or other peril; and 
  
 (iii) the Physical Media Warranty applies only while the relevant media remains unmodified. 
  
 Distributor’s sole remedy for breach of the Physical
Media Warranty, to the exclusion of all other remedies therefor, shall be replacement by Xenogen at Xenogen’s expense (including shipping and handling costs) of any copy provided by Xenogen that does not comply with the Physical Media Warranty.

  
 (d) Scope Limitation. Except to the
extent required by applicable law, Distributor shall not pass on to End Users a warranty of greater scope or protection than the foregoing warranty (including the limited remedy, exclusions, and limitation of liability) set forth herein. 

 
 16.6 Limitation of Warranties. EXCEPT AS
EXPLICITLY PROVIDED IN SECTIONS 16.1, 16.3, 16.4 AND 16.5 OR THE APPLICABLE END USER AGREEMENT, THE LICENSED PRODUCTS, DOCUMENTATION AND ALL OTHER SERVICES PROVIDED BY XENOGEN HEREUNDER ARE PROVIDED ON AN “AS IS” BASIS WITHOUT ANY
REPRESENTATIONS, WARRANTIES OR CONDITIONS OF ANY KIND, WHETHER EXPRESS OR IMPLIED, STATUTORY, ARISING OUT OF A COURSE OF DEALING OR 
  

 -21- 

 USAGE, TRADE OR OTHERWISE INCLUDING ANY IMPLIED WARRANTIES OR CONDITIONS OF MERCHANTABILITY, MERCHANTABLE
QUALITY, FITNESS FOR ANY PARTICULAR PURPOSE OR USE OR NON-INFRINGEMENT. NEITHER XENOGEN NOR ITS SUPPLIERS OR LICENSORS REPRESENTS OR WARRANTS THAT THE SOFTWARE WILL BE FREE OF NON-PHYSICAL DEFECT, UNINTERRUPTED, ACCURATE, COMPLETE, CURRENT, STABLE,
BUG-FREE, ERROR-FREE OR AVAILABLE AT ANY TIME. 
  
 17.
Limitation of Liability. OTHER THAN ITS INDEMNIFICATION OBLIGATIONS UNDER ARTICLE 18 AND TO THE MAXIMUM EXTENT PERMITTED BY LAW, IN NO EVENT SHALL XENOGEN, ITS LICENSORS OR SUPPLIERS, BE LIABLE TO DISTRIBUTOR OR END USERS FOR ANY
INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL, RELIANCE, PUNITIVE OR OTHER DAMAGES OR EXPENSES OF ANY KIND, INCLUDING BUT NOT LIMITED TO ANY LOSS OF PROFITS OR REVENUE, LOST SAVINGS, LOST BUSINESS, LOST BUSINESS OPPORTUNITIES, LOST DATA, LOST
GOODWILL, LOSS FROM WORK STOPPAGE, COSTS OF OVERHEAD, COSTS OF COVER, LOSS OF ANTICIPATED BENEFITS HEREUNDER, ARISING OUT OF OR RELATED TO THIS AGREEMENT, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, EVEN IF XENOGEN HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES, AND NOTWITHSTANDING THE FAILURE OF THE ESSENTIAL PURPOSE OF ANY LIMITED REMEDY STATED HEREIN. XENOGEN’S CUMULATIVE DIRECT DAMAGES TO DISTRIBUTOR FOR CLAIMS HEREUNDER SHALL BE LIMITED TO THE LESSER OF (i) FIVE
HUNDRED THOUSAND DOLLARS ($500,000); OR (ii) THE AMOUNTS PAID OR PAYABLE BY DISTRIBUTOR TO XENOGEN HEREUNDER IN THE TWELVE (12) MONTH PERIOD IMMEDIATELY PRIOR TO THE DATE SUCH CLAIM AROSE. 
  
 18. Indemnification 
  
 18.1 Xenogen Indemnity. Xenogen shall indemnify,
defend and hold Distributor, its Affiliates and their respective directors, officers, employees and agents (collectively the “Distributor Indemnitee(s)”) harmless from and against any and all liabilities, claims, demands, expenses
(including, without limitation, reasonable attorneys’ fees), losses or causes of action (each, a “Liability”) arising out of or relating to any third party claim of patent, trademark or copyright infringement due solely to
Distributor’s use, sale or distribution of the Licensed Products. The foregoing indemnification obligation will not apply to the extent such Liability is based on or caused by any of the following: 
  
 (a) Improper Use. Such Licensed Product is used
contrary to its Specifications, the Documentation, the End User Agreement or Xenogen’s reasonable instructions provided to Distributor. 
  
 (b) Unauthorized Combinations. Such Licensed Product is combined with or used in combination with any products, hardware, software,
materials or services not supplied or supported by Xenogen, or not authorized to be so combined or merged by Xenogen. 
  

 -22- 

 (c) Misuse. Modifications, alterations, changes or the like are made to such
Licensed Product by any person other than Xenogen or its authorized employees or agents, or such Licensed Product is tampered with or subjected to Misuse or unusual physical or electrical stress by any person. 
  
 (d) Unauthorized Marking. Any trademark infringements
involving any marking or branding not applied by or requested by Xenogen, or involving any marking or branding applied by Xenogen at the request of Distributor. 
  
 In addition, if a Liability subject to this Section 18.1 is found to be valid with respect to a Licensed
Product, or if Xenogen reasonably believes that the Licensed Product or any part thereof may be infringing on third party’s rights, Xenogen may, in its sole discretion: (i) modify the applicable Licensed Product to make it non-infringing; (ii)
procure for Distributor the right to continue reselling or distributing the applicable Licensed Product; or (iii) replace the applicable Licensed Product with a non-infringing Licensed Product or component thereof; or (iv) remove such Licensed
Project from the scope of Distributor’s rights hereunder, take back all unsold Distributor inventory and provide Distributor with a refund therefor. THE PROVISIONS OF THIS SECTION 18.1 SHALL BE XENOGEN’S SOLE LIABILITY AND
DISTRIBUTOR’S SOLE AND EXCLUSIVE REMEDY FOR ANY ALLEGED INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS BY THE LICENSED PRODUCTS. 
  
 18.2 Distributor’s Indemnity. Distributor shall indemnify each of Xenogen and its directors, officers, and employees and the
successors and assigns of any of the foregoing (each a “Xenogen Indemnitee”), and hold each Xenogen Indemnitee harmless from and against any Liability arising out of any claim, complaint, suit, proceeding or cause of action against a
Xenogen Indemnitee by a third party arising out of: (i) the use, marketing, sale or distribution of Licensed Products by Distributor or by third parties under authority of Distributor; (ii) Distributor’s willful or grossly negligent acts; (iii)
Distributor’s failure to notify Xenogen of material breaches by End Users of the End User Agreement, or cooperate with Xenogen regarding enforcement of such Agreements, as required under Section 10.5; (iv) Distributor’s breach of the
restrictions with respect to the Licensed Products and any of the licenses granted to Distributor hereunder; or (v) Distributor’s use of the Xenogen Imaging Technology or the Initial Systems (except for third party claims of patent, trademark
or copyright infringement relating solely to the Initial Systems). 
  
 18.3 Procedure. A Party (the “Indemnitee”) that intends to claim indemnification under this Article 18 shall promptly notify the other Party (the “Indemnitor”) in writing of
any claim, complaint, suit, proceeding, cause of action or other potential Liability in respect of which the Indemnitee intends to claim such indemnification (for purposes of this Section 18.3, each a “Claim”), and the Indemnitor
shall have sole control of the defense and/or settlement thereof; provided that the Indemnitee shall have the right to participate, at its own expense, with counsel of its own choosing in the defense and/or settlement of such Claim. The
indemnification under this Article 18 shall not apply to amounts paid with respect to settlement of any Claim if such settlement is effected without the consent of the Indemnitor, which consent will not be unreasonably withheld or delayed. The
failure to deliver written notice to the Indemnitor within a reasonable period of time after the commencement of any such claim, suit or proceeding, if prejudicial to its ability to defend such action, shall relieve such Indemnitor of any liability
to the Indemnitee under this Article 18, but 
  

 -23- 

 the failure to so timely deliver written notice to the Indemnitor shall not relieve the Indemnitor of any
liability to any Indemnitee otherwise than under this Article 18. Without limiting the foregoing, the Indemnitee shall keep the Indemnitor fully informed of the progress of any Claim for which it intends to claim indemnification under this Article
18. The Indemnitor shall not be responsible for any costs or expenses incurred by the Indemnitee without the Indemnitor’s prior written consent, which consent will not be unreasonably withheld. 
  
 19. Intellectual Property Rights. As between Distributor, the
End Users and Xenogen, Xenogen retains all right, title and interest in all Intellectual Property Rights embodied within the Licensed Products and improvements thereto, subject only to the limited use, distribution and resale rights explicitly
granted to Distributor herein. 
  
 20. Equitable
Relief. Distributor agrees that the infringement of Xenogen’s Intellectual Property Rights may cause irreparable injury. Accordingly, Distributor agrees that Xenogen shall be entitled to seek equitable relief, including such injunction
or injunctions as may be required to prevent any breach, infringement or further breach or infringement of any Intellectual Property provision herein or Intellectual Property Right of Xenogen and may specifically enforce such provisions or protect
such rights by an action instituted in any court having jurisdiction. Distributor acknowledges that damages will be an inadequate remedy for such a breach or infringement. Distributor covenants and agrees not to contest the availability to Xenogen
of such injunctive relief on any grounds to prevent such a breach or infringement, provided however that nothing herein shall prevent or prohibit Distributor from disputing the occurrence of such a breach or infringement, including the occurrence of
the default giving rise to the application for such injunctive relief, or from making submissions with respect to the amount and type of security to be posted by itself in connection with the grant of such injunctive relief. 
  
 21. Miscellaneous 
  
 21.1 Complete Agreement. This Agreement, including
the attached Exhibits, as amended or restated in writing, constitutes the entire agreement between the Parties with respect to the subject matter hereof and replaces any prior understandings, written or oral, express or implied and supercedes the
Letter of Intent between the Parties effective on November 11, 2002. This Agreement may not be modified except by a written instrument signed by both Parties. 
  

21.2 Conflicts. To the extent that this Agreement conflicts with or is inconsistent with any provision contained in any Purchase
Order or other document provided by Distributor to Xenogen, the provisions of this Agreement shall prevail. 
  
 21.3 Waiver. Failure by either Party to enforce any provision of this Agreement will not be deemed a waiver of that breach or a
waiver of future enforcement of that or any other provision. 
  
 21.4 Governing Law and Dispute Resolution. This Agreement shall be governed by the laws of the State of California and the United States without reference to conflict of laws principles. The U.N. Convention on
Contracts for the International Sale of Goods shall not apply to this Agreement. Except with respect to matters pertaining to injunctive relief, in the event of any 
  

 -24- 

 dispute, the Parties shall refer such dispute to the Chief Executive Officers of Xenogen and Distributor
(or their respective executive officer level designees) for attempted resolution by good faith negotiations within thirty (30) days after such referral is made. During such period of good faith negotiations, any applicable time periods under this
Agreement shall be tolled. In the event such executives are unable to resolve such dispute within such thirty (30) day period, the parties shall submit their dispute to binding arbitration held under the rules of the American Arbitration Association
then in effect and occurring in San Francisco, California by three arbitrators, with each of the Parties designating one (1) of the arbitrators and those two (2) arbitrators mutually agreeing on the third arbitrator, and provided that all such
arbitrators shall have experience in the field of the dispute. The Parties shall share equally the fees of the arbitrator, but each Party shall bear the costs of its own attorneys’ and experts’ fees; provided that the arbitrator may, in
its discretion award the prevailing Party all or part of the costs and expenses incurred by the prevailing Party in connection with the arbitration. Judgment upon the award may be entered in any court having jurisdiction, or application may be made
to such court for judicial acceptance of the award and/or an order of enforcement, as the case may be. No Party shall initiate arbitration hereunder unless it has attempted first to resolve the dispute by referral to the Chief Executive Officers of
the Parties as provided above. 
  
 21.5
Remedies Cumulative. Except as otherwise explicitly provided herein, each Party’s respective rights and remedies hereunder are cumulative and are in addition to any other rights or remedies provided hereunder or otherwise at law or in
equity. 
  
 21.6 Severability. If any
provision, or portion of any provision, contained in this Agreement is found by a court of competent jurisdiction to be invalid or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions, or portions
thereof, contained herein, shall not be in any way affected or impaired thereby. 
  
 21.7 Press Release. Within fifteen (15) days of the Effective Date (or such other date as the Parties may agree in writing), the
Parties shall agree upon and issue a joint press release: (i) announcing that the Parties have entered into this Agreement; (ii) generally describing the Parties’ relationship hereunder, including the general scope of this Agreement; and (iii)
indicating that Distributor is the “exclusive distributor” for Xenogen in the context of the Licensed Products for use by Local Customers in the Field and the Territory. 
  
 21.8 Publicity. Distributor agrees and acknowledges that Xenogen has the right to reasonably
reference, display, use and include Distributor’s name, trademarks, service marks, and logos in press releases, marketing brochures, prospectuses, advertisements, promotional materials, web pages, trade shows, customer demos and other
presentations and events, business plans and the like identifying Distributor as a Licensed Product distributor with a brief general description of the Parties’ relationship hereunder. 
  
 21.9 Notices. All notices under this Agreement shall
be in writing to respective address specified below, or such other address as may be specified in written notice to the other Party and will be deemed given: (a) when delivered personally; (b) when sent by confirmed telex or facsimile; (c) five (5)
days after having been sent by registered or certified mail, return receipt 
  

 -25- 

 requested; or (d) one (1) day after deposit with a commercial overnight carrier specifying next day
delivery, with written verification of receipt. 
  
  

			
	SCB:        	 	 Izumi Shiba-Daimon Bldg. 3F 2-2-11, Shiba-Daimon
 Minato-ku, Tokyo, 105-0012 Japan
 Attn: Mr. Junji Ozawa
 Telephone: 81-3-5777-6668
 Fax: 81-3-5777-6889

		
	Xenogen:	 	 Xenogen: Xenogen Corporation
 860 Atlantic
Avenue
 Alameda, CA 94501
 Attn: V.P., Commercial
Development

		
	Copy to:	 	 Xenogen Corporation
 860 Atlantic Avenue
 Alameda, CA 94501
 Attn: Legal Department
 Phone: 1-510-291-6251
 Fax: 1-510-291-6232

  
 21.10
No Third Party Beneficiaries. Unless otherwise expressly provided, no provisions of this Agreement are intended or shall be construed to confer upon or give to any person or entity other than Xenogen and Distributor any rights, remedies or
other benefits under or by reason of this Agreement. 
  
 21.11 Force Majeure. Failure of any Party to perform its obligations under this Agreement (except the obligation to make payments when properly due) shall not subject such Party to any liability or place them in breach of any term or
condition of this Agreement to the other Party if such failure is due to any cause beyond the reasonable control of such nonperforming Party (“force majeure”), unless conclusive evidence to the contrary is provided. Causes of
non-performance constituting force majeure shall include, without limitation, acts of God, fire, explosion, flood, drought, war, riot, sabotage, acts of terrorism, embargo, strikes or other labor trouble, failure in whole or in part of suppliers to
deliver on schedule materials, equipment or machinery, interruption of or delay in transportation, a national health emergency or compliance with any order or regulation of any government entity acting with color of right. The Party affected shall
promptly notify the other Party of the condition constituting force majeure as defined herein and shall exert reasonable efforts to eliminate, cure and overcome any such causes and to resume performance of its obligations with all possible speed;
provided that nothing herein shall obligate a Party to settle on terms unsatisfactory to such Party any strike, lockout or other labor difficulty, any investigation or other proceeding by any public authority or any litigation by any third party. If
a condition constituting force majeure as defined herein exists for more than ninety (90) consecutive days, the Parties shall meet to negotiate a mutually satisfactory resolution to the problem, if practicable. 
  
 21.12 Assignment. This Agreement shall not be
assignable by either Party without the written consent of the other Party; except that either Party may assign this Agreement, without 
  

 -26- 

 such consent, to an entity that acquires all or substantially all of the business or assets of such Party
whether by merger, reorganization, acquisition, sale, or otherwise; provided, however, that within thirty (30) days of such an assignment, the assignee shall agree in writing to be bound by the terms and conditions of this Agreement. No such
agreement in writing shall be required for an assignment that occurs by automatic operation of merger law, and the surviving entity shall be deemed to have agreed to be bound by the terms and conditions of this Agreement. Subject to the foregoing,
this Agreement will inure to the benefit of and be binding on the respective successors and permitted assigns of the Parties. 
  
 21.13 Interpretation. In this Agreement: (i) the division of this Agreement into separate articles, sections and subsections and
the Agreement’s title and the insertion of headings is for convenience of reference only and shall not affect the construction or interpretation of this Agreement; and (ii) words or abbreviations which have well known or trade meanings are used
herein in accordance with their recognized meanings. 
  
 21.14 Execution by Counterparts. This Agreement, Exhibits and any amendment, restatement or termination of any provision, may be executed and delivered in counterparts by facsimile, each of which so executed and delivered counterpart
is an original, and such counterparts, together, shall constitute but one and the same instrument. 
  
 IN WITNESS WHEREOF, Xenogen and Distributor, intending to be legally bound by the terms of this Agreement, have caused this Agreement to be executed by
their duly authorized representatives. 
  

									
	XENOGEN CORPORATION	 	 	 	SC BIOSCIENCES CORPORATION
					
	By:	 	 /s/    Paulette Dillon
	 	 	 	 By:
	 	 /s/    Junji Ozawa

	 	 	
	 	 	 	 	 	

					
	Name:	 	 Paulette Dillon
	 	 	 	 Name: 
	 	 Junji Ozawa

	 	 	
	 	 	 	 	 	

					
	Title:	 	 VP Commercial Development
	 	 	 	 Title:
	 	 Director of Marketing and Sales

	 	 	
	 	 	 	 	 	

					
	Date:	 	 January 27, 2003
	 	 	 	 Date:
	 	 January 27, 2003

	 	 	
	 	 	 	 	 	

  
  

 -27- 

 EXHIBIT A 
 DEFINITIONS 
  
 

 
  
 “Affiliate”
means any entity that is, directly or indirectly, is controlled by a Party. As used in this definition, the term “control” means possession, directly or indirectly, of power to direct or cause the direction of management or policies
through ownership of a majority of securities or other ownership interests in the entity. 
  
 “BiowareTM” is a Xenogen trademark that identifies certain prokaryotic or eukaryotic cells, bacteria and micro-organisms that are genetically engineered to produce light, and are owned or Controlled by Xenogen.

  
 “Control” or “Controlled”
means possession of the ability to grant a license or sublicense as provided for herein without violating the terms of any agreement or other arrangements with any third party. 
  
 “Documentation” means the set of documentation for a Licensed Product that: (i) Xenogen ships with that
Licensed Product; (ii) Xenogen provides to Distributor thereafter in connection with such Licensed Product; or (iii) that constitute versions of (ii) which Distributor has had translated into an appropriate local language for a country within the
Territory. 
  
 “Effective Date” means, with
respect to this Agreement as a whole, the date first set forth above. 
  
 “End User Agreement” means that certain agreement between Xenogen and an End User that sets forth the terms and conditions applicable to that End User’s use of certain Licensed Products (as identified in Exhibit B), as
set forth in Exhibits C-1 through C-4. 
  
 “End
User” means a Local Customer within the Territory that has purchased, Licensed Products from Distributor or Xenogen for its own internal use. 
  
 “Field” means pre-clinical use as a research instrument and/or reagent, specifically excluding diagnostic or therapeutic uses.

  
 “Imaging System” means Xenogen’s
IVISTM Series 100 Imaging System or IVISTM Series 50 Imaging System, consisting of the Equipment,
Software and associated Documentation. 
  
  

 A-1 

 “Initial System” means Xenogen’s IVISTM Series 100 Imaging System, associated Documentation and a specific set of accessories,
all as listed below: 
  

			
	 Component Name (per each Initial System)

	  	Part Designation

	 IVISTM 100 Series Imaging System
	  	 
	 Living Image® Software (includes 1 copy for image acquisition and 2 for independent image analysis)
	  	XLI-2.12
	 Work Station
	  	XW5-260
	 Gas Anesthesia System
	  	XGI-8
	 Reflective Hemisphere
	  	XRH-2
	 IVISTM Fluorescence Option (kit includes 1 pair of standard filters)
	  	XFO-6
	 Black Paper (includes 2 packages)
	  	XBP-24

  
 “Instrumentation” means the specific equipment provided by Xenogen as part of an Imaging System that constitutes a Licensed Product, as well as any hardware accessories that constitute Licensed Products. 
  
 “Intellectual Property” or “IP” means any
patents, patent rights, trademarks, service marks, designs, design rights, copyright, know-how, trade secrets, confidential information, moral rights and any other similar intellectual property and related rights recognized under the laws of each
applicable jurisdiction throughout the world including applications therefor and registrations thereof anywhere in the world; and “Intellectual Property Right” has a corresponding meaning. 
  
 “LPTA TM Animal Models” is a Xenogen trademark that identifies certain transgenic
laboratory animals that are genetically engineered to produce light, and are owned or Controlled by Xenogen. 
  
 “Licensed Product Literature” means the collateral marketing materials developed by Xenogen to promote and market the licensed Products
to prospective customers. 
  
 “Licensed Products”
means Xenogen’s Instrumentation (i.e. IVISTM
Imaging Systems and Accessories), Living Image® Software (the
“Software”), BiowareTM and
LPTATM animal models accompanied by a sublicense
under the Xenogen Imaging Technology. 
  
 “Local
Customers” means organizations headquartered in the Territory that seek to acquire one or more Licensed Products for delivery in the Territory and for use only in the Territory and the Field. Local Customers specifically excludes any
organization or entity with which Xenogen has an existing commercial relationship, including any affiliate of such organization or entity in the Territory, as identified in Appendix 1 to Exhibit B. 
  
 “Local Literature” means the collateral marketing materials
developed by Distributor or Licensed Product Literature translated by Distributor into a local language in the Territory to promote and market the Licensed Products to prospective customers in the Territory. 
  
 “Misuse” means, without limitation, (i) any use that is
inconsistent with, or in contradiction, to the instructions provided with a Licensed Product, (ii) intentional damage to or misuse of a Licensed Product, and (iii) damage due to negligence in connection with use of a Licensed Product. 
  
  

 A-2 

 “Product Services” means installation, End User training, support services and other
Licensed Product related services that are performed by Distributor with respect to Licensed Products. 
  
 “Return Merchandise Authorization Procedures” or “RMA Procedures” means Xenogen’s standard practices and procedures
for receiving and replacing Licensed Products as set forth in Section 5.6 and Exhibit E. 
  
 “Sales Agreement” means an agreement between Distributor and an End User, under which Distributor provides certain Licensed Products to such End User and which includes (or requires separate execution
of) an End User Agreement. 
  
 “Service Contract”
means the agreement between Distributor and an End User that sets forth the support obligations and related services that Distributor shall provide to such End User for an identified Imaging System, based on Xenogen’s form of Service and
Support Agreement attached as Exhibit F. 
  
 “Software” means the object code form of Xenogen’s Living Image® image processing and data analysis software intended for use with Imaging Systems, as well as updates and upgrades provided by Xenogen at its sole discretion, and Documentation related
thereto. 
  
 “Specifications” means, with respect
to Licensed Products, Xenogen’s published specifications for those Licensed Products in effect on the date such licensed Products are shipped. 
  
 “Term” means the period of time from the Effective Date set forth on the first page of this Agreement until the expiration or termination
of this Agreement. 
  
 “Territory” means Japan
and any other countries in Asia for which SCB exercises its Expansion Option. 
  
 “Versions” means, as the context requires, either: (i) major new releases of the Software, representing significant new functionality and designated by the number to the left of the decimal place
(e.g., Version 2.x, 3.x, etc) (“Major Version”); (ii) minor new releases, representing minor enhancements and/or feature upgrades for the existing content services or functionality and designated by the number to the right of the
decimal place (e.g., Version x.1, x.2, etc) (“Minor Version”); or (iii) an alpha-numeric version reflecting error corrections or bug fixes based on the latest/current code base and designated by the letter to the last number (e.g.,
Version x.x(a), x.x(b), etc) (“Patch Version”); or (iv) some combination of the foregoing, as the case requires. 
  
 “Xenogen Imaging Technology” means the patent applications JP97-519671 and JP2002-218983 for Japan and other patents and patent
applications (and any patents issuing thereon) in the Territory covering the practice of in vivo imaging now owned or acquired by Xenogen during the term of the Agreement, as well as divisions, continuations, and continuations-in-part (to the extent
it contains subject matter deriving a priority date from the original patent application), extensions, renewals, reissues and re-examinations of the foregoing patents (including patents issuing on the foregoing patent applications or resulting from
reissues or re-examinations) in the Territory. 
  

 A-3 

 “Xenogen Marks” means those certain trademarks, tradenames, and/or service marks adopted
for use and/or registered by Xenogen Corporation that are associated with the Licensed Products and are identified in Appendix 1 to this Exhibit. 
  

							
	 

	  	 Appendix 1
 Xenogen Marks
	  	 	  	 

  
 

 
  
 For PMS colors and sizing
information, or for high resolution versions of Xenogen marks for 4-color printing, please contact Erika Reynolds, Manager of Creative Services, Xenogen Corporation, 860 Atlantic Ave., Alameda, 94501. Phone 510.291.6285, e-mail:
erika.reynolds@xenogen.com 
  

					
	 

	  	 EXHIBIT B
  
 SCOPE OF DISTRIBUTORSHIP
	  	 

  
 The following sets
forth the range of Licensed Products that Distributor is entitled to resell and distribute, the Territory in which Distributor is entitled to resell and distribute those Licensed Products, the distributor discount that Xenogen will apply to its U.S.
list price to result in the transfer price that Distributor will pay Xenogen for purchase of the Licensed Products for sale or distribution in the Territory; and the U.S. list price for such Licensed Products. 
  

	 	•	Instrumentation 

  

								
	 	  	Part
Designation

	  	List Price
(US$)

	  	Distributor
Discount

	 Imaging Systems and Software
	  	 	  	 	 	  	 
	 IVISTM 100 Series‡
	  	 	  	$	195,000	  	***
	 IVISTM 50 Series‡
	  	 	  	$	123,500	  	***
	 Work Station Complete
	  	XWC-360	  	$	13,990	  	***
	 Living Image® Software‡
	  	XLI-2.12	  	$	499	  	***
				
	 Accessories
	  	 	  	 	 	  	 
	 Calibrated Light Source
	  	XLS-4	  	$	975	  	***
	 Gas Anesthesia System
	  	XGI-8	  	$	11,690	  	***
	 Anesthesia Manifold
	  	XAM-5	  	$	346	  	***
	 Anesthesia Manifold Nose Cones (set of 5)
	  	XNC-2	  	$	18	  	***
	 Manifold Dividers (set of 5)
	  	XMD-2	  	$	8	  	***
	 Anesthesia Filter
	  	XAF-8	  	$	24	  	***
	 System Cart
	  	XSC-1	  	$	747	  	***
	 Work Station
	  	XWS-260	  	$	2,951	  	***
	 Uninterruptible Power Supply (110V)
	  	XPS-110	  	$	1,301	  	***
	 UPS external battery (110V)
	  	XEB-110	  	$	798	  	***
	 Plate Positioner
	  	XPP-1	  	$	349	  	***
	 Reflective Hemisphere
	  	XRH-2	  	$	300	  	***
	 Black Paper
	  	XBP-24	  	$	15	  	***
	 Animal Shield Kit
	  	XAS-3	  	$	227	  	***
	 IVISTM Fluorescence Option (kit includes 1 pair of standard filters)
	  	XFO-6	  	$	35,000	  	***

	‡	Indicates that either a Commercial or a Non-Commercial Imaging End-User Agreement is required (see Exhibits C-1 and C-2). 

  
 *** Confidential treatment requested 
  

	 	o	Imaging Technology License Fee 

  

	 	§	Commercial Local Customer: *** of Xenogen’s net revenue from the license fee paid by the Commercial End User (see Exhibit C-1) to practice the Xenogen Imaging Technology.
Xenogen’s minimum net revenue for each Imaging Technology license fee is *** per month for the first year of such license and *** per month thereafter. For purposes of this fee, “net revenue” means and refers to the amount payable to
Xenogen after deduction of any applicable withholding taxes. 

  

	 	§	Non-Commercial Local Customer: Waived in consideration for stating the use of Xenogen Imaging Technology” and/or of IVISTM Imaging System (or named accessories)” in publications. 

 

	 	•	Biological Materials 

  

	 	o	BiowareTM‡‡: *** for one (1) year evaluation fee (plus shipping). *** initial
commercial access fee (plus shipping) for first year thereafter (or first year if no evaluation period entered into), with *** annual renewal fee per tumor cell line or bacterial strain. Execution of standard Xenogen material transfer form by Local
Customer required. Creation of custom cell lines or bacterial strains to be addressed on a case-by-case basis. 

  

	 	o	LPTA TM animal models‡‡‡: 

  

	 	§	*** per animal (no breeding rights) plus shipping. Execution of standard Xenogen material transfer form by Local Customer required. 

  

	 	§	*** initial access fee for three (3) breeding pairs (plus shipping), with *** annual renewal fee per model with breeding rights plus shipping. Execution of standard Xenogen material
transfer form by Local Customer required. 

  
 Creation of custom animal models to be addressed on a case-by-case basis. 

	‡‡	Indicates that an MTA for BiowareTM is required (see Exhibit C-3). 

	‡‡‡	Indicates that an MTA for LPTATM animal models is required (see Exhibit C-4). 

  
 *** Confidential treatment requested 

					
	 

	  	 Appendix 1
  
 Local Customer Exclusions
	  	 

  
 Novartis 
  
 GlaxoSmithKline 
  
 Roche (but not including Chugai Pharmaceuticals Co., Ltd.) 
  
 Merck and Co. (but not including Banyu Pharmaceutical Co.) 
  
 AstraZeneca 
  
 BristolMeyersSquibb 

 EXHIBIT C-1 
  

			
		
	

	  	NON-COMMERCIAL IMAGING LICENSE END USER AGREEMENT

  
 THIS NON-COMMERCIAL
IMAGING LICENSE END USER AGREEMENT (the “License”), between Xenogen of business at 860 Atlantic Avenue, Alameda, CA 94501 USA (“XENOGEN”) and
                                        
                                 ,with a principal place of business at
                                        
                                 (“INSTITUTION”) (each a “Party”
and collectively, the “Parties”), is entered into as of                              (the
“Effective Date”). 
  
 Background. INSTITUTION
desires to purchase, through XENOGEN’s authorized distributor, SC BioSciences Corporation (“DISTRIBUTOR”), an IVISTM Imaging System; and INSTITUTION desires to acquire, and XENOGEN agrees to grant to INSTITUTION, a limited license to XENOGEN’s in-vivo
bioluminescent imaging technology and Living Image® Software; under the terms of sale
agreed to between INSTITUTION and DISTRIBUTOR (such sale contract referred to as the “Sales Agreement”), and the following terms and conditions: 
  

	1.	Definitions. 

  
 1.1 The capitalized terms in this Agreement shall have the meanings ascribed to them in this Agreement or in the Sales Agreement. 
  
 1.2 “Affiliate” means an individual who is, with respect to
INSTITUTION, either: (i) an employee, currently enrolled student in good standing, a postdoctoral fellow or a research fellow; or (ii) a visiting scientist at INSTITUTION who is primarily employed by another academic or non-profit research
institution. It is understood that “Affiliate” shall not be construed to include individuals whose primary employment and/or responsibility is with a commercial or for-profit entity. 
  
 1.3 “Equipment” means the specific equipment described in
the Sales Agreement. 
  
 1.4 “imaging System”
means XENOGEN’s IVISTM Imaging System as
described in the Sales Agreement, consisting of the Equipment, Living Image® Software and
any related components delivered to and installed at INSTITUTION and purchased or licensed by INSTITUTION. 
  
 1.5 “Software” means the object code form of Xenogen’s Living Image® image processing and data analysis software included with the Imaging System, as well
as updates and upgrades provided by XENOGEN at its sole discretion, and documentation related thereto. 
  
 1.6 “Xenogen Imaging Technology” means the patent applications JP97-519671 and JP2002-218983 for Japan and other patents and patent
applications (and any patents issuing thereon) in the Territory covering the practice of in vivo imaging now owned or acquired by Xenogen during the term of the Agreement, as well as divisions, continuations, and continuations-in-part (to the

  

 C1-1 

 extent it contains subject matter deriving a priority date from the original patent application)
extensions, renewals, reissues and reexaminations of the foregoing patents (including patents issuing on the foregoing patent applications or resulting from reissues or re-examinations) in the Territory. 
  

	2.	Living Image® Software License and Restrictions. 

  
 2.1 License. XENOGEN hereby grants to INSTITUTION a non-exclusive, non-transferable license, without the right to sublicense, to use, store and display the Software with the practice of the Xenogen Imaging
Technology only in conjunction with (i) the Equipment at site authorized in the Sales Agreement, and (ii) up to five (5) desktop computers at such site for reasonable analysis of data obtained using the Imaging System. INSTITUTION may make copies of
the Software as necessary to exercise the rights granted herein, as well as an additional copy for backup purposes. Licenses for additional copies of the Software may be purchased from XENOGEN at its then-applicable retail price. 
  
 2.2 Restrictions. INSTITUTION may not load, run or operate the
Software other than in conjunction with the Equipment. INSTITUTION shall not pledge, lease, rent, distribute or share INSTITUTION’s rights under this License. INSTITUTION shall not alter the Software in any manner whatsoever, and INSTITUTION
agrees that it will not, without XENOGEN’s prior written consent, directly or indirectly, modify, make derivative works, or make any additional copies of the Software, except as expressly authorized in this Article 2. INSTITUTION further agrees
that it shall not, directly or indirectly, attempt to reverse engineer or decompile the Software or otherwise derive source code from the Software and shall not allow third parties to do so. INSTITUTION shall not make the Software available to any
other third party or provide services to third parties based on the Software without XENOGEN’s express written consent. INSTITUTION shall not cause or permit any combining of the Software with other computer program materials to form a
derivative work without XENOGEN’s express written permission, and in the event such permission has been granted, INSTITUTION shall, upon discontinuance or termination of this license, remove the Software from the derivative work and return it
to XENOGEN or, at XENOGEN’s option, destroy the Software and certify such destruction to XENOGEN. 
  
 2.3 Ownership. The copyright of the Software is, and shall remain owned, by XENOGEN. As between XENOGEN and INSTITUTION, title to and ownership of
the Software, and all copies thereof, as well as any improved, updated, modified or additional parts thereof, and all copyright, patent, trade secret, trademark and other intellectual property rights embodied in the Equipment, shall at all times
remain the property of XENOGEN. This License conveys only a limited right of use revocable in accordance with the terms of this License. 
  

	3.	License Fees. XENOGEN and INSTITUTION acknowledge that XENOGEN has received fair consideration for the license granted hereunder. use, both for itself and for its Affiliates,
Xenogen Imaging Technology solely with the Imaging System and solely for non-profit educational and non-commercial academic research purposes at the System Site. 

  

	4.	Disclaimer of Warranties. DISTRIBUTOR’S LIMITED WARRANTY SET FORTH IN THE SALES AGREEMENT IS THE EXCLUSIVE WARRANTY WITH RESPECT TO THE IMAGING SYSTEM. XENOGEN MAKES NO
OTHER WARRANTIES (EXPRESS, IMPLIED, 

  

 C1-2 

 STATUTORY OR OTHERWISE) WITH RESPECT TO THE IMAGING SYSTEM OR XENOGEN IMAGING TECHNOLOGY PROVIDED
HEREUNDER, AND SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE AND ALL WARRANTIES OF NON INFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. XENOGEN DOES NOT REPRESENT OR WARRANT
THAT THE EQUIPMENT OR SOFTWARE WILL BE FREE OF DEFECT, UNINTERRUPTED, ACCURATE, COMPLETE, CURRENT, STABLE, BUG-FREE, ERROR-FREE, OR AVAILABLE AT ANY TIME. 
  

	5.	Indemnification. XENOGEN SHALL NOT BE LIABLE FOR ANY USE OF THE IMAGING SYSTEM OR XENOGEN IMAGING TECHNOLOGY BY INSTITUTE, OR FOR ANY LOSS, CLAIM, DAMAGE, OR LIABILITY OF ANY
KIND, THAT MAY ARISE FROM OR IN CONNECTION WITH THE USE, HANDLING OR STORAGE OF THE IMAGING SYSTEM OR XENOGEN IMAGING TECHNOLOGY. NO INDEMNIFICATION FOR ANY LOSS, CLAIM, DAMAGE, OR LIABILITY IS INTENDED OR SHALL BE PROVIDED BY ANY PARTY UNDER THIS
AGREEMENT. IN NO EVENT SHALL XENOGEN HAVE ANY LIABILITY TO INSTITUTE FOR ANY CONSEQUENTIAL, INDIRECT, INCIDENTAL OR SPECIAL DAMAGES (INCLUDING LOST PROFITS, LOSS OF DATA, OR COST OF SUBSTITUTE GOODS OR SERVICES) REGARDLESS OF THE THEORY OF
LIABILITY, WHETHER BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE), OR OTHERWISE, AND REGARDLESS OF WHETHER INSTITUTE HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

  

	6.	Imaging License. 

  
 6.1 Non-Commercial Imaging License. As of the Installation Date, XENOGEN grants to INSTITUTION a non-exclusive, non-transferable, royalty-free
license, without the right to sublicense, (“Imaging License”) to use, both for itself and for its Affiliates, Xenogen Imaging Technology solely for non-profit educational and non-commercial academic research purposes at the System Site.

  
 6.2 No Implied Licenses. Only the licenses granted
pursuant to the express terms of Articles 2 and 6 shall be of any legal force or effect. No other license rights shall be granted or created by implication, estoppel or otherwise. Under no circumstances will an Imaging License be implied to any
individual who is not an Affiliate. 
  
 6.3 Limitations. In
the event that noncommercial academic research employing the Xenogen Imaging Technology is funded in whole or in part by a for-profit or commercial entity, INSTITUTION shall notify XENOGEN in writing of the identity of such for-profit or commercial
entity. INSTITUTION shall not use nor allow an Affiliate to use the Imaging System with the Xenogen Imaging Technology for fee-for-service or contract research and accordingly, shall not permit use (i) by any third party who is not an Affiliate, or
(ii) where any commercial or for-profit entity retains any ownership interest in data generated using the Imaging System with the Xenogen Imaging Technology, without the express prior written consent of XENOGEN. For the avoidance of doubt, an entity
is deemed to retain an ownership interest in any data where that entity has the right to block publication of the data for more than ninety (90) days after first learning of the data. 
  

 C1-3 

 6.4 Automatic Termination. Without limiting any other remedies that XENOGEN may have hereunder,
the licenses granted herein shall automatically terminate in the event that INSTITUTION sells or otherwise transfers the Equipment to a third party. 
  

	7.	Miscellaneous. 

  
 7.1 Waiver. No waiver of any rights, shall be effective unless consented to in writing by the Party to be charged and the waiver of any breach or
default shall not constitute a waiver of any other right hereunder or any subsequent breach or default. 
  
 7.2 Severability. In the event that any provisions of this License are determined to be invalid or unenforceable by a court of competent
jurisdiction, the remainder of the License shall remain in full force and effect without said provision. 
  
 7.3 Relationship of the Parties. Nothing in this License is intended or shall be deemed to constitute a license, partnership, agency,
employer-employee, or joint-venture relationship between the Parties. Except as specifically provided herein, neither INSTITUTION nor XENOGEN shall make any representations or commitments on behalf of the other. 
  
 7.4 Use of Name. With the exception of the following, neither Party
shall use the name or trademarks of the other Party without the prior written consent of such other Party. INSTITUTION agrees to acknowledge the use of XENOGEN’s Living Image® software, IVISTM Imaging System and Xenogen Imaging Technology in any publication or press release relating to data generated using the Software, Equipment or Xenogen
Imaging Technology, respectively. XENOGEN may use the INSTITUTION’s name in lists of laboratories/sites where XENOGEN’s imaging systems are installed. 
  

7.5 Assignment. INSTITUTION may not assign the rights and obligations of this License without the prior written consent of XENOGEN. Any transfer
or assignment not authorized hereunder will be null and void. Any permitted assignee shall assume all of the assignor’s obligations under this License. This License shall be binding upon, and inure to the benefit of, the Parties and their
permitted successors and assigns. 
  
 7.6 Entire License.
This License constitutes the entire and exclusive agreement between the Parties with respect to the subject matter hereof and supercedes and cancels all terms in any purchase order relating to the subject matter hereof, and supercedes and cancels
all previous discussions, agreements, commitments and writings in respect thereof. No amendment or addition to this License shall be effective unless reduced to writing and executed by the authorized representatives of the Parties. 
  
 7.7 Compliance with Laws. In exercising its rights under the Imaging
License, INSTITUTION shall fully comply in all material respects with the requirements of any and all applicable laws, rules, regulations and orders of any governmental body having jurisdiction over the exercise of rights under this License.

  

 C1-4 

	

 7.8 Governing Law; Venue. This License and any dispute, including without limitation
any arbitration, arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with the laws of the state of California, without reference to conflicts of laws principles. The exclusive venue of any
dispute arising out of or in connection with the performance or breach of this License shall be the U.S. district court for the Northern District of California, and the Parties hereby consent to the exclusive and personal jurisdiction of such courts
for the purposes of this License and this Section 7.8. In the event that such jurisdiction is rejected by such district court, the Parties agree to binding arbitration held under the rules of the American Arbitration Association then in effect, in
the English language and occurring in San Francisco, California by a mutually agreeable arbitrator with experience in the field of the dispute. The Parties shall share equally the fees of the arbitrator, but each Party shall bear the costs of its
own attorneys’ and experts’ fees; provided that the arbitrator may, in its discretion award the prevailing Party all or part of the costs and expenses incurred by the prevailing Party in connection with the arbitration. Judgment upon the
award may be entered in any court having jurisdiction, or application may be made to such court for judicial acceptance of the award and/or an order of enforcement, as the case may be. 
  
 7.9 Headings. The captions to the several Sections and Articles hereof are not a part of this License, but are
included merely for convenience of and shall not affect its meaning or interpretation. 
  
 7.10 Counterparts. This License may be executed in two counterparts, each of which shall be deemed an original and which together will constitute one instrument. 
  
 7.11 Notices. All notices, requests and other communications hereunder
shall be in writing and shall be (i) personally delivered, (ii) sent by electronic facsimile transmission or (iii) sent by registered or certified mail, return receipt requested, postage prepaid, in each case to the respective address specified
below, or such other address as may be specified in writing to the other Party: 
  
 Xenogen Corporation 
 860 Atlantic Avenue 
 Alameda, CA 94501 USA 
 Attn: Legal Department 
 Fax: (510) 291-6232 
  
 [INSTITUTION] 
 [                        ] 
 [                        ] 
 [                        ] 
  
 Any notice shall be deemed to have been given on the date of delivery in (i), the business day of delivery in (ii) and five
(5) business days after transmission in (iii). 
  

 C1-5 

 8. Termination. 
  
 8.1 Termination for Cause. XENOGEN may terminate this License in the event INSTITUTION has materially breached or defaulted in the performance of
any of its obligations hereunder, and such default has continued for thirty (30) days after providing written notice thereof to INSTITUTION. Termination will become effective at the end of such thirty (30) say period unless INSTITUTION has cured any
such breach or default prior to the expiration of such period. 
  
 8.2 Termination without Cause. INSTITUTION may terminate this License for any reason upon thirty (30) days written notice to XENOGEN. 
  
 8.3 Effect of Termination. Upon the termination of this License for any reason: (a) INSTITUTION shall have no further right to use the Software and
Xenogen Imaging Technology; and (b) all licenses granted by XENOGEN to INSTITUTION will be terminated; (c) all rights and obligations of the parties under this License shall be discharged, except that Articles 1, 5, 7 and 8 and Sections 2.2 and 2.3
shall survive any termination hereof; and (d) INSTITUTION shall return to XENOGEN the Software provided to INSTITUTION under this License within thirty (30) days of the termination of this License. INSTITUTION shall ship the Software, at its
expense, F.O.B. XENOGEN’s facility at the address specified in Section 7.11. 
  
 8.4 Accrued Rights and Obligations. Termination of this License for any reason shall not release any Party hereto from any liability which, at the time of such termination, has already accrued to the other
Party or which is attributable to a period prior to such termination nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any breach of this License. 
  

 C1-6 

 IN WITNESS WHEREOF, INSTITUTION and XENOGEN hereby execute this License by their duly authorized
representatives. 
  
 INSTITUTION 
  

			
		
	Signed:	 	 
	 	 	

		
	Name:	 	 
	 	 	

		
	Title:	 	 
	 	 	

		
	 	 	 
	 	 	

  
 XENOGEN CORPORATION 
  

			
		
	Signed:	 	 
	 	 	

		
	Name:	 	 
	 	 	

		
	 	 	 
	 	 	

		
	 	 	 
	 	 	

  
  
  

 C1-7 

 EXHIBIT C-2 

			
	 

	  	 COMMERCIAL IMAGING LICENSE END USER AGREEMENT

  
 THIS COMMERCIAL
IMAGING LICENSE END USER AGREEMENT (the “License”), between Xenogen of business at 860 Atlantic Avenue, Alameda, CA 94501 USA (“XENOGEN”) and
                                
                                , with a principal place of business at
                                
                         (“COMPANY”) (each a “Party” and collectively, the “Parties”), is
entered into as of                          (the “Effective Date”). 
  
 Background. COMPANY desires to purchase, through XENOGEN’s
authorized distributor, SC BioSciences Corporation (“DISTRIBUTOR”), an IVISTM Imaging System; and COMPANY desires to acquire, and XENOGEN agrees to grant to COMPANY, a limited license to XENOGEN’s in-vivo imaging technology and Living Image® Software; under the terms of sale agreed to between COMPANY and DISTRIBUTOR (such sale contract referred to as the
“Sales Agreement”), and the following terms and conditions. 
  
 1.
Definitions. 
  
 1.1 The capitalized terms in this
Agreement shall have the meanings ascribed to them in this Agreement or in the Sales Agreement. 
  
 1.2 “Affiliate” means any corporation, firm, partnership or other legal entity which, directly or indirectly, controls, is controlled by
or is under common control with a Party. For the purposes of this definition only, “control” shall mean (i) the direct or indirect ownership of fifty percent (50%) or more of the outstanding voting securities or capital stock of such
entity, or (ii) such other relationship as in fact results in actual control over the management, business and affairs of such entity. 
  
 1.3 “Authorized Site” means COMPANY’s designated research facility(ies) where the System(s) will be installed and used, located at
[                            ]. COMPANY may designate an alternate/additional Authorized Site in
accordance with the terms of this Agreement. 
  
 1.4
“Control” or “Controlled” means possession of the ability to grant a license or sublicense as provided for herein without violating the terms of any agreement or other arrangements with any third party. 

 
 1.5 “Equipment” means the specific equipment described in
the Sales Agreement. 
  
 1.6 “Field” means
internal pharmaceutical preclinical research in the therapeutic area of [                        ], but excluding Third
Party Research. 
  

 C2-1 

 1.7 “Imaging System” means XENOGEN’s IVISTM Imaging System as described in the Sales Agreement, consisting of the Equipment,
Living Image® Software and any related components delivered to and installed at COMPANY
and purchased or licensed by COMPANY. 
  
 1.8
“Installation Date” shall have the meaning set forth in the Sales Agreement. 
  
 1.9 “Software” means the object code form of Xenogen’s Living Image® image processing and data analysis software included with the Imaging System, as well as updates and upgrades provided by XENOGEN at its sole
discretion, and documentation related thereto. 
  
 1.10
“Strategic Alliance” means an agreement between COMPANY and a third party that establishes a collaboration, joint venture, corporate partnership or other similar type of strategic alliance between COMPANY and such third party
involving collaborative research and development in a specified field of interest to the parties, and where such collaborative research includes access to and use of material COMPANY technology and intellectual property other than the Xenogen
Imaging Technology, and in which COMPANY contributes substantial scientific effort, and under which COMPANY has been granted or retains proprietary rights for significant intellectual property generated under the work conducted pursuant to such
agreement. For clarity, it is acknowledged that the term “Strategic Alliance” does not cover Third Party Research or other arrangements between COMPANY and a third party under which COMPANY only performs contract services for such third
party on a fee for service basis, where COMPANY provides such third party the data or other information resulting from such service and COMPANY retains no material rights in any such data or information. 
  
 1.11 “Term” means the term of this License as set forth in
Section 9.1. 
  
 1.12 “Third Party Research”
means research conducted by COMPANY in support of any relationship or agreement between COMPANY and a for-profit, third-party entity and for which COMPANY does not retain, or is not granted, proprietary rights for significant intellectual property
generated under the work conducted pursuant to such relationship or agreement. 
  
 1.13 “Xenogen Imaging Technology” means the patent applications JP97-519671 and JP2002-218983 for Japan and other patents and patent applications (and any patents issuing thereon) in the Territory
covering the practice of in vivo imaging now owned or acquired by Xenogen during the term of the Agreement, as well as divisions, continuations, and continuations-in-part (to the extent it contains subject matter deriving a priority date from
the original patent application), extensions, renewals, reissues and reexaminations of the foregoing patents (including patents issuing on the foregoing patent applications or resulting from reissues or re-examinations) in the Territory. 

 
 2. Living Image® Software License and Restrictions. 
  
 2.1 License. XENOGEN hereby grants to COMPANY a non-exclusive, non-transferable license, without the right to
sublicense, to use, store and display the Software solely in connection with the practice of the Xenogen Imaging Technology only in conjunction with (i) the Imaging System at the Authorized Site, and (ii) up to five (5) desktop computers at such
site for reasonable analysis of data obtained using the Imaging System. COMPANY may make copies of the Software 
  

 C2-2 

 as necessary to exercise the rights granted herein, as well as an additional copy for backup purposes. During the Term,
licenses for additional copies of the Software may be purchased from DISTRIBUTOR at its then-applicable retail price. 
  
 2.2 Restrictions. COMPANY may not load, run or operate the Software other than in conjunction with the Equipment. COMPANY shall not pledge, lease,
rent, distribute or share COMPANY’s rights under this license. COMPANY shall not alter the Software in any manner whatsoever, and COMPANY agrees that it will not, without XENOGEN’s prior written consent, directly or indirectly, modify,
make derivative works, or make any additional copies of the Software, except as expressly authorized in this Article 2. COMPANY further agrees that it shall not, directly or indirectly, attempt to reverse engineer or decompile the Software or
otherwise derive source code from the Software and shall not allow third parties to do so. COMPANY shall not make the Software available to any other third party or provide services to third parties based on the Software without XENOGEN’s
express written consent. COMPANY shall not cause or permit any combining of the Software with other computer program materials to form a derivative work without XENOGEN’s express written permission, and in the event such permission has been
granted, COMPANY shall, upon discontinuance or termination of this license, remove the Software from the derivative work and return it to XENOGEN or, at XENOGEN’s option, destroy the Software and certify such destruction to XENOGEN. 

 
 2.3 Ownership. The copyright of the Software is, and shall remain
owned, by XENOGEN. As between XENOGEN and COMPANY, title to and ownership of the Software, and all copies thereof, as well as any improved, updated, modified or additional parts thereof, and all copyright, patent, trade secret, trademark and other
intellectual property rights embodied in the Software, shall at all times remain the property of XENOGEN. This License conveys only a limited right of use revocable in accordance with the terms of this License. 
  
 3. License Fees.
[                                        ]

  
 4. Representations and Warranties. 
  
 4.1 Representations and Warranties by the Parties. Each of COMPANY and
XENOGEN hereby represents and warrants to the other Party that: 
  
 (a) it is a corporation duly organized and validly existing under the laws of the state or other jurisdiction of its incorporation; 
  
 (b) the execution, delivery and performance of this Agreement by such Party has been duly authorized by all
requisite corporate action; 
  
 (c) it has the
power and authority to execute and deliver this Agreement and to perform its obligations hereunder; 
  
 (d) the execution, delivery and performance by such Party of this Agreement and its compliance with the terms and provisions hereof does
not and will not conflict with or result in a breach of any of the terms and provisions of or constitute a default under (i) a loan agreement, 
  

 C2-3 

 guaranty, financing agreement, agreement affecting a product or other agreement or instrument binding or
affecting it or its property; (ii) the provisions of its corporate charter or other operative documents or bylaws; or (iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which any of its
property is bound; 
  
 (e) this Agreement has
been duly authorized, executed and delivered and constitutes such Party’s legal, valid and binding obligation enforceable against it in accordance with its terms subject, as to enforcement, to bankruptcy, insolvency, reorganization and other
laws of general applicability relating to or affecting creditors’ rights and to the availability of particular remedies under general equity principles; and 
  
 (f) it shall comply with all applicable laws, rules and regulations relating to the performance of its
activities under this Agreement. 
  
 4.2 No Inconsistent
Agreements. Neither Party has in effect, and after the Effective Date neither Party shall enter into, any oral or written agreement or arrangement that would be inconsistent with its obligations under this Agreement. 
  
 4.3 Disclaimer of All Other Warranties. DISTRIBUTOR’S LIMITED
WARRANTY SET FORTH IN THE SALES AGREEMENT IS THE EXCLUSIVE WARRANTY WITH RESPECT TO THE IMAGING SYSTEM. XENOGEN MAKES NO OTHER WARRANTIES (EXPRESS, IMPLIED, STATUTORY OR OTHERWISE) WITH RESPECT TO THE IMAGING SYSTEM OR XENOGEN IMAGING TECHNOLOGY,
AND SPECIFICALLY DISCLAIMS ANY AND All IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE AND All WARRANTIES OF NONINFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. XENOGEN DOES NOT REPRESENT OR WARRANT THAT THE
EQUIPMENT OR SOFTWARE WILL BE FREE OF DEFECT, UNINTERRUPTED, ACCURATE, COMPLETE, CURRENT, STABLE, BUG-FREE, ERROR-FREE, OR AVAILABLE AT ANY TIME. 
  
 5. Indemnification and Limitation of Liability. 
  
 5.1 Indemnification by COMPANY. COMPANY shall indemnify, defend and hold XENOGEN and its directors, officers, employees and agents and the Trustees
of Leland Stanford Jr. University (“Stanford”), Stanford Health Services and their respective trustees, officers, employees, students and agents (collectively the “Xenogen Indemnitee(s)”) harmless from and against any and all
liabilities, claims, demands, expenses (including, without limitation, reasonable attorneys’ fees), losses or causes of action (each, a “Liability”) arising out of or relating to COMPANY’s use of the Xenogen Imaging Technology or
the Imaging System (except for third party claims of patent, trademark or copyright infringement relating solely to the Imaging System), or (ii) a material breach of this Agreement by COMPANY. Notwithstanding the foregoing, COMPANY shall have no
indemnification obligation under this Section 5.1 to the extent that such Liability is caused by the gross negligence or willful misconduct of XENOGEN. 
  
 5.2 Indemnification by XENOGEN. XENOGEN shall indemnify, defend and hold COMPANY and its directors, officers, employees and agents (collectively
the “Company 
  

 C2-4 

 Indemnitee(s)”) harmless from and against any and all Liabilities arising out of or relating to any third party
claim of patent, trademark or copyright infringement due solely to COMPANY’s use of the Imaging System (except to the extent such third party claim would not have arisen but for COMPANY’s use of the Imaging System with processes or
materials not provided by XENOGEN hereunder). In addition, XENOGEN shall indemnify and hold COMPANY harmless from and against any Liabilities arising at any time in connection with XENOGEN’s use of any COMPANY images (except that XENOGEN shall
have no indemnification obligation under this Section 5.2 for Liabilities arising out of or relating to any third party claim of copyright infringement in connection with XENOGEN’s use of any COMPANY images in the event that COMPANY approves
the use of such images by Xenogen pursuant to Section 7.3 but fails to identify such images as being subject to a third party copyright). Notwithstanding the foregoing, XENOGEN shall have no indemnification obligation under this Section 5.2 to the
extent that such Liability is caused by the gross negligence or willful misconduct of COMPANY. If the Software is, or in the opinion of XENOGEN may become, the subject of any claim for infringement then XENOGEN shall, at its option and expense,
either (a) procure for COMPANY the right to use the Software, or (b) replace or modify the Software with other suitable and reasonably equivalent products so that the Software becomes non-infringing, or (c) if (a) and (b) are not practicable, as
determined in XENOGEN’s sole discretion, terminate COMPANY’s license with respect to such Software and refund a pro rata and proportional portion of the license fees paid based on use of the Software. 
  
 5.3 Procedure. A Party (the “Indemnitee”) that intends to
claim indemnification under this Article 5 shall promptly notify the other Party (the “Indemnitor”) in writing of any claim, complaint, suit, proceeding, cause of action or other potential Liability in respect of which the Indemnitee
intends to claim such indemnification (for purposes of this Section 5.3, each a “Claim”), and the Indemnitor shall have sole control of the defense and/or settlement thereof; provided that the Indemnitee shall have the right to
participate, at its own expense, with counsel of its own choosing in the defense and/or settlement of such Claim. The indemnification under this Article 5 shall not apply to amounts paid with respect to settlement of any Claim if such settlement is
effected without the consent of the Indemnitor, which consent will not be unreasonably withheld or delayed. The failure to deliver written notice to the Indemnitor within a reasonable period of time after the commencement of any such claim, suit or
proceeding, if prejudicial to its ability to defend such action, shall relieve such Indemnitor of any liability to the Indemnitee under this Article 5, but the omission to so deliver written notice to the Indemnitor shall not relieve the Indemnitor
of any liability to any Indemnitee otherwise than under this Article 5. Without limiting the foregoing, the Indemnitee shall keep the Indemnitor fully informed of the progress of any Claim for which it intends to claim indemnification under this
Article 5. The Indemnitor shall not be responsible for any costs or expenses incurred by the Indemnitee without the Indemnitor’s prior written consent, which consent will not be unreasonably withheld. 
  
 5.4 EXCEPT FOR XENOGEN’S INDEMNIFICATION OBLIGATIONS UNDER THIS ARTICLE
5, XENOGEN SHALL NOT BE LIABLE FOR ANY USE OF THE IMAGING SYSTEM OR XENOGEN IMAGING TECHNOLOGY BY COMPANY, OR FOR ANY LOSS, CLAIM, DAMAGE, OR LIABILITY OF ANY KIND, THAT MAY ARISE FROM OR IN CONNECTION WITH THE USE, HANDLING OR STORAGE OF THE
IMAGING SYSTEM OR XENOGEN IMAGING TECHNOLOGY. NO INDEMNIFICATION FOR ANY LOSS, CLAIM, 
  

 C2-5 

 DAMAGE, OR LIABILITY IS INTENDED OR SHALL BE PROVIDED BY ANY PARTY UNDER THIS AGREEMENT. IN NO EVENT SHALL XENOGEN HAVE
ANY LIABILITY TO COMPANY FOR ANY CONSEQUENTIAL, INDIRECT, INCIDENTAL OR SPECIAL DAMAGES (INCLUDING LOST PROFITS, LOSS OF DATA, OR COST OF SUBSTITUTE GOODS OR SERVICES) REGARDLESS OF THE THEORY OF LIABILITY, WHETHER BASED ON CONTRACT, TORT (INCLUDING
NEGLIGENCE), OR OTHERWISE, AND REGARDLESS OF WHETHER COMPANY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 
  
 6. Imaging License. 
  
 6.1 Non-Commercial Imaging License. As of the Installation Date, XENOGEN grants to COMPANY and Affiliates a non-exclusive, non-transferable,
royalty-free license, without the right to sublicense, (“Imaging License”) to use Xenogen Imaging Technology solely within the Field at the Authorized Site. 
  
 6.2 No Implied Licenses. Only the licenses granted pursuant to the express terms of Sections 2.1 and 6.1 shall be of
any legal force or effect. No other license rights shall be granted or created by implication, estoppel or otherwise. 
  
 6.3 Limitations. The licenses granted in Sections 2.1 and 6.1 are only for use at the Authorized Site(s). Use at other geographic locations
requires negotiation of a separate agreement with Xenogen. COMPANY may not exercise the licenses granted herein in support of any relationship or agreement with a third-party, commercial entity, including Third Party Research or in connection with
Strategic Alliances. No other license or rights shall be deemed granted or created by implication, estoppel or otherwise. 
  
 6.4 Automatic Termination. Without limiting any other remedies that XENOGEN may have hereunder, the licenses granted herein shall automatically
terminate in the event that COMPANY sells or otherwise transfers the Equipment to a third party. 
  
 7. Intellectual Property Rights. 
  
 7.1 Ownership of Inventions. The Parties acknowledge and agree that ownership of all inventions, discoveries and innovations (including any patent applications, patents or other intellectual property rights arising directly related
thereto) arising hereunder by COMPANY (hereinafter “Inventions”) shall be determined as follows: 
  
 (a) XENOGEN Intellectual Property. XENOGEN shall be the sole and exclusive owner of any Invention to the extent related to the
Imaging System or the Xenogen Imaging Technology. COMPANY hereby assigns all its title to and interest in any and all such inventions to XENOGEN, and upon request and at XENOGEN’s expense, agrees to reasonably cooperate with XENOGEN to enable
XENOGEN to perfect its interest in any and all such Inventions. 
  
 (b) COMPANY Intellectual Property. COMPANY shall be the sole and exclusive owner of any Invention to the extent related to any subject matter other than the Imaging 
  

 C2-6 

 System or Xenogen Imaging Technology. XENOGEN hereby assigns all its title to and interest in any and all
such inventions to COMPANY, and upon request and at COMPANY’s expense, agrees to reasonably cooperate with COMPANY to enable COMPANY to perfect its interest in any and all such Inventions. 
  
 7.2 Patent Prosecution. Each Party shall be responsible, at its own
expense for the preparation, filing, prosecution, maintenance, enforcement or defense of any patent applications or patents claiming Inventions owned by it pursuant to Section 7.1. Nothing herein shall be construed as granting to either Party any
license or other rights with respect to any Inventions, or any patent applications or patents directed thereto, which are owned by the other Party pursuant to Section 7.1. Inventorship shall be determined in accordance with U.S. patent law.

  
 7.3 Publications. In accordance with scientific
custom, the contribution of each Party will be expressly noted in all written or oral public disclosures, by acknowledgment or co-authorship, as appropriate. In the event that either Party publishes such results in the scientific literature,
acknowledgment will be made to the other Party and its personnel in the accepted style consistent with customary scientific practices, as appropriate. COMPANY agrees to provide XENOGEN with a copy of any publications or presentations by COMPANY
referencing the Xenogen Imaging Technology or present images taken using the Xenogen Imaging Technology at least forty-five (45) days prior to submission to a publisher or presentation to any third party. Thereafter, XENOGEN may use such materials
in its own presentations regarding the efficacy of Xenogen Imaging Technology. 
  

	8.	Miscellaneous. 

  
 8.1 Audits. During the Term of this Agreement and thereafter, XENOGEN shall have the right to audit or have audited, by an independent public
accountant designated by XENOGEN and reasonably acceptable to COMPANY, no more than once in each calendar year during the term of this Agreement and no more than twice during the three (3) calendar years following the expiration or termination of
this Agreement, COMPANY’s books and records with at least fifteen (15) business days prior written notice and at COMPANY’s normal business hours for the purpose of verifying compliance with the terms of this Agreement. XENOGEN shall bear
the cost of such audits. All information learned in the course of any such audit(s), excluding amounts due to XENOGEN, shall be considered Confidential Information and shall be subject to confidentiality obligations of this Agreement. Moreover,
COMPANY agrees that XENOGEN shall have the right, from time to time, to review electronic image files produced by COMPANY using the Imaging System, in order to insure proper use of the Xenogen Imaging Technology and any Imaging System with which it
is used, as well as compliance with the license granted herein. 
  
 8.2 Waiver. No waiver of any rights, shall be effective unless consented to in writing by the Party to be charged and the waiver of any breach or default shall not constitute a waiver of any other right hereunder or any subsequent
breach or default. 
  
 8.3 Severability. In the event that
any provisions of this License are determined to be invalid or unenforceable by a court of competent jurisdiction, the remainder of the License shall remain in full force and effect without said provision. 
  

 C2-7 

 8.4 Relationship of the Parties. Nothing in this License is intended or shall be deemed to
constitute a license, partnership, agency, employer-employee, or joint-venture relationship between the Parties. Except as specifically provided herein, neither COMPANY nor XENOGEN shall make any representations or commitments on behalf of the
other. 
  
 8.5 Use of Name. With the exception of the
following, neither Party shall use the name or trademarks of the other Party without the prior written consent of such other Party. COMPANY agrees to acknowledge the use of XENOGEN’s Living Image® software, IVISTM Imaging System and Xenogen Imaging Technology in any publication or press release relating to data generated using the
Software, Equipment or Xenogen Imaging Technology, respectively. XENOGEN may use the COMPANY’s name in lists of laboratories/sites where XENOGEN’s imaging systems are installed. 
  
 8.6 Assignment. COMPANY may not assign the rights and obligations of this License without the prior written consent
of XENOGEN. Any transfer or assignment not authorized hereunder will be null and void. Any permitted assignee shall assume all of the assignor’s obligations under this License. This License shall be binding upon, and inure to the benefit of,
the Parties and their permitted successors and assigns. 
  
 8.7
Entire License. This License constitutes the entire and exclusive agreement between the Parties with respect to the subject matter hereof and supercedes and cancels all terms in any purchase order relating to the subject matter hereof, and
supercedes and cancels all previous discussions, agreements, commitments and writings in respect thereof. No amendment or addition to this License shall be effective unless reduced to writing and executed by the authorized representatives of the
Parties. 
  
 8.8 Compliance with Laws. In exercising its
rights under this License, COMPANY shall fully comply in all material respects with the requirements of any and all applicable laws, rules, regulations and orders of any governmental body having jurisdiction over the exercise of rights under this
License. 
  
 8.9 Governing Law; Venue. This License and any
dispute, including without limitation any arbitration, arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with the laws of the state of California, without reference to conflicts of laws
principles. The exclusive venue of any dispute arising out of or in connection with the performance or breach of this License shall be the U.S. district court for the Northern District of California, and the Parties hereby consent to the exclusive
and personal jurisdiction of such courts for the purposes of this License and this Section 8.9. In the event that such jurisdiction is rejected by such district court, the Parties agree to binding arbitration held under the rules of the American
Arbitration Association then in effect, in the English language and occurring in San Francisco, California by a mutually agreeable arbitrator with experience in the field of the dispute. The Parties shall share equally the fees of the arbitrator,
but each Party shall bear the costs of its own attorneys’ and experts’ fees; provided that the arbitrator may, in its discretion award the prevailing Party all or part of the costs and expenses incurred by the prevailing Party in
connection with the arbitration. Judgment upon the award may be entered in any court having jurisdiction, or application may be made to such court for judicial acceptance of the award and/or an order of enforcement, as the case may be. 

 

 C2-8 

 made to such court for judicial acceptance of the award and/or an order of enforcement, as the case may be. 

 
 8.10 Headings. The captions to the several Sections and Articles
hereof are not a part of this License, but are included merely for convenience of and shall not affect its meaning or interpretation. 
  
 8.11 Counterparts. This License may be executed in two counterparts, each of which shall be deemed an original and which together will constitute
one instrument. 
  
 8.12 Notices. All notices, requests and
other communications hereunder shall be in writing and shall be (i) personally delivered, (ii) sent by electronic facsimile transmission or (iii) sent by registered or certified mail, return receipt requested, postage prepaid, in each case to the
respective address specified below, or such other address as may be specified in writing to the other Party: 
  
 Xenogen Corporation 
 860 Atlantic Avenue 
 Alameda, CA 94501 USA 
 Attn: Legal Department 
 Fax: (510) 291-6232 
  
 [COMPANY] 
 [                    ] 
 [                    ] 
 [                    ]

  
 Any notice shall be deemed to have been given on the date of
delivery in (i), the business day of delivery in (ii) and five (5) business days after transmission in (iii). 
  
 9. Termination. 
  
 9.1
Term. This License will commence on the Installation Date and, unless terminated earlier as provided in this Article 9, will expire      years after such Date (the “Term”). 
  
 9.2 Termination for Cause. XENOGEN may terminate this License in the
event COMPANY has materially breached or defaulted in the performance of any of its obligations hereunder, and such default has continued for thirty (30) days after providing written notice thereof to COMPANY. Termination will become effective at
the end of such thirty (30) day period unless COMPANY has cured any such breach or default prior to the expiration of such period. 
  
 9.3 Termination without Cause. COMPANY may terminate this License for any reason upon thirty (30) days written notice to XENOGEN. 
  
 9.4 Effect of Termination. Upon the termination of this License for
any reason: (a) COMPANY shall have no further right to use the Software and Xenogen Imaging Technology; 
  

 C2-9 

 and (b) all licenses granted by XENOGEN to COMPANY will be terminated; (c) all rights and obligations of the parties
under this License shall be discharged, except that Articles 1, 5, 7 and 8 and Sections 2.3, 4.3, 6.2, 9.4 and 9.5 shall survive any termination hereof; and (d) COMPANY shall return to XENOGEN the Software provided to COMPANY under this License
within thirty (30) days of the termination of this License. COMPANY shall ship the Software, at its expense, F.O.B. XENOGEN’s facility at the address specified in Section 8.11. 
  
 9.5 Accrued Rights and Obligations. Termination of this License for any reason shall not release any Party hereto
from any liability which, at the time of such termination, has already accrued to the other Party or which is attributable to a period prior to such termination nor preclude either Party from pursuing any rights and remedies it may have hereunder or
at law or in equity with respect to any breach of this License. 
  
 IN WITNESS WHEREOF, COMPANY and XENOGEN hereby execute this License by their duly authorized representatives. 
  

			
	 COMPANY

		
	 Signed:
  
	 	  

	 	 	  

	 Title:
  
	 	  

	 Date:
  
	 	  

  

			
	 XENOGEN CORPORATION

		
	 Signed:
  
	 	  

	 Name:
  
	 	  

	 	 	  

	 	 	  

  

 C2-10 

 EXHIBIT C-3 

			
	

	  	BiowareTM MATERIAL TRANSFER AGREEMENT

  
 This Agreement is made
as of [                ], 2003 (the “Effective Date”) by and between Xenogen Corporation, having a principal place of business at 860 Atlantic Avenue,
Alameda, California 94501 (“XENOGEN”) and [                ], having a principal place of business at
[                ], (“RECIPIENT”) (each a “Party” and collectively, the “Parties”). 
  
 BACKGROUND 
  
 A. XENOGEN has expertise in the development and detection of living cells or
organisms that have the property of bioluminescence, and owns or has proprietary rights relating thereto. 
  
 B. RECIPIENT wishes to obtain access to certain bioluminescent living cells or organisms, owned or controlled by XENOGEN (and marketed under the trademark
BiowareTM), for use in the discovery and/or
preclinical development of therapeutic products. 
  
 NOW,
therefore, the Parties agree as follows: 
  
 1. Materials.

  
 1.1 Transfer and Use. XENOGEN shall
transfer to RECIPIENT the BiowareTM living
cell/strain lines listed on Exhibit A attached hereto in the quantities specified in Appendix A (the “Materials”) for use by RECIPIENT solely in internal drug discovery and/or preclinical drug development research. XENOGEN will transfer
the Materials to RECIPIENT as soon as practicable following the Effective Date. As used herein, the term “Materials” includes the original materials transferred to RECIPIENT, as well as any Derivatives, Progeny, or improvements thereof. As
used herein, the term “Progeny” shall mean and refer to both unmodified descendents and modified descendents of the Materials that occur as a result of a naturally occurring mutation or other spontaneous process. The term
“Derivative” shall mean a substance that is directly or indirectly derived from the Materials or any Progeny thereof, including, without limitation, a product expressed by or generated from the Materials or Progeny. For the avoidance of
doubt, a “Derivative” shall not include any pharmaceutical products (or any predecessor substances of such products) of RECIPIENT even if Materials are utilized in studies by RECIPIENT to evaluate such pharmaceutical product; provided that
such pharmaceutical product does not contain any substance or material obtained from the Materials. 
  
 1.2 Care in Use of Materials. RECIPIENT acknowledges that the Materials are experimental in nature and may have unknown
characteristics. RECIPIENT therefore agrees to use prudence and all reasonable care in the use, handling, storage, transportation and disposition and containment of the Materials, and to maintain the Materials under suitable containment conditions
in compliance with all applicable national, state and local laws, regulations, rules and ordinances. 
  

 C-3-1 

 2. Consideration and Tax Responsibility. 
  
 2.1 Consideration. In consideration for delivery of
the Materials and the bailment(s) provided to RECIPIENT herein for the first year after the date of delivery, RECIPIENT shall pay to XENOGEN a non-refundable access fee (“Initial Fee”) of
[            ] dollars ($            ), according to the itemized schedule in Exhibit A. This Initial Fee is due
within ten (10) days after delivery of the Materials. Thereafter, unless RECIPIENT terminates this Agreement pursuant to Section 11.2, RECIPIENT shall pay to XENOGEN a non-refundable annual fee of
[            ] dollars ($            ), according to the itemized schedule in Exhibit A (“Subsequent
Fee”) in consideration for continued access to, and use of, the Materials for a Subsequent Year (as defined in Section 11.1) below. RECIPIENT understands and acknowledges that the Initial and Subsequent Fees apply only to RECIPIENT’s use
of the Materials at the Authorized Site described in Section 4.3, and that any transfer of the Materials requires XENOGEN’s express written consent and a separate, fee-bearing agreement. 
  
 2.2 Tax Responsibility. RECIPIENT shall pay or
reimburse XENOGEN as appropriate for any sales tax, use tax, excise tax, withholding tax, customs duty (including any applicable V.A.T. tax) or other tax imposed or levied with respect to the payment of the Fee by RECIPIENT. In no event shall
RECIPIENT be responsible for any tax imposed upon XENOGEN based upon XENOGEN’s income or for the privilege of doing business. 
  
 3. Ownership; Bailment. RECIPIENT agrees that, as between the Parties, the Materials and all Derivatives, Progeny and/or variants thereof are and
shall be owned and/or controlled exclusively by Xenogen, and that this Agreement creates a bailment by RECIPIENT with respect to any and all such Materials, Derivatives, Progeny and/or variants thereof. RECIPIENT agrees that all intellectual
property rights relating to the Materials (including, but not limited to, those rights concerning the composition, methods of production, or uses, of the Materials) are and shall continue to be owned and/or controlled exclusively by XENOGEN.
However, RECIPIENT shall exclusively own any invention made by RECIPIENT using the Materials but which relates to subject matter other than the Materials (which includes, but is not limited to, the composition, methods of production, or uses, of the
Materials). 
  
 4. Limitations on Use. 
  
 4.1 No Human Use. RECIPIENT shall not use the
Materials for any human in vivo use whatsoever, or for any human in vitro diagnostic or therapeutic applications. 
  
 4.2 No Transfer to Third Parties. RECIPIENT shall not transfer the Materials to any person who is not under the immediate and
direct employment of RECIPIENT. 
  
 4.3
Authorized Site. The Materials are provided to RECIPIENT for use solely at the Authorized Site listed in Appendix B hereto. RECIPIENT shall not transfer the Materials to any place other than Recipient’s facilities at the Authorized Site.

  
 4.4 No Contract Research. RECIPIENT
shall not use the Materials in the performance of or in conjunction with, any contract research service for a third party. 
  

 C3-2 

 4.5 No Modification. RECIPIENT shall not attempt to alter or modify the Materials
in any way without the further prior written consent of XENOGEN, or attempt, directly or indirectly, to re-engineer the Materials, or extract or transfer any genetic material from the Materials to another organism. 
  
 5. Warranty. 
  
 5.1 Disclaimer of Warranties. EXCEPT AS EXPRESSLY
STATED IN SECTION 5.2 BELOW, THE MATERIALS ARE PROVIDED “AS-IS” AND XENOGEN MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES, EXPRESS OR IMPLIED WITH RESPECT TO THE MATERIALS, AND EXPRESSLY DISCLAIMS ANY WARRANTY OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE. XENOGEN DISCLAIMS ANY WARRANTY THAT THE MATERIALS OR THE USE THEREOF Will NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT OF ANY THIRD PARTY. 
  
 5.2 Limited Replacement. To the extent the Materials are not living or fail to exhibit any
luminescent properties upon delivery to RECIPIENT, and RECIPIENT notifies XENOGEN thereof within seven (7) days after receipt of the Materials, XENOGEN shall provide replacement Materials to RECIPIENT. The foregoing constitutes RECIPIENT’s sole
remedy for dissatisfaction with the Materials or failure of the Materials to perform in accordance with XENOGEN’s specifications of the Materials existing at the time of delivery. 
  
 6. Indemnification. 
  
 6.1 Indemnification of XENOGEN. RECIPIENT agrees to indemnify, defend and hold XENOGEN and its directors, officers, employees and
agents (the “Indemnitee(s)”) harmless from and against any and all liabilities, claims, demands, expenses (including, without limitation, attorneys and professional fees and other costs of litigation), losses or causes of action (each, a
“liability”) arising out of or relating in any way to RECIPIENT’s possession, propagation or use of the Materials, whether based on negligence, product liability or otherwise, or any breach of this Agreement by RECIPIENT, except to
the extent, in each case, that such Liability is caused by infringement of a third party intellectual property right by the Materials or by the gross negligence or willful misconduct by XENOGEN as determined by a court of competent jurisdiction.
Notwithstanding the above, RECIPIENT shall not enter into any settlement or other agreement which makes any admission of negligence or wrongdoing on the part of any Indemnitee without the prior written consent of XENOGEN. 
  
 6.2 Indemnification of RECIPIENT. XENOGEN, at its
expense, shall indemnify, defend and hold RECIPIENT and its directors, officers, employees and agents (the “RECIPIENT Indemnitee(s)”) harmless from and against all liabilities, claims, demands and expenses (including without limitation
reasonable attorneys’ fees and other costs of litigation) of any action, suit or proceeding brought against RECIPIENT which alleges that any Material infringes any copyright, patent or any intellectual property right or other proprietary right
of any third party. Notwithstanding the foregoing, XENOGEN shall have no liability for any infringement or claim thereof based upon: (a) the combination of the Materials with products not provided by XENOGEN; (b) modification or alteration of the
Materials by any person or entity other than XENOGEN; or 
  

 C3-3 

 (c) uses of the Materials with products or processes not provided by Xenogen. XENOGEN may, at its sole
option and at its expense, either: (i) replace or modify the Materials to make it non-infringing without material impairment of its functionality; (ii) require RECIPIENT to remove and return to XENOGEN the Materials involved and refund RECIPIENT a
portion of the fee thereof; or (iii) obtain for RECIPIENT the right to continue using the Materials. THIS SECTION STATES XENOGEN’S SOLE LIABILITY, AND RECIPIENT’S SOLE REMEDY, HEREUNDER WITH RESPECT TO INFRINGEMENT OF ANY INTELLECTUAL
PROPERTY AND PROPRIETARY RIGHTS AS DESCRIBED HEREIN. 
  
 7.
Licenses. 
  
 7.1 Imaging License.
RECIPIENT agrees to secure and maintain (via a separate agreement with Xenogen) an Imaging License in force so long as the Materials are being used for applications covered by one or more claims in U.S. Patent Nos. 5,650,135, 6,217,847 and
continuations, continuations-in-part, divisionals, and foreign counterparts thereof (including patent applications JP97-519671 and JP2002-218983 in Japan). An “Imaging License” is a license from Xenogen under U.S. Patent No. 5,650,135 and
6,217,847 and any continuations, continuations-in-part, divisionals, and foreign counterparts thereof (including patent applications JP97-519671 and JP2002-218983 in Japan). 
  
 7.2 No Implied License. Only the bailment granted pursuant to the express terms of this Agreement
shall be of any legal force or effect. No other license rights shall be granted or created by implication, estoppel or otherwise. (including patent applications JP97-519671 and JP2002-218983 in Japan) shall retain all right, title and interest in
and to its Confidential Information and the Materials. 
  
 8.
Confidentiality. 
  
 8.1 Confidential
Information. All oral and/or written communications either received by Recipient from Xenogen and relating to the Materials, or received by XENOGEN and relating to the means and results of Recipient’s use of the Materials, are, and shall
remain, proprietary and confidential information of either XENOGEN or RECIPIENT, respectively (“Confidential Information”). Except as expressly provided herein, the Parties agree that, for the term of this Agreement and for three (3) years
thereafter, the receiving Party shall keep completely confidential and shall not publish or otherwise disclose and shall not use for any purpose except for the purposes contemplated by this Agreement any Confidential Information furnished to it by
the disclosing Party hereto. Confidential Information, if disclosed in written or graphic form must be marked as “Confidential” at the time of disclosure, and if disclosed orally, must be expressly identified as “Confidential” at
the time of oral disclosure, and be confirmed as “Confidential” in a written or tangible form that is delivered to the receiving Party within thirty (30) days of oral disclosure. Each Party acknowledges that the Confidential Information of
the other Party constitutes highly valuable, proprietary information that is not publicly available. To the extent that it can be established by the receiving Party by competent written evidence, Confidential Information shall not include
information that: 
  
 (a) was already known to
the receiving Party, other than under an obligation of confidentiality, at the time of disclosure; 
  

 C3-4 

 (b) was generally available to the public or otherwise part of the public domain at the
time of its disclosure to the receiving Party; 
  
 (c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 
  
 (d) was subsequently lawfully disclosed to the receiving
Party by a person other than a Party; or 
  
 (e)
was independently developed without reference to or the use of information provided by the disclosing Party. 
  
 8.2 Permitted Use and Disclosures. Each Party may use or disclose information disclosed to it by the other Party to the extent such
use or disclosure is reasonably necessary in complying with applicable law, legal process or governmental regulations, or exercising its rights hereunder, provided that if a Party is required to make any such disclosure of the other Party’s
Confidential Information, other than pursuant to a confidentiality agreement, give reasonable advance notice to the other Party of such disclosure and, will provide such Party with an opportunity to secure confidential treatment of such information
prior to its disclosure (whether through protective orders or otherwise), and thereafter the Party making the disclosure shall disclose only the minimum information required to be disclosed in order to comply, whether or not a protective order or
other similar order is obtained. 
  
 8.3
Confidential Terms. Except as expressly provided herein, each Party agrees not to disclose any terms of this Agreement to any third party without the consent of the other Party; provided, disclosures may be made to actual or prospective
corporate partners or investors, or to a Party’s accountants, attorneys and other professional advisors under appropriate conditions of confidentiality. 
  
 9. Intellectual Property. 
  
 9.1 Inventions. If RECIPIENT’s use of the Materials hereunder results in an invention or discovery, including a new use,
improvement, or enhancement of the Materials, whether patentable or not, (“Invention”) RECIPIENT shall promptly disclose such Invention to XENOGEN. XENOGEN shall retain (or be assigned by RECIPIENT) all intellectual property rights in, and
title to, any Invention, and RECIPIENT shall retain title to any patent or other intellectual property rights in and to any or other invention, discovery, or commercially useful result. 
  
 9.2 No Blocking. RECIPIENT agrees not to assert any patent or other proprietary right obtained as a
result of any use of the Materials that interferes with any manufacture, offer for sale, sale or use of the Materials (or any product made using the Materials or XENOGEN’s Confidential Information) by XENOGEN or any customer or affiliate of
XENOGEN. RECIPIENT 
  

 C3-5 

 agrees that such non-assertion of rights shall run with all licenses, sublicenses and assignments of
RECIPIENT’s rights in any invention hereunder. 
  
 10. No
Conflicts. Each of RECIPIENT and XENOGEN represents and warrants that it is authorized to enter into this Agreement and that no other contract or obligation conflicts with the obligations to be assumed by it under this Agreement. 
  
 11. Term and Termination. 
  
 11.1 This Agreement will commence on the Effective Date and,
unless terminated earlier as provided in this Article 11, will expire four (4) years after the delivery of the Materials (the ‘Term”). Beginning on the first anniversary of the delivery date of the Materials, each one (1) year period
thereafter is referred to as a “Subsequent Year.” 
  
 11.2 Termination without Cause. Not later than ten (10) days prior to each anniversary of the delivery date of the Materials, RECIPIENT may terminate this Agreement without cause, effective upon such
anniversary by written notice to XENOGEN, and, in such event, no Subsequent Fee shall be due for the remaining Subsequent Years of this Agreement. 
  
 11.3 Termination for Cause. Either Party may terminate this Agreement in the event the other Party has materially breached or
defaulted in the performance of any of its obligations hereunder, and such default has continued for thirty (30) days after written notice thereof was provided to the breaching Party by the non-breaching Party. Any termination shall become effective
at the end of such thirty (30) day period unless the breaching Party has cured any such breach or default prior to the expiration of such period. Notwithstanding the above, in the case of a failure to pay any amount due hereunder the period for cure
of any such default following notice thereof shall be ten (10) days and, unless payment is made within such period, the termination shall become effective at the end of such ten day period. 
  
 11.4 Effects of Termination. Termination of this
Agreement for any reason shall not release either Party from any liability which, at the time of such termination, has already accrued to the other Party or which is attributable to a period prior to such termination nor preclude either Party from
pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement. Upon the expiration or termination of this Agreement for any reason: (a) RECIPIENT shall have no further right to use
Materials; and (b) RECIPIENT shall promptly return (to the extent such return is technically feasible) to Xenogen or destroy the Materials, including all Derivatives and Progeny thereof, and all Confidential Information disclosed to RECIPIENT by
XENOGEN hereunder. Expiration or termination of this Agreement shall discharge all rights and obligations of the Parties hereunder, except that Sections 3,5.1,6,7.2,8.1-8.3,9.1,9.2,11.4 and 16 shall survive any termination hereof. 
  
 12. Relationship of the Parties. Nothing in this Agreement is intended
or shall be deemed to constitute a license, partnership, agency, employer-employee, or joint-venture relationship between the Parties. Except as specifically provided herein, neither Party shall make any representations or commitments on behalf of
the other. 
  

 C3-6 

 13. Amendments; Notice. This Agreement may not be amended or modified except by a written
agreement signed by the Parties. Any notice required hereunder shall be in writing and mailed via certified mail, return receipt requested, courier, or facsimile transmission addressed to those addresses indicated at the beginning of this Agreement,
or to such other address as may be designated from time to time. Notices shall be deemed given as of the date received at the specified address. In the case of XENOGEN, such notices should be sent to the attention of “Legal Department.”

  
 14. Assignability. The Parties’ rights and
obligations will bind and inure to the benefit of their respective successors, heirs, executors and administrators and permitted assigns. The rights and obligations of Recipient under this Agreement shall not be assignable without the prior written
consent of XENOGEN. Any attempted transfer or assignment in violation of this Section 14 shall be void. 
  
 15. Severability. If any provision of this Agreement is or becomes invalid or is ruled invalid by any court of competent jurisdiction or is deemed
unenforceable, it is the intention of the Parties that the remainder of the Agreement shall not be affected so long as the essential benefits of this Agreement remain enforceable and obtainable. 
  
 16. Governing Law. This Agreement and any dispute, including without
limitation arbitration, arising from the performance or breach hereof, shall be governed by and construed in accordance with the laws of the State of California without regard for conflict of laws principles. The exclusive venue of any dispute
arising out of or in connection with the performance or breach of this Agreement shall be the U.S. district court for the Northern District of California. Each of the Parties expressly consents to personal jurisdiction in the State of California
with respect to such action, cause of action, or dispute. Each Party irrevocably and unconditionally waives any objection to the jurisdiction and venue required in this Section 16, and agrees not to plead or claim in any such court that any such
suit, action, or proceeding has been brought in an inconvenient forum. The Parties further agree that service of process accomplished by the methods specified for notices in Section 13 shall be deemed good and sufficient service of process in the
State of California. In the event that such jurisdiction is rejected by such district court, the Parties agree to binding arbitration held under the rules of the American Arbitration Association then in effect, in the English language and occurring
in San Francisco, California by a mutually agreeable arbitrator with experience in the field of the dispute. The Parties shall share equally the fees of the arbitrator, but each Party shall bear the costs of its own attorneys’ and experts’
fees; provided that the arbitrator may, in its discretion award the prevailing Party all or part of the costs and expenses incurred by the prevailing Party in connection with the arbitration. Judgment upon the award may be entered in any court
having jurisdiction, or application may be made to such court for judicial acceptance of the award and/or an order of enforcement, as the case may be. 
  
 17. Integration. This Agreement, including the Exhibits hereto, shall constitute the entire agreement between the Parties and shall supersede all
other agreements, whether written or oral, relating to the subject matter hereof. 
  

 C3-7 

 IN WITNESS WHEREOF, the Parties have, by duly authorized persons, executed this Agreement, as of the date
first above written. 
  

									
	XENOGEN CORPORATION	 	 	 	RECIPIENT
					
	Signed:.	 	 	 	 	 	 Signed:
	 	 
	 	 	
	 	 	 	 	 	

	 Name:
	 	 	 	 	 	 Name:
	 	 
	 	 	
	 	 	 	 	 	

	 Title:
	 	 	 	 	 	 Title:
	 	 
	 	 	
	 	 	 	 	 	

	 Date:
	 	 	 	 	 	 Date:
	 	 
	 	 	
	 	 	 	 	 	

  

 C3-8 

 APPENDIX A 
  

Description of Materials 
  

					
	 Xenogen BiowareTM

	  	Access Fee

	  	Subsequent Fee

	 [_____] [2 vials or Petri plates for strains]
	  	 	  	 
	 [_____] [1 vial for cell lines]
	  	 	  	 

 APPENDIX B 
  

Authorized Site 

			
	

	  	EXHIBIT C-4
	  	LPTATM ANIMAL MODEL MTA (END USER AGREEMENT)

  
 This Agreement is made
as of [            ], 2003 (the “Effective Date”) by and between Xenogen Corporation, having a principal place of business at 860 Atlantic Avenue, Alameda, California 94501
(“XENOGEN”) and [            ], having a principal place of business at [            ]
(“RECIPIENT”) (each a “Party” and collectively, the “Parties”). 
  
 BACKGROUND 
  
 A. XENOGEN has
expertise in the development and detection of living cells or organisms that have the property of bioluminescence, and owns or has proprietary rights relating thereto. 
  
 B. RECIPIENT wishes to obtain certain bioluminescent transgenic animals, owned or controlled by XENOGEN (and marketed under
the trademark LPTATM), for use in the discovery
and/or preclinical development of therapeutic products. 
  
 NOW,
therefore, the Parties agree as follows: 
  
 1. Materials.

  
 1.1 Transfer and Use. XENOGEN shall
transfer to RECIPIENT a quantity of the specific LPTATM transgenic animals model listed on Exhibit A attached hereto (the “Materials”) for use by RECIPIENT solely in internal drug discovery and/or preclinical drug development research. XENOGEN will transfer the
Materials to RECIPIENT as soon as practicable following the Effective Date. As used herein, the term “Materials” includes the original materials transferred to RECIPIENT, as well as any Derivatives or improvements thereof. As used herein,
the term “Derivative” shall mean a substance that is directly or indirectly derived from the Materials, including, without limitation, a product expressed by or generated from the Materials. For the avoidance of doubt, a
“Derivative” shall not include any pharmaceutical products (or any predecessor substances of such products) of RECIPIENT even if Materials are utilized in studies by RECIPIENT to evaluate such pharmaceutical product; provided that such
pharmaceutical product does not contain any substance or material obtained from the Materials. 
  
 1.2 Care in Use of Materials. RECIPIENT acknowledges that the Materials are experimental in nature and may have unknown
characteristics. RECIPIENT therefore agrees to use prudence and all reasonable care in the use, handling, storage, transportation and disposition and containment of the Materials, and to maintain the Materials under suitable containment conditions
in compliance with all applicable national, state and local laws, regulations, rules and ordinances. 
  

 C4-1 

 2. Consideration and Tax Responsibility. 
  
 2.1 Consideration. In consideration for delivery of
the Materials and the bailment(s) provided to RECIPIENT herein for the Materials, RECIPIENT shall pay to XENOGEN a non-refundable access fee (“Fee”) of [            ] U.S.
dollars (US$            ), according to the itemized schedule in Exhibit A. This Fee is due within ten (10) days after delivery of the Materials. RECIPIENT understands and
acknowledges that the Fee applies only to RECIPIENT’s use of the Materials at the Authorized Site described in Section 4.3, and that any transfer of the Materials requires XENOGEN’s express written consent and a separate, fee-bearing
agreement. 
  
 2.2 Tax Responsibility.
RECIPIENT shall pay or reimburse XENOGEN as appropriate for any sales tax, use tax, excise tax, withholding tax, customs duty (including any applicable V.A.T. tax) or other tax imposed or levied with respect to the payment of the Fee by RECIPIENT.
In no event shall RECIPIENT be responsible for any tax imposed upon XENOGEN based upon XENOGEN’s income or for the privilege of doing business. 
  
 3. Ownership; Bailment. RECIPIENT agrees that, as between the Parties, the Materials and all Derivatives and/or variants thereof are and shall be
owned and/or controlled exclusively by XENOGEN, and that this Agreement creates a bailment by RECIPIENT with respect to any and all such Materials, Derivatives and/or variants thereof. RECIPIENT agrees that all intellectual property rights relating
to the Materials (including, but not limited to, those rights concerning the composition, methods of production, or uses, of the Materials) are and shall continue to be owned and/or controlled exclusively by XENOGEN. However and as further provided
In Section 9.1, RECIPIENT shall exclusively own any invention made by RECIPIENT using the Materials but which relates to subject matter other than the Materials (which includes, but is not limited to, the composition, methods of production, or uses,
of the Materials). 
  
 4. Limitations on Use. 

 
 4.1 No Human Use. RECIPIENT shall not use the
Materials for any human in vivo use whatsoever or for any human in vitro diagnostic or therapeutic applications. 
  
 4.2 No Transfer to Third Parties. RECIPIENT shall not transfer the Materials to any person who is not under the immediate and
direct employment of RECIPIENT. 
  
 4.3
Authorized Site. The Materials are provided to RECIPIENT for use solely at the Authorized Site listed in Exhibit B hereto. RECIPIENT shall not transfer the Materials to any place other than RECIPIENT’s facilities at the Authorized Site.

  
 4.4 No Contract Research. RECIPIENT
shall not use the Materials in the performance of or in conjunction with, any contract research service for a third party. 
  
 4.5 No Modification or Breeding. RECIPIENT shall not attempt to breed, create any progeny of, alter or modify the Materials in any
way without the further prior written consent of XENOGEN, or attempt, directly or indirectly, to re-engineer the Materials, or extract or transfer any genetic material from the Materials to another organism. 
  

 C4-2 

 5. Warranty. 
  
 5.1 Disclaimer of Warranties. EXCEPT AS EXPRESSLY STATED IN SECTION 5.2 BELOW, THE MATERIALS ARE PROVIDED “AS-IS” AND
XENOGEN MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES, EXPRESS OR IMPLIED WITH RESPECT TO THE MATERIALS, AND EXPRESSLY DISCLAIMS ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. XENOGEN DISCLAIMS ANY WARRANTY THAT THE
MATERIALS OR THE USE THEREOF Will NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT OF ANY THIRD PARTY. 
  
 5.2 Limited Replacement. To the extent the Materials are not living or fail to exhibit any luminescent properties upon delivery to
RECIPIENT, and RECIPIENT notifies XENOGEN thereof within seven (7) days after receipt of the Materials, XENOGEN shall provide replacement Materials to RECIPIENT. The foregoing constitutes RECIPIENT’s sole remedy for dissatisfaction with the
Materials or failure of the Materials to perform in accordance with XENOGEN’s specifications of the Materials existing at the time of delivery. 
  
 6. Indemnification 
  
 6.1 Indemnification of XENOGEN. RECIPIENT agrees to indemnify, defend and hold XENOGEN and its directors, officers, employees and
agents (the “Indemnitee(s)”) harmless from and against any and all liabilities, claims, demands, expenses (including, without limitation, attorneys and professional fees and other costs of litigation), losses or causes of action (each, a
“Liability”) arising out of or relating in any way to RECIPIENT’s possession, propagation or use of the Materials, whether based on negligence, product liability or otherwise, or any breach of this Agreement by RECIPIENT, except to
the extent, in each case, that such Liability is caused by infringement of a third party intellectual property right by the Materials or by the gross negligence or willful misconduct by XENOGEN as determined by a court of competent jurisdiction.
Notwithstanding the above, RECIPIENT shall not enter into any settlement or other agreement which makes any admission of negligence or wrongdoing on the part of any Indemnitee without the prior written consent of XENOGEN. 
  
 6.2 Indemnification of RECIPIENT. XENOGEN, at its
expense, shall indemnify, defend and hold RECIPIENT and its directors, officers, employees and agents (the “RECIPIENT Indemnitee(s)”) harmless from and against all liabilities, claims, demands and expenses (including without limitation
reasonable attorneys’ fees and other costs of litigation) of any action, suit or proceeding brought against RECIPIENT which alleges that any Material infringes any copyright, patent or any intellectual property right or other proprietary right
of any third party. Notwithstanding the foregoing, XENOGEN shall have no liability for any infringement or claim thereof based upon: (a) the combination of the Materials with products not provided by XENOGEN; (b) modification or alteration of the
Materials by any person or entity other than XENOGEN; or (c) uses of the Materials with products or processes not provided by Xenogen. XENOGEN may, at its sole option and at its expense, either: (i) replace or modify the Materials to make it
non-infringing without material impairment of its functionality; (ii) require RECIPIENT to remove and return to XENOGEN the Materials involved and refund RECIPIENT a portion of the fee thereof; or (iii) obtain for RECIPIENT the right to continue
using the Materials. THIS SECTION STATES 
  

 C4-3 

 XENOGEN’S SOLE LIABILITY, AND RECIPIENT’S SOLE REMEDY, HEREUNDER WITH RESPECT TO INFRINGEMENT OF ANY
INTELLECTUAL PROPERTY AND PROPRIETARY RIGHTS AS DESCRIBED HEREIN. 
  
 7. Licenses. 
  
 7.1 Imaging
License. RECIPIENT agrees to secure and maintain (via a separate agreement with XENOGEN) an Imaging License in force so long as the Materials are being used for applications covered by one or more claims in U.S. Patent Nos. 5,650,135, 6,217,847
and continuations, continuations-in-part, divisionals, and foreign counterparts thereof (including patent applications JP97-519671 and JP2002-218983 in Japan). An “Imaging License” is a license from XENOGEN under U.S. Patent No. 5,650,135
and 6,217,847 and any continuations, continuations-in-part, divisionals, and foreign counterparts thereof (including patent applications JP97-519671 and JP2002-218983 in Japan). 
  
 7.2 No Implied License. Only the bailment granted pursuant to the express terms of this Agreement
shall be of any legal force or effect. No other license rights shall be granted or created by implication, estoppel or otherwise. XENOGEN shall retain all right, title and interest in and to its Confidential Information and the Materials.

  
 8. Confidentiality. 
  
 8.1 Confidential Information. All oral and/or written
communications either received by RECIPIENT from XENOGEN and relating to the Materials, or received by XENOGEN and relating to the means and results of RECIPIENT’s use of the Materials, are, and shall remain, proprietary and confidential
information of either XENOGEN or RECIPIENT, respectively (“Confidential Information”). Except as expressly provided herein, the Parties agree that, for the term of this Agreement and for three (3) years thereafter, the receiving Party
shall keep completely confidential and shall not publish or otherwise disclose and shall not use for any purpose except for the purposes contemplated by this Agreement any Confidential Information furnished to it by the disclosing Party hereto.
Confidential Information, if disclosed in written or graphic form must be marked as “Confidential” at the time of disclosure, and if disclosed orally, must be expressly identified as “Confidential” at the time of oral disclosure,
and be confirmed as “Confidential” in a written or tangible form that is delivered to the receiving Party within thirty (30) days of oral disclosure. Each Party acknowledges that the Confidential Information of the other Party constitutes
highly valuable, proprietary information that is not publicly available. To the extent that it can be established by the receiving Party by competent written evidence, Confidential Information shall not include information that: 
  
 (a) was already known to the receiving Party, other than
under an obligation of confidentiality, at the time of disclosure; 
  
 (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party; 
  

 C4-4 

 (c) became generally available to the public or otherwise part of the public domain after
its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 
  
 (d) was subsequently lawfully disclosed to the receiving Party by a person other than a Party; or 
  
 (e) was independently developed without reference to or the
use of information provided by the disclosing Party. 
  
 8.2 Permitted Use and Disclosures. Each Party may use or disclose information disclosed to it by the other Party to the extent such use or disclosure is reasonably necessary in complying with applicable law, legal process or
governmental regulations, or exercising its rights hereunder, provided that if a Party is required to make any such disclosure of the other Party’s Confidential Information, other than pursuant to a confidentiality agreement, give reasonable
advance notice to the other Party of such disclosure and, will provide such Party with an opportunity to secure confidential treatment of such information prior to its disclosure (whether through protective orders or otherwise), and thereafter the
Party making the disclosure shall disclose only the minimum information required to be disclosed in order to comply, whether or not a protective order or other similar order is obtained. 
  
 8.3 Confidential Terms. Except as expressly provided herein, each Party agrees not to disclose any
terms of this Agreement to any third party without the consent of the other Party; provided, disclosures may be made to actual or prospective corporate partners or investors, or to a Party’s accountants, attorneys and other professional
advisors under appropriate conditions of confidentiality. 
  
 9.
Intellectual Property. 
  
 9.1
Inventions. If RECIPIENT’s use of the Materials hereunder results in an invention or discovery, including a new use, improvement, or enhancement of the Materials, whether patentable or not, (“Invention”) RECIPIENT shall
promptly disclose such Invention to XENOGEN. XENOGEN shall retain (or be assigned by RECIPIENT) all intellectual property rights in, and title to, any Invention, and RECIPIENT shall retain title to any patent or other intellectual property rights in
and to any or other invention, discovery, or commercially useful result. 
  
 9.2 No Blocking. RECIPIENT agrees not to assert any patent or other proprietary right obtained as a result of any use of the Materials that interferes with any manufacture, offer for sale, sale or use of the
Materials (or any product made using the Materials or XENOGEN’s Confidential Information) by XENOGEN or any customer or affiliate of XENOGEN. RECIPIENT agrees that such non-assertion of rights shall run with all licenses, sublicenses and
assignments of RECIPIENT’s rights in any invention hereunder. 
  
 10. No Conflicts. Each of RECIPIENT and XENOGEN represents and warrants that it is authorized to enter into this Agreement and that no other contract or obligation conflicts with the obligations to be assumed by it under this
Agreement. 
  

 C4-5 

 11. Term and Termination. 
  
 11.1 Term. This Agreement will commence on the Effective Date and, unless terminated earlier as
provided in this Article 11, will expire upon the death of the Materials (the “Term”). 
  
 11.2 Termination without Cause. RECIPIENT may terminate this Agreement, without cause, upon written notice to XENOGEN. 

 
 11.3 Termination for Cause. Either Party may
terminate this Agreement in the event the other Party has materially breached or defaulted in the performance of any of its obligations hereunder, and such default has continued for thirty (30) days after written notice thereof was provided to the
breaching Party by the non-breaching Party. Any termination shall become effective at the end of such thirty (30) day period unless the breaching Party has cured any such breach or default prior to the expiration of such period. Notwithstanding the
above, in the case of a failure to pay any amount due hereunder the period for cure of any such default following notice thereof shall be ten (10) days and, unless payment is made within such period, the termination shall become effective at the end
of such ten day period. 
  
 11.4 Effects of
Termination. Termination of this Agreement for any reason shall not release either Party from any liability which, at the time of such termination, has already accrued to the other Party or which is attributable to a period prior to such
termination nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement. Upon expiration or termination of this Agreement for any reason: (a) RECIPIENT
shall have no further right to use Materials; and (b) RECIPIENT shall promptly destroy all Materials, including all Derivatives thereof, and all Confidential Information disclosed to RECIPIENT by XENOGEN hereunder. Expiration or termination of this
Agreement shall discharge all rights and obligations of the Parties hereunder, except that Sections 3, 5.1, 6, 7.2, 8.1-8.3, 9.1, 9.2, 11.4 and 16 shall survive any termination hereof. 
  
 12. Relationship of the Parties. Nothing in this Agreement is intended or shall be deemed to constitute a license,
partnership, agency, employer-employee, or joint-venture relationship between the Parties. Except as specifically provided herein, neither Party shall make any representations or commitments on behalf of the other. 
  
 13. Amendments; Notice. This Agreement may not be amended or modified
except by a written agreement signed by the Parties. Any notice required hereunder shall be in writing and mailed via certified mail, return receipt requested, courier, or facsimile transmission addressed to those addresses indicated at the
beginning of this Agreement, or to such other address as may be designated from time to time. Notices shall be deemed given as of the date received at the specified address. In the case of XENOGEN, such notices should be sent to the attention of
“Legal Department.” 
  
 14. Assignability. The
Parties’ rights and obligations will bind and inure to the benefit of their respective successors, heirs, executors and administrators and permitted assigns. The rights and obligations of RECIPIENT under this Agreement shall not be assignable
without the prior written 
  

 C4-6 

 consent of XENOGEN. Any attempted transfer or assignment in violation of this Section 14 shall be void. 
  
 15. Severability. If any provision of this Agreement is or becomes
invalid or is ruled invalid by any court of competent jurisdiction or is deemed unenforceable, it is the intention of the Parties that the remainder of the Agreement shall not be affected so long as the essential benefits of this Agreement remain
enforceable and obtainable. 
  
 16. Governing Law. This
Agreement and any dispute, including without limitation arbitration, arising from the performance or breach hereof, shall be governed by and construed in accordance with the laws of the State of California without regard for conflict of laws
principles. The exclusive venue of any dispute arising out of or in connection with the performance or breach of this Agreement shall be the U.S. district court for the Northern District of California. Each of the Parties expressly consents to
personal jurisdiction in the State of California with respect to such action, cause of action, or dispute. Each Party irrevocably and unconditionally waives any objection to the jurisdiction and venue required in this Section 16, and agrees not to
plead or claim in any such court that any such suit, action, or proceeding has been brought in an inconvenient forum. The Parties further agree that service of process accomplished by the methods specified for notices in Section 13 shall be deemed
good and sufficient service of process in the State of California. In the event that such jurisdiction is rejected by such district court, the Parties agree to binding arbitration held under the rules of the American Arbitration Association then in
effect, in the English language and occurring in San Francisco, California by a mutually agreeable arbitrator with experience in the field of the dispute. The Parties shall share equally the fees of the arbitrator, but each Party shall bear the
costs of its own attorneys’ and experts’ fees; provided that the arbitrator may, in its discretion award the prevailing Party all or part of the costs and expenses incurred by the prevailing Party in connection with the arbitration.
Judgment upon the award may be entered in any court having jurisdiction, or application may be made to such court for judicial acceptance of the award and/or an order of enforcement, as the case may be. 
  
 17. Integration. This Agreement, including the Exhibits hereto, shall
constitute the entire agreement between the Parties and shall supersede all other agreements, whether written or oral, relating to the subject matter hereof. 
  
 IN WITNESS WHEREOF, the Parties have, by duly authorized persons, executed this Agreement, as of the date first above written. 
  

									
	XENOGEN CORPORATION	 	 	 	RECIPIENT
					
	Signed:	 	 	 	 	 	Signed:	 	 
	 	 	
	 	 	 	 	 	

					
	 Name:
	 	 	 	 	 	 Name:
	 	 
	 	 	
	 	 	 	 	 	

					
	Title:	 	 	 	 	 	Title:	 	 
	 	 	
	 	 	 	 	 	

					
	 Date:
	 	 	 	 	 	 Date:
	 	 
	 	 	
	 	 	 	 	 	

  

 C4-7 

 APPENDIX A 
  

Description of Materials 
  

			
	 Xenogen LPTATM

	  	Fees

	 XXXX-luc transgenic mice
	  	 

 APPENDIX B 
  

Authorized Site 

 EXHIBIT D 
  

FORM OF PURCHASE ORDER 
  
 Xenogen Corporation Purchase Order 
  
 Date:
[                                    ] 
  
 Purchase Order #
[                                        
    ] 
  
 This offer is made according to the terms and
conditions below. 
  
 By submitting this Purchase Order, the undersigned hereby
offers to purchase the products listed below. 
  

					
	 Licensed Product: [____________]
	 	 Part Number/
 BiowareTM Strain/
 LPTATM animal
model: [_________]
	 	Quantity: [___________]
	
	End User:
[                                        
                                        
                                        
                                        
                    ]
	
	Desired Delivery Date:
[                                ]
	
	Additional Comments:
[                                        
                                        
                                        
                                       
 ]
	
	[                                      
                                        
                                        
                                        
                                        
  ]
	
	[                                      
                                        
                                        
                                        
                                        
  ]
	
	[                                      
                                        
                                        
                                        
                                        
  ]
	
	[                                      
                                        
                                        
                                        
                                        
  ]
	
	[                                      
                                        
                                        
                                        
                                        
  ]

  
 BY SUBMITTING THIS PURCHASE ORDER, THE
UNDERSIGNED HEREBY AGREES TO THE FOLLOWING TERMS AND CONDITIONS: 
  
 Terms
of Sale: This Purchase Order is subject to all terms and conditions of the Distributor Agreement previously executed by the Parties. Terms and conditions included with this Purchase Order or in any correspondence from Distributor that
deviate from the aforementioned Agreement are null and void unless separately agreed upon by the parties in writing. No purchase orders are effective and no acceptance is formed until Xenogen’s written or electronic acceptance of this Purchase
Order. Xenogen has the right to accept or reject any purchase order in full or in part. 
  
 By submitting this Purchase Order, the undersigned has read and agree to all terms above and all documents incorporated by reference. The undersigned represents that he or she has been properly authorized to act on behalf of the business
entity listed below and to bind that entity to the terms of this Purchase Order. 
  
  

 Name 
  
  

 Position 
  

 D-1 

 EXHIBIT E 
  

RMA PROCEDURE 
  
 Distributor must obtain a Return Merchandise Authorization (“RMA”) number from Xenogen prior to returning a Licensed Product to Xenogen for
repair, replacement or any other reason. Failure to obtain an RMA number by the Distributor before returning a Licensed Product to Xenogen will result in Xenogen’s refusal to accept delivery of said Licensed Product. 
  

	1.	Distributor has five (5) business days after receipt of any delivered Licensed Products to perform any inspection and to notify Xenogen of Distributor’s rejection of any
alleged defective Licensed Product and to request an RMA number from Xenogen. Licensed Products not rejected within the foregoing time period shall be deemed accepted by Distributor. 

  

	2.	A request for an RMA number must be submitted to Xenogen in writing and should include the following information: 

  

	 	a.	Distributor’s Name and Address a 

  

	 	b.	Requester’s Name, Phone Number and Fax Number 

  

	 	c.	Licensed Product Name and Description, Xenogen Part Number, Quantity 

  

	 	d.	Licensed Product Unit Price, Date of Purchase and Date of Delivery (if possible) 

  

	 	e.	Reason for Licensed Product Return 

  

	 	f.	Purchase Order Number if Repair or Replacement Licensed Product is required. 

  

	3.	Upon Distributor’s compliance with all of the foregoing, Xenogen will issue an RMA number to Distributor for such rejected Licensed Product. 

  

	4.	Distributor must return such rejected Licensed Product to Xenogen within ten (10) days of receipt of the RMA number, freight prepaid and properly insured. 

 

	5.	The returning Licensed Product should be properly packaged for shipment of electronic parts (if applicable), including anti-static packing for circuit boards. Failure to properly
package rejected Licensed Product for return is grounds for Xenogen’s refusal of said Licensed Product. 

  

	6.	The RMA number issued by Xenogen must be clearly referenced on the outside of all shipping containers and packing lists packed and prepared by Distributor so that identification is
possible when returning Licensed Product is received by Xenogen. Failure to identify the rejected Licensed Product with an RMA number is grounds for Xenogen’s refusal of such Licensed Product. 

  

 E-1 

	7.	Distributors who are located outside the U.S. must fax Xenogen a copy of the packing list when the rejected Licensed Product is packed and ready to return to Xenogen so that Xenogen
can arrange the freight and brokerage. Distributor cooperation in this matter would be appreciated to avoid Licensed Products being held, unclaimed, in customs. 

  

	8.	In the event that Xenogen determines that the returned Licensed Product was defective at the time of its delivery to Distributor and properly rejected by Distributor, Xenogen shall,
at its option, repair or replace such defective Licensed Product, or accept return of such defective Licensed Product for credit, and Xenogen shall reimburse Distributor for the shipping costs paid therefor by Distributor. Xenogen shall return to
Distributor, freight prepaid, all repaired or replaced Licensed Products properly rejected by Distributor. In the event that any rejected Licensed Product is reasonably determined by Xenogen to not have been defective at the time of delivery to
Distributor or to have been modified or subjected to unusual electrical or physical stress, Misuse, abuse or unauthorized repair, Distributor shall reimburse Xenogen for all costs and expenses related to the inspection, repair, if any, and return of
such Licensed Product to Distributor. 

  

 E-2 

 EXHIBIT F 

			
	

	  	 IVISTM IMAGING SYSTEM SERVICE AND SUPPORT AGREEMENT

  
 The following Service
and Support Agreement (the “Service Agreement”) between Xenogen Corporation (“Xenogen”), and (“Customer”) is subject to the terms and conditions herein as well as those in the relevant agreement
between the parties providing for purchase of the applicable Imaging System. 
  
 1. Service Programs 
  
 Asia Programs 
  

									
	 	  	Premium

	  	Standard

	 	Basic

	  	No
Subscription

	 Routine Maintenance
	  	 	  	YES	 	YES	  	N/A
	 24 x 7 Emergency Support
	  	YES	  	 	 	NO	  	N/A
	 9 x 5 Technical Support
	  	YES	  	 	 	YES	  	N/A
	 Technical Support Response Time
	  	 	  	 	 	 	  	 
	 On-Site Support
	  	YES	  	 	 	 	  	 
	 On-Site Response Time
	  	£ 4 business days	  	£ 12 business days	 	£ 4 weeks	  	 
	 Annual Fee (U.S. $)
	  	$49,500	  	$23,650	 	$6,000	  	 
	 Flat Rate Repair Cost
	  	N/A	  	N/A*	 	$13,100	  	 

  

	*	Annual Fees for the Premium and Standard Programs include the Flat Rate Repair Cost. 

  
 2. Definitions 
  
 2.1 “9 x 5 Technical Support” means Xenogen email, telephone, web and fax support from 8:00 AM- 5:00 PM PST /PDT and EST/EDT Monday
through Friday, excluding weekends and holidays. 
  
 2.2
“24 x 7 Emergency Support” means Xenogen email, telephone, web and fax support available around the clock via cellular phone access for mission critical problems, such as when the Covered System is non-functional, partially
functional, or only intermittently functional, and, in all cases, causing critical impact to time-sensitive research/development operations. 
  
 2.3 “Annual Fee” means the annual, renewable subscription fee for subscribing a Covered System to a specified level of Service Program.
The Annual Fee is non-refundable and creditable only to a Service Program upgrade made pursuant to Section 3.3. 
  
 2.4 “Contact(s)” means Customer’s employee(s) having authority to initiate Service Requests. 
  
 2.5 “Covered System(s)” means a specific Imaging System
covered by a Service Program. 
  

 F-1 

 2.6 “Evaluation Visit” or “EV” means the evaluation of the operation
and overall condition of a Customer’s Imaging System by an authorized Xenogen service technician to determine such Imaging System’s suitability for a new or upgraded Service Program. 
  
  
 2.7 “Evaluation Visit Fee” means the total amount charged by Xenogen to conduct an Evaluation Visit for a single Imaging System as follows: nine hundred twenty-five dollars (US$925) for System Sites located within fifty
(50) miles of Alameda, CA or Cranbury, NJ; two thousand, six hundred fifty dollars (US$2,650) for other System Sites located within the United States; and five thousand dollars (US$5,000) for System Sites located outside the United States.

  
 2.8 “Flat Rate Repair Cost” means the flat
rate for any and all parts, labor, shipping, decontamination and travel costs per each repair by Xenogen of an Imaging System that is not a Covered System. 
  
 2.9 “Imaging System” means a specific Xenogen IVISTM Imaging System purchased by Customer. 
  
 2.10 “On-Site Response Time” means the time as measured from SR submission until the arrival of
Xenogen’s authorized service technician at the System Site. 
  
 2.11 “On-Site Support” means the service provided by a Xenogen service technician at the System Site to replace Field Replacement Units (FRUs), the entire Covered System and/or to assist Customer in troubleshooting problems
with the Covered System. Xenogen will provide On-Site Support as needed and based upon its discretion and the severity of the problem. 
  
 2.12 “Order” means and refers to the purchase order or other agreement between Customer and Xenogen providing for purchase of the Covered
System or Imaging System, as applicable. 
  
 2.13 “Routine
Maintenance” means hardware and software maintenance service conducted once per year by Xenogen, at a date to be mutually determined by Xenogen and Customer, to maintain the operational condition of a Covered System. Routine maintenance may
include these and other similar services: conducting a visual inspection of the Covered System, verifying proper function of the Covered System, refreshing the CCD camera vacuum, checking the focus, the field of view, sample stage temperature, and
calibration, cleaning the heat exchanger, updating the Software and running hard drive diagnostics. 
  
 2.14 “Service Request” or “SR” means a record created when a Contact submits a service request regarding a problem with
a Covered System to Xenogen via email, telephone, Internet or fax. 
  
 2.15 “System Site” means the designated laboratory or facility within the Authorized Site where Xenogen has installed the specific Imaging System owned by Customer. 
  
 2.16 ‘Technical Assistance Center” or “TAC”
means email, telephone, Internet and/or fax based technical support by Xenogen. 
  

 F-2 

 2.17 “Technical Support Response Time” means the time between SR submission for
technical support and the first response to Customer from the TAC. 
  
 3.
Service Program Subscription 
  
 3.1 Enrollment:

  
 3.1.1 A Customer may first enroll an Imaging
System in a Service Program by including a subscription to a selected Service Program, and the applicable Annual Fee, into the terms of the applicable Order. Alternatively, a Customer may request enrollment of an Imaging System into a Service
Program at a later time in accordance with the provisions of Section 3.1.2 or 5.2, as applicable. Once enrolled in a Service Program, a Covered System continues as such and is automatically renewed for the selected Service Program unless Customer
notifies Xenogen to the contrary as specified in Section 8.1 or unless Customer requests an upgrade to the Service Program pursuant to Section 3.4. 
  
 3.1.2 Regardless of enrollment hereunder, and unless the Order expressly provides to the contrary, Xenogen’s limited warranty
accompanying each new Imaging System sold by Xenogen includes a non-renewable subscription of that Covered System to the Basic Service Program for the first year after its Installation Date (as that term is defined in the Order); except that such
subscription expressly excludes Routine Maintenance, and Customer will not be charged for any Covered System repairs made within the scope of Xenogen’s limited warranty for such Covered System. Customer may elect to continue with the Basic
Service Program by providing Xenogen with written notice of such election, accompanied by payment of the appropriate amount due, prior to the first anniversary of the Installation Date, or may elect to upgrade its level of Service Program by
following the procedures in Section 3.4 below. 
  
 3.2
Payments: Any payments due hereunder should be mailed to Xenogen at the following address Attn: Finance Department, Xenogen Corporation, 860 Atlantic Avenue, Alameda, CA 94501, U.S.A. 
  
 3.3 Xenogen’s Obligations: In consideration for the Annual Fee
received hereunder and during the term of this Service Agreement, Xenogen will provide Customer with the services described in the Service Program selected by Customer and described in Section 1, in accordance with the terms and conditions of this
Service Agreement, for the Covered System identified by Customer pursuant to Section 3.1 and located at the System Site. Xenogen also will provide Customer with the name and contact numbers of Xenogen personnel when severe problems are encountered
that may require Emergency Support. 
  
 3.4 Upgrading Service
Programs: 
  
 3.4.1 A Customer may upgrade
its current level of Service Program for a Covered System by providing Xenogen with a written request for the desired level of Service Program upgrade accompanied by payment of the applicable Evaluation Visit Fee. Unless the service history of the
Covered System indicates otherwise, Xenogen will send Customer notice of upgrade approval within thirty (30) days of receiving such request, accompanied by an invoice for the applicable 
  

 F-3 

 Annual Fee, pro-rated for the remaining period in the then-current Term and less a credit for the
Evaluation Visit Fee and Annual Fee already paid. The upgraded Service Program will be deemed effective upon receipt of the foregoing amount. 
  
 3.4.2 Alternatively, if indicated by the service history of the Covered System, or otherwise in Xenogen’s discretion, Xenogen will
schedule and conduct an Evaluation Visit within sixty (60) days of receipt of Customer’s upgrade request. Upon successful completion of the Evaluation Visit, Xenogen will send Customer notice of upgrade approval, accompanied by an invoice for
the applicable Annual Fee, prorated for the remaining period in the then-current Term and less a credit for the Annual Fee already paid. The upgraded Service Program will be deemed effective upon receipt of the foregoing amount. If the Covered
System does not pass the Evaluation Visit, Xenogen will so notify Customer and provide an estimate of the repairs needed for approval of the Service Program upgrade. Upon completion and payment of such repairs, Customer may then upgrade the
applicable Service Program. 
  
 3.5 Fee Changes: Xenogen
reserves the right to vary the fees associated with the Service Programs and/or Flat Rate Repair Cost by providing Customer with thirty (30) days written notice of such change. Notwithstanding the foregoing, increases to the Annual Fee will not
exceed fifteen percent (15%) of the Annual Fee paid for the prior term. Additionally, Annual Fee increases for a specific Customer may automatically result (and are exempt from the foregoing cap) if there has been Misuse, abnormal conditions,
unauthorized modification (e.g. unauthorized installation of hardware or software), unauthorized repair or servicing, neglect, abuse, accident or alteration of a Covered System or any use inconsistent with Covered System instruction manual.

  
 3.6 SRs not covered under the Annual Fee or Flat Fee Repair
Cost per Repair: In the event that Customer requests a SR that Xenogen determines resulted from any Misuse, abnormal conditions, unauthorized modification (e.g. unauthorized installation of hardware or software), unauthorized repair or
servicing, neglect, abuse, accident or alteration of a Covered System or any use inconsistent with Covered System instruction manual, Customer shall pay for any travel, labor, shipping, decontamination, on-site service, materials and actual repair
costs in providing such Service. Xenogen may interrupt the operation of the Covered System to ensure such receipt of payment from the Customer. 
  
 3.7 No Hardware Upgrade: No Service Program includes upgrade to a different model of the Imaging System hardware. 
  
 3.8 Software Releases: New Imaging Systems will be delivered with a CD
containing then-current Software and Documentation. Customers will receive Patches and Minor version Software releases providing bug fixes and enhancements to the existing functionality licensed by the Customer in conjunction with Routine
Maintenance and/or On-Site Support of a Covered System. No Service Program includes upgrades to a new Major-version of the Software. Xenogen distributes Software with a Major-version (M), Minor-version(m), Patch-version(P) nomenclature as follows:

  

			
	Major-version (number):	  	Major versions reflect significant new functionality that is added to the Software.

	

  

 F-4 

			
	Minor-version (number):	  	Minor versions reflect minor enhancements and/or feature upgrades for the existing content services or functionality.
		
	Patch-version (number):	  	Patches reflect error corrections or bug fixes based on the latest/current code base.

  
 3.9 End-of-Support
(EOS) Policy: The goal of Xenogen’s End-of-Support (EOS) policy is to offer superior support and service levels to Customers through regular and orderly transition from previous Software Major versions to current Software Major versions.
EOS of a Xenogen Software Major version means that the particular version is no longer supported, updated, patched or maintained. Xenogen’s policy is to provide support for the two most recent Major-versions of the Software, including a
twenty-four (24) month period after the second most recent Major-version has been first superceded (such support excludes further modifications or changes to the second most recent Major-version). Advance notification will be made to all Service
Program Customers of record, advising them of the EOS dates and phase out period for EOS revisions, and notifications may also be published on Xenogen’s Internet site. 
  
 4. Customer Responsibilities 
  
 4.1 Providing Information: To enable Xenogen to meet its support goals and to best assist Customer, it is Customer’s responsibility to provide
complete documentation for the submitted SR, provide a Contact as an interface to Xenogen support personnel, Xenogen’s access to the System Site if needed, and other information and resources reasonably required by Xenogen for its performance
hereunder. Customer will be responsible for, and assumes the risk of any problems resulting from, the content, accuracy, completeness and consistency of all such data, materials and information supplied by Customer. 
  
 4.2 Initiating an SR: Customer will initiate an SR for a Covered
System by contacting the Xenogen TAC during the support times identified for Customer’s selected Support Program using either of the email, fax, or phone numbers provided by Xenogen upon initiation of the Service Program hereunder. Customer is
required to collect the following information prior to contacting Xenogen Technical Support to report an SR: 
  
 Define the problem 
  

	 	•	Articulate the symptom(s) of the problem 

  

	 	•	Provide any error messages or error output associated with the issue 

  

	 	•	Provide as many details related to the issue as possible 

  
 Gather relevant information 
  

	 	•	Determine associated system software versions 

  

	 	•	Determine the Covered System type and serial number 

  

	 	•	Determine if this problem has occurred before, or if this is an isolated incident 

  

	 	•	Determine what occurred before the problem was detected 

  

	 	•	Determine if any recent changes have occurred in the Covered System’s use or its environment 

  

	 	•	Collect proper/updated Contact Information, as well as alternate contact information and phone numbers, if possible 

  

 F-5 

 Define the research/development impact 
  

	 	•	Determine the severity level -how this affects the Covered System and Customer’s ability to meet research/development schedules and tasks 

  
 5. Support for Non-Subscribers 
  
 5.1 Non-Subscription Support: Even if Customer chooses not to
subscribe to, or renew, a Service Program, Customer may still receive access to the TAC at the No Subscription, Flat Rate Repair Cost as published in Section 1 (and as may be changed pursuant to Section 3.5) and subject to scheduling/availability of
Xenogen’s technical support personnel. Xenogen must receive full payment before any such service or repair by Xenogen authorized personnel is initiated. In the event Xenogen determines that there has been Misuse, abnormal conditions,
unauthorized modification (e.g. unauthorized installation of hardware or software), unauthorized repair or servicing, neglect, abuse, accident or alteration of a Covered System or any use inconsistent with Covered System instruction manual, Customer
shall pay for any travel, labor, shipping, decontamination, on-site service, material and actual repair costs in excess of the then-current No Subscription, Flat Rate Repair Cost, Xenogen may interrupt the operation of the Covered System to ensure
such receipt of payment from the Customer. 
  
 5.2
Warranty/Service Program Lapse: In the event that Customer chooses not to subscribe to, or renew, a Service Program for an Imaging System such that the System is no longer a Covered System, then Xenogen will not be obligated to enter into a
Service Agreement for such Imaging System if Customer so requests at a later time. However, subject to Xenogen’s sole discretion and based on the results of an evaluation Visit for such Imaging System, Customer may later reinstate or subscribe
to a desired Service Program for such Imaging System after its warranty or former Service Program has expired in accordance with the following procedures of this Section 5.2. 
  
 5.2.1 To reinstate or subscribe to a Service Program for a specific Imaging System, Customer may provide
Xenogen with a written request to such effect, accompanied by the applicable Evaluation Visit Fee. Within sixty (60) days of receipt of such request and payment, Xenogen will schedule and conduct an Evaluation Visit for such Imaging System. Upon
successful completion of the Evaluation Visit, Xenogen will send Customer notice of upgrade approval, accompanied by an invoice for the applicable Annual Fee. The Service Program will be deemed effective upon receipt of the foregoing amount, with
the term of such Service Program beginning on such date. 
  
 5.2.2 If the Imaging System does not pass the Evaluation Visit, Xenogen will so notify Customer and provide an estimate of the repairs needed for approval of Service Program coverage. Upon completion and payment of
such repairs, Customer may then initiate Service Program coverage upon payment of the applicable Annual Fee. 
  
 6. Request for Re-installation of Imaging System. Customer can access the TAC for On-Site Support to re-install or move an Imaging System within the System Site upon request and payment of the applicable fee as
published below (or as may be updated) and invoiced by Xenogen. Payment must be received before the reinstallation or relocation occurs. Other move options not listed below may be available and priced on a case-by-case basis. Xenogen shall devote
such time and effort it 
  

 F-6 

 deems commercially reasonable under the circumstances to Customer’s request under this Section. Xenogen cannot
guarantee that it can provide such Services by Customer’s request date, but agrees to try to do so. For purposes of this Section 6, “notice” means and refers to the period measured from the date of Xenogen’s receipt of the SR to
the requested move or re-installation date. 
  
 Reinstallation/Relocation of the Imaging System 
  

							
	 	  	System Site is within U.S.
and less than 50 miles
from Cranbury, NJ or
Alameda, CA

	  	System
Site is
within U.S.

	  	System Site is
outside of U.S.

	 At least 14 days notice
	  	U.S.$925	  	 	  	 
	 Less than 14 days notice
	  	 	  	 	  	U.S.$6,300

  
 7. Limited Warranty of Service.
Xenogen represents and warrants that it will perform its obligations hereunder in a professional and workmanlike manner, and for a period of ninety (90) says after any service performed hereunder by an authorized Xenogen personnel that the Imaging
System shall be in operational condition and in material conformance with its specification. If a problem relating to a repair develops during this limited warranty of service period, Customer’s remedy shall be to contact TAC, and Xenogen will
use commercially reasonable efforts to correct such problem at the same level of effort as specified in the applicable Service Program. Except as set forth in the preceding sentence, All SERVICES PROVIDED PURSUANT TO THIS SERVICE AGREEMENT ARE
PROVIDED “AS IS”, AND XENOGEN DISCLAIMS All WARRANTIES, EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE REGARDING OR RELATING TO ANY MATERIALS OR SERVICES FURNISHED OR PROVIDED TO CUSTOMER UNDER THIS SERVICE AGREEMENT. XENOGEN SPECIFICALLY
DISCLAIMS All IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO SAID MATERIALS AND SERVICES, AND WITH RESPECT TO THE USE OF ANY OF THE FOREGOING. The foregoing Limited Warranty and remedy is the
Customer’s sole and exclusive warranty and remedy and in lieu of all other warranties, expressed or implied, and remedies. 
  
 8. Term and Termination 
  
 8.1 Term: Unless otherwise terminated pursuant to Section 8.2, this Service Agreement will have a one (1) year term from date of expiration of
Xenogen’s limited warranty for the Covered System that is the subject hereof. Thereafter, this Service Agreement will automatically renew for subsequent one (1) year periods unless Customer provides Xenogen with written notice of
Customer’s intent not to renew the Service Program for the Covered System at least thirty (30) days prior to the expiration of the then-current term of this Service Agreement. 
  
 8.2 Termination: Xenogen may terminate Customer’s Service Program immediately and without prior notice if: (i)
Customer is in material breach of its agreement with Xenogen providing for the purchase of the Covered System; or (ii) Customer has not paid its Annual Fee when due. Notwithstanding the above, in the case of a failure to pay any amount due
hereunder, the period for cure of any such default following notice, if any, thereof shall be ten (10) days and, unless payment is made within such period, the termination shall become effective at the end of such ten (10) day period. 
  

 F-7 

 8.3 Effect of Termination: Customer agrees to pay any fees accrued hereunder prior to termination.
At Xenogen’s discretion, a Customer that terminates this Agreement may reinitiate its former Service Program or subscribe to a different Service Program pursuant to Section 5.2. 
  
 9. Online Support: At a future time, Xenogen may provide online support such as authenticated access to the Xenogen support website
(located at http:/ /www.Xenogen.com/) that provides software downloads, technical documentation, field bulletins, FAQs, knowledge base, and Customer’s ability to submit and track SRs, etc. Xenogen will notify Customer of its availability.
Xenogen may use email alerts and field bulletins, as two forms of proactive communication tools, to notify Customer of useful and possibly critical information about Xenogen products. 
  

 F-8Marketing Services Agreement

 [CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND FILED SEPARATELY
WITH THE COMMISSION.] 
  
 Exhibit 10.26 
  
 MARKETING SERVICES AGREEMENT 
  
 This Marketing Services Agreement (the “Agreement”) is entered into
as of Apr 2, 2003 (the “Effective Date”) by and between Charles River Laboratories, Inc., a Delaware corporation with its principal place of business at 251 Ballardvale Street, Wilmington, Massachusetts 01887 (“Charles River”),
Xenogen Corporation, a Delaware corporation with its principal place of business a 860 Atlantic Avenue, Alameda, California, 94501 (“Xenogen”) and Xenogen Biosciences Corporation, an Ohio corporation with its principal place of business at
5 Cedar Brook Drive, Cranbury, NJ 08512 (“XenogenBio”). 
  
 Whereas, Charles River is a supplier of laboratory research models and related products and services for use in biomedical research and development; and 
  
 Whereas, XenogenBio is a wholly owned subsidiary of Xenogen, and a creator of laboratory research models and related
services for use in biomedical research and development (“Creation Services”), which Creation Services are more fully described on Exhibit A attached hereto; and 
  
 Whereas, Charles River, Xenogen and XenogenBio wish to enter into a business arrangement that will enable them to work
together to market and sell the Creation Services. 
  
 Now,
therefore, in consideration of the mutual covenants herein contained and for other good and valuable consideration, the parties hereto, intending to be legally bound, agree as follows: 
  

	1.	Joint Responsibilities. Charles River and Xenogen will coordinate efforts and assist each other in the marketing and selling of the Creation Services.

  

	2.	Responsibilities of Charles River. Charles River shall: 

  

	 	(a)	Market the Creation Services in the United States and Canada (“North America”) and forward information regarding sales leads of the Creation Services to XenogenBio in
accordance with the Marketing Plan attached hereto as Exhibit B (“Marketing Plan”). 

  

	 	(b)	Participate in quarterly conference calls with XenogenBio to provide updates and manage the marketing collaboration. 

  

	 	(c)	Provide quarterly reports to XenogenBio specifying the marketing activities undertaken, together with a summary of all sales leads previously provided to XenogenBio.

  

	 	(d)	Designate a representative to be the primary contact for the management and execution of this Agreement. 

  

	3.	Responsibilities of Xenogen and XenogenBio. 

  

	 	(a)	Xenogen and XenogenBio shall pursue all sales leads provided by Charles River, including without limitation, closing sales and servicing customers in the manner that Xenogen and
each would ordinarily and typically pursue and close similar sales leads. 

  

 Confidential - Xenogen Corporation 

	 	(b)	XenogenBio shall perform Creation Services for customers, in a timely fashion and in accordance with customer specifications with the same level of diligence and skill as XenogenBio
ordinarily and typically provides for its other customers. 

  

	 	(c)	Xenogen and XenogenBio, as appropriate, shall provide training for Charles River’s sales force and other personnel as set forth in the Marketing Plan. 

 

	 	(d)	Xenogen and XenogenBio, as appropriate, shall provide technical content for the marketing and sales materials described in the Marketing Plan and assist Charles River in the
creation of the technical content for the marketing and sales materials. 

  

	 	(e)	Xenogen and XenogenBio, as appropriate, shall participate in quarterly conference calls with Charles River to provide updates and manage the marketing collaboration.

  

	 	(f)	XenogenBio shall provide quarterly written reports to Charles River specifying the sales leads received, both directly and indirectly. 

  

	 	(g)	Xenogen shall designate a representative to be the primary contact for the management and execution of this Agreement. 

  

	4.	Compensation. Either of Xenogen or XenogenBio shall make the following payments to Charles River; 

  

	 	(a)	Xenogen or XenogenBio shall pay Charles River an annual nonrefundable fee ***. 

  

	 	(b)	Subject to Section 4(d) and 4(e) below, Xenogen or XenogenBio shall pay Charles River a commission on revenue from the Creation Services (“Revenue”) for Revenue received
sixty (60) days after the Effective Date through sixty (60) days after the termination or expiration date of this Agreement. 

  
 The commission rates are as follows: 
  

	 	(i)	For all Revenue up to ***, the commission rate shall be ***; 

  

	 	(ii)	For all Revenue between *** and ***, the commission rate shall be ***; and 

  

	 	(iii)	For all Revenue in excess of ***, the commission rate shall be ***. 

  

	 	(c)	Revenue shall mean the amount invoiced by XenogenBio to third parties for the Creation Services less: 

  

	 	(i)	charges for insurance, freight and other transportation costs directly related to the delivery of the Creation Services to the extent included in the gross invoiced sales price;

  

	 	(ii)	credits or allowances actually granted upon claims, rejections or returns of sales of the Creation Services; and 

  
 Confidential - Xenogen Corporation 
  

	***	Confidential treatment requested 

	 	(iii)	any sales, excise, use or ad valorem taxes and any direct governmental charges included in such invoice as a separately stated charge, as adjusted for rebates, charge backs and
refunds. 

  

	 	(d)	The parties agree and acknowledge that with respect to those certain customers set forth on Exhibit D attached hereto, only the amounts received from those customers in excess of
the amounts set forth on Exhibit D shall be included in Revenue for the purposes of this Agreement. 

  

	 	(e)	All commission payments shall be made on a calendar quarter basis within thirty (30) days after the end of each quarter for which commissions are due. Each commission payment shall
be accompanied by a written report setting forth the calculation of Revenue and the calculation of commission due. Such reports shall include at least the total amount invoiced for the Creation Services, the amount of the allowable deductions and
the amount of the total commissions due. If no commission payments are due for a particular quarter, the report shall be delivered as required above and shall state that no commissions are due. 

  

	 	(f)	All commissions shall be payable in full in United States Dollars, regardless of the countries in which sales are made. For the purpose of computing Revenue for which a currency
other than United States Dollars is received, such currency shall be converted into United States dollars at the exchange rate for buying United States Dollars set forth in The Wall Street Journal for the last business day of the calendar
quarter. 

  

	 	(g)	Any payment due and payable by Xenogen and XenogenBio to Charles River under this Agreement not made on the date such payment is due and payable, including without limitation any
installment of the Annual Fee, shall bear interest as of the date such payment was due and shall continue to accrue interest until such payment is made at a rate equal to the lesser of one and one-half percent (1.5%) interest per month or the
maximum rate permitted by applicable law. 

  

	5.	 Record Retention; Audits. XenogenBio shall keep for three (3) years from the date of each commission payment complete and accurate records of sales by
XenogenBio of the Creation Services in sufficient detail to allow the accruing commissions hereunder to be determined accurately. Charles River shall have the right for a period of three (3) years after receiving any report or statement with respect
to commissions due and payable to appoint an independent certified public accountant, at Charles’s expense, to inspect the relevant records of Xenogen to verify such report or statement. XenogenBio shall make its records available for
inspection by such independent certified public accountant during regular business hours at such place or places where such records are customarily kept, upon reasonable notice from Charles River, solely to verify the accuracy of the reports and
payments. Such inspection right shall not be exercised more than once in any calendar year. Charles River agrees to hold in strict confidence all information concerning commission payments and reports, and all information learned in the course of
any audit or inspection, except to the extent necessary for Charles River to reveal such information in order to enforce its rights under this Agreement or if disclosure is required by law, regulation or judicial order. The results of each
inspection, if any, shall be binding on both Parties. The cost of the inspection shall be borne by Charles River, provided however that if the inspection reveals that the records were not kept as required hereunder, or that an underpayment of ten

  

 Confidential - Xenogen Corporation 

	 	 
percent (10%) or more has occurred in any quarterly period, XenogenBio shall pay the cost of the inspection, together with the underpayment and interest
calculated as set forth above. 

  

	6.	Term and Termination. 

  

	 	(a)	The term of the Agreement shall expire twenty-four (24) months following the Effective Date. The parties acknowledge that in order for the Creation Services to be included in the
next annual Charles River printed catalogue of services (the “Charles River Catalogue”), this Agreement must be in full force and effect on October 1 of the preceding year and not due to expire during the next full calendar year. This
Agreement may be renewed by the mutual agreement of the parties. 

  

	 	(b)	The Agreement may be terminated at any time by any party in the following ways: 

  
 (i) by Xenogen, XenogenBio or Charles River, upon written notice effective immediately, in the event any of them acquires or
is acquired by a competitor; or 
  
 (ii) upon written notice in
the event (a) that any party shall have dissolved, ceased active business operations or liquidated itself, or (b) of bankruptcy or insolvency proceedings, including any proceeding under Title 11 of the United States Code, have been brought by or
against another party and remains undismissed or unwithdrawn for a period of thirty (30) days, or (c) an assignment has been made for the benefit of another party’s creditors or a receiver of such party’s assets has been appointed

  
 (iii) by a non-defaulting party upon thirty (30) days’
written notice to the defaulting party (which notice shall specify the nature of the default), if any party shall have failed in the full and timely observance or performance of any of its covenants or obligations under this Agreement, provided
however that if the default is cured within the thirty (30) day period, the notice shall be withdrawn and of no effect. Notwithstanding anything contained herein to the contrary, upon the third occurrence of the same or similar default in a twelve
(12) month period, no thirty (30) day cure period shall be available and the non-defaulting party may terminate the Agreement immediately upon written notice. 
  

	 	(c)	In the event of termination by either party, Xenogen and XenogenBio shall remain responsible for all payments due and payable through the termination date, except as otherwise set
forth herein. If the Agreement is terminated pursuant to Section 6(b)(i), the following will apply: (i) in the event that Charles River is acquired by or acquires a competitor pursuant to that Section, no further installments of the Annual Fee for
that calendar year shall be due, and (ii) in the event that Xenogen or XenogenBio is acquired by or acquires a competitor pursuant to that Section, all remaining installments of the Annual Fee for that calendar year shall become immediately due and
payable, but no further commission payments shall be due and payable. If the Agreement is terminated pursuant to Section 6(b)(iii), the following will apply: (i) in the event that Xenogen or XenogenBio terminates this Agreement pursuant to that
Section, no further installments of the Annual Fee or commission payments shall be due and payable; and (ii) in the event that Charles River terminates the Agreement pursuant to that Section, all remaining installments of the Annual Fee for that
calendar year shall become immediately due and payable and commission payments shall continue to be due and payable as set forth in Section 4. 

  
 Confidential - Xenogen Corporation 
  

	 	 
Charles River shall own all marketing materials developed pursuant to this Agreement after the termination or expiration of this Agreement for any reason,
although Charles River shall no longer have a license to use any of Xenogen’s trademarks or service marks in any manner. 

  

	 	(d)	Termination and expiration of this Agreement for any reason shall be without prejudice to the rights and obligations of the parties provided in Sections 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14 and 21, all of which shall survive such termination and any other rights or remedies provided at law or equity which either party may otherwise have against the other. 

  

	7.	Confidentiality. 

  

	 	(a)	The parties anticipate that they will exchange proprietary and confidential information during the term of this Agreement. The parties shall identify, in writing, such information
as confidential and/or proprietary. Each party shall maintain such information in confidence and will employ reasonable and appropriate procedures to prevent its unauthorized publication or disclosure unless required to disclose such information.
Neither party shall use the other party’s proprietary or confidential information for any purpose other than in performance of this Agreement. Each party, upon the others request, will return all the confidential information disclosed or
transferred to it by the other party pursuant to this Agreement, including all copies and extracts of documents and all manifestations in whatever form, within sixty (60) days of the request following the termination of this Agreement; provided that
one copy of the confidential information may be retained in inactive archives solely for the purpose of ensuring compliance herewith. The obligations of confidentiality set forth in this paragraph will survive termination or expiration of this
Agreement for a period of five (5) years. The confidentiality provisions of this paragraph shall not apply to any part of such information, for which it can be established by competent written proof that: 

  

	 	(i)	is known to the receiving party, other than under an obligation of confidentiality, at the time it was obtained from the disclosing party; 

  

	 	(ii)	is acquired by receiving party from a third party and such third party did not obtain such information directly or indirectly from the disclosing party under obligation not to
disclose; 

  

	 	(iii)	is or becomes published or otherwise in the public domain other than by violation of this Agreement by the receiving party; or 

  

	 	(iv)	is independently developed by the receiving party without reference to or use of the information provided by the disclosing party. 

  

	 	(b)	Neither Xenogen nor XenogenBio, on the one hand, or Charles River may publicly disclose the existence or terms of this Agreement without the prior written consent of the other
provided, however, that Charles River may disclose the existence of the Agreement for the purposes of marketing and selling the Creation Services and any party may make such a disclosure to the extent required by law, including the rules of a stock
exchange on which it is listed. Such disclosure shall be on reasonable notice to the other parties and after taking all reasonable steps to maintain confidentiality. A party may disclose the existence and terms of this Agreement to (i) members of
its board of directors, and (ii) existing or potential institutional financial investors (but not a corporate investor) or to professional advisors (e.g., attorneys, accountants and prospective investment bankers) involved in such investment; in all
cases for the limited purpose of evaluating such investment and under appropriate conditions of confidentiality, only to the extent necessary and with the agreement by these permitted individuals to maintain such confidential information in strict
confidence. Further, upon written notice to Charles River hereto, Xenogen or XenogenBio may disclose the existence and terms of this Agreement to any existing or potential investors or acquirers or merger partners, or to professional advisors (e.g.,
attorneys, accountants and prospective investment bankers) involved in such investment or transaction who have signed or agreed to a letter of intent or term sheet regarding such potential transaction and that has been approved by Xenogen’s
president; in all cases for the limited purpose of evaluating such investment or transaction and under appropriate conditions of confidentiality, only to the extent necessary and with the agreement by these permitted individuals to maintain such
confidential information in strict confidence. Such notice will disclose the fact of disclosure, but need not reveal the identity of the entity or person to which the information was disclosed. 

  
 Confidential - Xenogen Corporation 

	8.	Trademarks and Copyrights. Xenogen grants Charles River a non-exclusive license in its trademarks, service marks, tradenames and copyrights related to the Creation Services
(the “Xenogen Rights”) for the term of this Agreement solely for the purposes of marketing and selling the Creation Services as described in the Marketing Plan. Xenogen reserves all rights not expressly granted herein. Charles River
acknowledges that it has no interest in the Xenogen Rights other than the licenses granted under this Agreement, and that Xenogen will remain the sole and exclusive owner of all right, title and interest in the Xenogen Rights. Charles River agrees
that Charles River’s use of the Xenogen Rights and any good will in such trademarks, service marks, tradenames and copyrights resulting from Charles River’s use will inure solely to the benefit of Xenogen and will not create any right,
title or interest for Charles River in the Xenogen Rights. Charles River shall not contest, oppose or challenge Xenogen’s ownership of the Xenogen Rights. Charles River agrees that it will do nothing to impair Xenogen’s ownership or rights
in the Xenogen Rights. Charles River shall not, during the term of this Agreement or thereafter, register, use, or attempt to obtain any right in and to any Xenogen Right (other than those rights granted herein) or in and to any name, logo or
trademark confusingly similar thereto or any derivative work of a Xenogen Right. Charles River agrees that at no time during or after the term of this Agreement to challenge or assist others to challenge the Xenogen Rights or the registration
thereof or attempt to register any trademarks, marks or trade names confusingly similar to such Xenogen Rights or that are derivative works of a Xenogen Right. Charles River shall not use any Xenogen Right or other proprietary mark of Xenogen or
Xenogen’s suppliers or licensors in a manner that has not been approved by Xenogen, and shall only use such Xenogen Rights in conformity with the style and usage developed by Xenogen. 

  

	9.	Warranties and Representations. 

  

	 	(a)	XenogenBio warrants that it owns or has rights of sufficient scope to the intellectual property included within the Creation Services, and that, as of the Effective Date, it is not
the subject of a claim or suit by a third party that XenogenBio’s own marketing and sale of the Creation Services infringes the intellectual property rights of such third party. 

  

 Confidential - Xenogen Corporation 

	 	(b)	Charles River, Xenogen and XenogenBio each represents and warrants to the other, as of the Effective Date, as follows: 

  
 (i) It is a corporation duly organized, validly existing and is in good
standing under the laws of the state in which it is incorporated, is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the performance of its obligations hereunder requires such qualification and
has all requisite power and authority, corporate or otherwise, to conduct its business as now being conducted, to own, lease and operate its properties and to execute, deliver and perform this Agreement. 
  
 (ii) The execution, delivery and performance by it of this Agreement have
been duly authorized by all necessary corporate action and do not and will not (a) require any consent or approval of its stockholders or (b) violate any provision of any agreement, law, rule, regulation, order, writ, judgment, injunction, decree,
determination or award presently in effect having applicability to it or any provision of its charter documents. 
  
 (iii) This Agreement is a legal, valid and binding obligation of it enforceable against it in accordance with its terms and conditions. 
  
 (iv) It is not under any obligation to any person, or entity, contractual or
otherwise, that is conflicting or inconsistent in any respect with the terms of this Agreement or that would impede the diligent and complete fulfillment of its obligations hereunder and that it has all power and authority under all instruments or
agreements to which it is a party to enter into this Agreement and to perform its obligations hereunder. 
  

	10.	Warranty Disclaimer. EXCEPT AS STATED ABOVE, EACH PARTY DISCLAIMS ALL WARRANTIES, WHETHER EXPRESS, IMPLIED OR STATUTORY, WRITTEN OR ORAL, INCLUDING WITHOUT LIMITATION, ANY
WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR FOR NON-INFRINGEMENT OF A PATENT, TRADEMARK OR OTHER INTELLECTUAL PROPERTY RIGHT. 

  

	11.	Indemnification and Covenant not to Sue. 

  

	 	(a)	 In the event of any claim or allegation against Charles River by a third party of (i) infringement or misappropriation of copyright, patent, trade secret or any
other intellectual property right included within the Creation Services arising out of XenogenBio’s performance of such Creation Services, or (ii) breach of warranty by XenogenBio relating to the Creation Services performed for such third
party, personal injury or product liability or any other matter regarding Charles River’s marketing or advertising of the Creation Services and related to XenogenBio’s performance of such Creation Services for such third party, or (iii)
any other matter arising from the negligence or wilful misconduct of Xenogen or XenogenBio hereunder, Xenogen and XenogenBio will, at their expense, indemnify, defend and hold Charles River harmless from any such claim, 

  

 Confidential - Xenogen Corporation 

	 	 
damages, losses, liabilities, fines, penalties, costs and expenses (including reasonable attorneys’ fees) (any of the foregoing, a “Claim”)
incurred by Charles River and pay any damages awarded or settlement reached in connection therewith, provided that Charles River shall promptly notify Xenogen of any such Claim, and Xenogen shall have the sole and exclusive authority to defend
and/or settle any such Claim; provided that Charles River shall have the right to participate, at its own expense, with counsel of its own choosing in the defense and/or settlement of such Claim. The foregoing indemnification shall not apply to
amounts paid with respect to settlement of any Claim if such settlement is effected without the consent of Charles River, which consent will not be unreasonably withheld or delayed. Xenogen and XenogenBio shall keep Charles River informed of the
progress of such litigation. 

  

	 	(b)	Xenogen and XenogenBio acknowledge and agree that any services performed by Charles River on genetically manipulated stocks and strains delivered to Charles River by non-affiliated
third parties, other than creation services utilizing (i) those patented technologies that XenogenBio uses in the course of performing any of the Creation Services and has the exclusive right to sublicense to others, or (ii) services or materials
related to detection, observation and reporting of light emitted from within living mammals (the “CRL Services”) do not infringe upon Xenogen’s or XenogenBio’s intellectual property rights. Xenogen and XenogenBio agree that
neither will bring or threaten suit against Charles River for infringement of any of Xenogen’s or XenogenBio’s intellectual property rights, cooperate with third parties in bringing suit against Charles River for infringement of any of
Xenogen’s or Xenogen’s intellectual property rights or otherwise seek to impose legal or equitable constraints on Charles River for infringement of Xenogen’s or XenogenBio’s intellectual property rights due to the CRL Services.

  

	 	(c)	In the event of any claim or allegation against Xenogen or XenogenBio by a third party arising from (i) the negligence or wilful misconduct of Charles River hereunder, or (ii)
Charles River’s marketing and sales of the Creation Services, Charles River will, at its expense, indemnify, defend and hold Xenogen and XenogenBio harmless from any such Claim, incurred by Xenogen and XenogenBio and pay any damages awarded or
settlement reached in connection therewith, provided that Xenogen or XenogenBio shall promptly notify Charles River of any such Claim, and Charles River shall have the sole and exclusive authority to defend and/or settle any such Claim; provided
that Xenogen and XenogenBio shall have the right to participate, at their own expense, with counsel of their own choosing in the defense and/or settlement of such Claim. The foregoing indemnification shall not apply to amounts paid with respect to
settlement of any Claim, if such settlement is effected without the consent of Xenogen or XenogenBio, which consent will not be unreasonably withheld or delayed. Charles River shall keep Xenogen and XenogenBio informed of the progress of such
litigation. 

  

	12.	 Limitation of Liability. IN NO EVENT SHALL ANY PARTY BE LIABLE TO THE OTHER FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES INCURRED BY THE

  

 Confidential - Xenogen Corporation 

	 	 
OTHER, INCLUDING, BUT NOT LIMITED TO, LOSS OF PROFITS, LOSS OF OPPORTUNITIES, LOSS OF DATA, LOSS OF USE DAMAGES OR COST OF PROCUREMENT OF SUBSTITUTE GOODS OR
SERVICES, ARISING OUT OF THIS AGREEMENT. 

  
 ***

  

	14.	Notices. All notices shall be in writing mailed via certified mail, return receipt requested, courier, or facsimile transmission addressed as follows, or to such other
address as may be designated from time to time: 

  

			
	If to Xenogen	  	 Xenogen Corporation
 860 Atlantic
Avenue
 Alameda, CA 94501
 Attn: V.P., Corporate
Development

		
	With a copy to:	  	 Xenogen Biosciences
 5 Cedar Brook Drive
 Cranbury, NJ 08512
 Attn: Legal Department

		
	If to Charles River:	  	 Charles River Laboratories, Inc.
 251 Ballardvale
Street
 Wilmington, MA 01887
 Attn: General
Counsel

  
 Notices shall be
deemed given as of the date received. 
  

	15.	Relationship of Parties. The parties to this Agreement are independent contractors. There is no relationship of partnership, joint venture, employment, franchise or agency
between the parties. No party shall have any authority to act, or attempt to act, or represent itself, directly or by implication, as an agent of the other or in any manner assume or create or attempt to assume or create, any obligation on behalf of
or in the name of the other, nor shall either be deemed the agent or employee of the other. 

  

	16.	Assignment and Successors. Neither this Agreement nor any obligation of a party hereunder may be assigned by a party without the consent of the other which shall not be
unreasonably withheld, except that each party may assign this Agreement and the rights, obligations and interests of such party, to any of its affiliates without such consent. A change in control of any Party shall be deemed an assignment hereunder.

  
 Confidential - Xenogen Corporation

  

	***	Confidential treatment requested 

	17.	Force Majeure. None of Charles River, Xenogen or XenogenBio shall be liable for failure of or delay in performing obligations set forth in this Agreement, and neither shall
be deemed in breach of its obligations, if such failure or delay is due to natural disasters, explosion, strike, acts of terrorism, war, government requirement, civil or military authority, act of God or any causes beyond the reasonable control of
Charles River, Xenogen or XenogenBio. In event of such force majeure, the party affected thereby shall use reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder. 

  

	18.	Dispute Resolution. The parties shall attempt, in good faith, to resolve through negotiations any controversy, claim, or dispute arising out of this Agreement. In the event
that negotiations are not successful, the controversy, claim, or dispute shall be submitted to third party mediation upon terms reasonably acceptable to the parties. If such claim, controversy or dispute is not resolved through mediation, upon
written demand of either party, the claim, controversy or dispute shall be submitted to arbitration before three (3) arbitrators. Such arbitration shall take place in Boston, Massachusetts if Xenogen or XenogenBio is the plaintiff and in New York,
New York if Charles River is the Plaintiff, and shall proceed in accordance with the Commercial Arbitration Rules of the American Arbitration Association and the laws of the Commonwealth of Massachusetts. Within seven (7) calendar days after either
party makes a written demand on the other for arbitration, each of Charles River on the one hand and Xenogen and XenogenBio on the other shall select one (1) arbitrator. A third arbitrator shall be chosen by the arbitrators selected by the parties
involved within thirty (30) days of the demand for arbitration, and shall act as chairman. In the event that any arbitrator is not appointed in the prescribed time period, either party involved may apply to the American Arbitration Association for
the appointment of such arbitrator. A record and transcript of the proceedings shall be maintained. Any award shall be made in writing and in reasonable detail, setting forth the findings of fact and conclusion of law supporting the award. The
determination of a majority of the panel of arbitrators shall be the decision of the arbitrators, which shall be binding regardless of whether one of the parties involved fails or refuses to participate in the arbitration. The decision shall be
enforceable by a court of law, provided that the decision is supported by substantial fact and is without material error of law. All costs of such arbitration, except expert fees and attorneys’ fees, shall be shared equally by the parties
involved in such arbitration. 

  

	19.	Entire Agreement. This Agreement constitutes the entire agreement between Charles River, Xenogen and XenogenBio with respect to the subject matter hereof and supersedes all
prior agreements, promises, understandings and negotiations, whether written or oral, regarding the subject matter hereof. No waiver, consent, modification, amendment or change of the terms of this Agreement shall bind a party unless in writing and
signed by duly authorized representatives of the other parties. 

  

	20.	Severability. In the event that any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable because it is invalid or in conflict with any
law of any relevant jurisdiction, the validity of the remaining provisions shall not be affected, and the rights and obligations of the parties shall be construed and enforced as if the Agreement did not contain the particular provisions held to be
unenforceable and the unenforceable provisions shall be replaced by mutually acceptable provisions which, being valid, legal and enforceable, come closest to the intention of the parties underlying the invalid or unenforceable provision.

  

 Confidential - Xenogen Corporation 

	21	Governing Law. The validity, construction and interpretation of this Agreement, and the rights and duties of the parties, shall be governed by and construed in accordance
with the laws of the Commonwealth of Massachusetts. 

  

	22.	Authority. Each party has full power and authority to enter into and perform this Agreement and the person signing this Agreement on behalf of each party hereto has been
properly authorized and empowered to enter into this Agreement. 

  

	23.	Joint and Several Liability. Xenogen and XenogenBio shall be jointly and severally liable under this Agreement and Charles River may proceed against either one without having
commenced any action or obtained any judgment against the other. 

  
 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year indicated above. 
  

			
	 Charles River Laboratories, Inc.

		
	By:	 	 /s/ James C. Foster

			
	 Print Name:
	 	 

			
	 Title:
	 	 

  

			
	 Xenogen Biosciences Corporation:

		
	By:	 	 /s/ Pamela Reilly Contag

			
	 Print Name:
	 	 Pamela Reilly Contag

			
	 Title:
	 	 CEO

  

			
	 Xenogen Corporation:

		
	By:	 	 /s/ Pamela Reilly Contag

			
	 Print Name:
	 	 Pamela Reilly Contag

			
	 Title:
	 	 President

  

 Confidential - Xenogen Corporation 

 EXHIBIT A 
 DESCRIPTION OF CREATION SERVICES 
  
 Creation Services is broadly defined as the standard and custom services offered to create transgenic, knockout or mutant animals. May involve part of (e.g., creation of construct only) or the entire creation process, including: 

 
 Transgenic Production Programs (pronuclear
microinjection) including: 
  

	 	•	DNA microinjection 

  

	 	•	Gene integration analysis 

  

	 	•	Design and generation of transgenes 

  

	 	•	Custom microinjection programs 

  
 Custom Gene Targeting Programs 
  

	 	•	Transfection using targeting construct through breeding of mice 

  

	 	•	ES cell transfection 

  

	 	•	Blastocyst injection 

  

	 	•	Custom gene targeting programs 

  
 It is understood that Creation Services specifically excludes sublicenses to distribute the resulting transgenic, knockout or mutant animals or any follow-on or other
services related to those animals. 
  
 It is understood that Creation Services
includes specialty custom creation projects, including projects to create custom light producing transgenic animals (LPTATM animal models). 
  

 Confidential - Xenogen Corporation 

 EXHIBIT B 
 MARKETING PLAN 
  
 I. Creative Work
Plan: 
  
 Website: CRL will add Xenogen services to its website
in the section noted Transgenic Services. ***. 
  

	 	2.	Catalog: CRL will add a Xenogen section to its online and printed 2004 Product Catalog under the section dedicated to Transgenic Services. ***. 

  

	 	3.	Technical Data Sheets: New technical data sheets will be created to be included in CRL’s Transgenic Services marketing folder. ***. 

  

	 	4.	Xenogen Marketing Brochures: Brochures centered on the principle theme of Xenogen Bioscience’s Animal Creation Services will be produced for distribution at Tradeshows, and by
CRL Sales Representatives. ***. 

  

	 	5.	***. 

  

	 	6.	Advertising: Xenogen’s Animal Creation Services will be added to CRL’s Transgenic Services advertisements placed in Laboratory Animal Journals. ***.

  

	 	7.	***. 

  

	 	8.	***. 

  
 II. Execution Plan: 
  
 Press Release: Immediately upon
completion of the agreement, CRL and Xenogen will produce and send to the trade press an announcement of the relationship. This press release will also be added to all CRL TG marketing folders immediately while the new data sheets are created. This
press release will also be featured on the CRL website. 
  

	 	2.	***. 

  

	 	3.	Marketing Brochures: To be distributed by sales reps as they visit clients and at relevant tradeshows (see attached Tradeshow Schedule/Plan). 

  

	 	4.	Advertising: Once ads have been created they will be placed in the relevant laboratory animal journals. ***. 

  
 III. Training: 
  
 An introductory conference call will be scheduled for the week after the effective date. This will be for CRL sales and
marketing staff members and will provide an opportunity for CRL TGS and Xenogen to present the details of the new partnership. 
  

	 	2.	Two training sessions will be planned for the sales force. One on the West Coast and One on the East Coast. The East Coast session will be held at CRL in Wilmington so that other
relevant people can be included (Technical Assistance, Marketing Staff, TGS and Lab Product Management team, etc.). 

  
 IV. ***. 
  
 Confidential - Xenogen Corporation 
  

	***	Confidential treatment requested 

  

 Charles River Laboratories 2003 Tradeshow Schedule 
  
 Distribution Date: 1-27-03 
  
 Gray Line Items = Indicates shows/events under consideration, non-exhibit events, cancelled
events 
 White Line Items = Confirmed shows 
  
 Listing is subject to change 
  
 CRL will cover the cost of one Booth/Exhibit Hall registration for a Xenogen attendee, if desired, for any show. Publication, posters, platform presentations by a Xenogen scientist are encouraged. 
 A Xenogen representative is welcome to participate in pre-show planning meetings. Xenogen literature 
 will be 
 Available and distributed as noted. 
  
 Past = Not available due to the date 
 N/R = Not
Recommended for Xenogen 
 Optional = Xenogen may want to attend (pre-show planning meeting may help to make that decision). 
  

									
	 DATE

	  	 TRADESHOW / EVENT

	  	 LOCATION

	  	 BUSINESS

	  	Xenogen Brochures

	 JAN 14
	  	Albert Einstein College of Medicine	  	Bronx, NY	  	Rodent/Transgenic	  	Past
	 JAN 27-31
	  	Sales Meeting	  	Boston, MA	  	N/A	  	Past
	 JAN 30-31
	  	SEAALAS	  	Atlanta, GA	  	Sponsor Only	  	Past
	 JAN 30
	  	Texas Medical Center BioFaire	  	Houston, TX	  	Rodent/Transg	  	Past
	 JAN 31
	  	Texas A & M University BioFaire	  	College Station, TX	  	Rodent/Transg	  	Past
	 FEB 5
	  	Harvard Vendor Day	  	Cambridge, MA	  	Rodent/Transgenic	  	Past
	 	  	 	  	 	  	 	  	Past, N/R
	 	  	 	  	 	  	 	  	Past
	 	  	 	  	 	  	 	  	Past, N/R
	 	  	 	  	Lake Buena Vista, FL	  	 	  	Past
	 	  	 	  	Washington, DC	  	 	  	Past, N/R
	 FEB 25
	  	Pediatric Drug Development Post Conference Workshop	  	Washington, DC	  	DDS	  	Past, N/R
	 FEB 27
	  	University of Florida BioFaire	  	Gainesville, FL	  	Rodent/Transgenic	  	Past
	 MARCH 3-4
	  	 	  	La Jolla, CA	  	 	  	Past, N/R
	 MARCH 5-7
	  	 	  	La Jolla, CA	  	 	  	Past, N/R
	 	  	 	  	Durham, NC	  	Rodent/Transgenic	  	Past
	 	  	Research Triangle Park BioFaire	  	Durham, NC	  	Rodent/Transgenic	  	Past
	 MARCH 9-13
	  	SOT	  	Salt Lake City, UT	  	All Businesses	  	Past
					
	 	  	 •      C. Adams, L. Arp, D. Auyeung,
T. Barfknecht, J. Barnett, G. Beattie, J. Beaver, L. Black, K. Bonnette, K. Braybrook, T. Buono, M. Butt, R. Cavallaro, C. Chan, G. Chellman, T. Claggett, C. Clifford, M. Cunningham, D. Curry, S. Cyrek, G. Dearlove, K. Denny, T.
Dicke, S. Eldridge, R. Erwin, H. Esber, K. Ewing, D Forbes, J. Foster
	  	 •      M. Giknis, N. Gillett, M. Godin, A. Hall,
H, Helle, S. Hersey, A. Hoberman, B. Hobson, M. Horner, I. Jester, J. Kapeghian, T. Kern, D. Kornbrust, G. Knutsen, J. LaBarge, P. Lappin, D. Learn
	  	 •      A. Trombino, L. Turner, M. Willis, A. Wilson, S. Wilson, R. York, T. Zoetis
	  	 
					
	 MAR 12
	  	WA Branch AALAS Spring Trade Fair	  	Seattle, WA	  	Rodent/Transgenic	  	Past

  

 Confidential - Xenogen Corporation 

									
	 •      MAR 19-21
 DATE
 CORRECTION!
	  	District 4 AALAS	  	Raleigh, NC	  	Rodent/Transgenic	  	Past
	 MARCH 20
	  	University of Arizona BioFaire	  	Tucson, AZ	  	Rodent/Transg	  	Past
	 APRIL 2-4
	  	 •      Texas/Louisiana Joint AALAS
	  	Galveston, TX	  	Rodent/Transgenic	  	Yes
	 APRIL 3
	  	Washington University Bio Faire	  	St. Louis, MO	  	Rodent/Transgenic	  	Yes
	 APRIL 5-9
	  	 	  	 	  	Rodent/Transgenic	  	Yes
	 	  	 	  	 	  	Rodent/Transgenic	  	Yes
	 APR 11-15
	  	Experimental Biology	  	San Diego, CA	  	Consomic, ZDF, Surgical, DSI, Transgenic	  	Yes
	 APRIL 17
	  	Los Angeles Vendor Showcase	  	Los Angeles, CA	  	 Rodent/Transgenic
 •      LAL
	  	Yes
	 APRIL 24
	  	University of Illinios BioFaire	  	Chicago, IL	  	 Rodent/Transgenic
 •      LAL
	  	Yes
	 APR 24-25
	  	FDA Science Forum	  	Washington, DC	  	N/A	  	N/R
	 APR 30–MAY 3
	  	Society for Biomaterials	  	 	  	 	  	N/R
	 MAY 1
	  	Emory University BioFaire	  	 	  	Rodent/Transgenic	  	Yes
	 MAY 3-7
	  	Wound Healing Society 13th Annual	  	Seattle, WA	  	DDS/Rodent Diabetic Model	  	Optional
	 MAY 4-7
	  	Waterside Monocional B-T-B w/Transgenic BioProcessing	  	San Francisco, CA	  	BPS	  	N/R
	 MAY 7
	  	Waterside Monoclonal Workshop	  	San Francisco, CA	  	BPS	  	N/R
	 	  	ARVO	  	Fort Lauderdale, FL	  	 	  	N/R
	 MAY 8-9
	  	Transgenics BioProcessing B-T-B w/Waterside (May 4-7)	  	San Francisco, CA	  	BPS	  	N/R
	 MAY 13-17
	  	Am Society of Hypertension	  	NY, NY	  	Rodent CV Models, Surgical Svcs, DSI / DDS	  	Optional
	 MAY 14-15
	  	Quad AALAS	  	Albany, NY	  	Rodent	  	Yes
	 	  	CHI Recombinant Antibodies	  	 	  	 	  	N/R
	 	  	Baylor College of Medicine Vendor	  	 	  	 	  	Yes
	 MAY 15
	  	University of Utah BioFaire	  	Salt Lake City, UT	  	 Rodent/Transg
 •      LAL
	  	N/R
	 MAY 18-22
	  	ASM	  	Washington, DC	  	LAL	  	N/R
	 MAY 28
	  	San Diego Discussion Group	  	San Deigo, CA	  	 	  	N/R
	 JUNE 2003
	  	DDS Symposium	  	TBD	  	 	  	N/R
	 JUNE ??
	  	 	  	 	  	DDS	  	N/R
	 JUNE 2-4
	  	 	  	 	  	 	  	N/R
	 JUNE 4-8
	  	ASGT	  	Washington, DC	  	BPS/DDS/Transg	  	Yes
	 JUNE 8-12
	  	ASMS	  	Montreal, CANADA	  	DDS	  	N/R
	 	  	 	  	 	  	 	  	Yes
	 JUNE 10-13
	  	FDA/IAB “State of the Art Analytical Methods for Characterization of Biological Products	  	Bethesda, MD	  	N/A	  	N/R
	 JUNE 11
	  	University of CA Berkley	  	Berkeley, CA	  	Rodent/Transg	  	Yes
	 JUNE 12
	  	San Franscisco Vendor Showcase	  	San Francisco, CA	  	 Rodent/Transg
 LAL
	  	Yes
	 JUNE 14-16
	  	ADA	  	New Orleans, LA	  	Rodent Disease Models	  	Yes

  

 Confidential - Xenogen Corporation 

									
	 JUNE 14-17
	  	AAMI	  	Long Beach, CA	  	LAL	  	N/R
	 JUNE 15-19
	  	DIA	  	San Antonio, TX	  	Milestone	  	N/R
	 JUNE 16-19
	  	STP	  	Savannah, GA	  	DDS	  	N/R
	 JUNE 16-19
	  	CRL Short Course	  	Danvers, MA	  	 	  	2004 Possible
	 JUNE 18-19
	  	 Beyond Genome 2003
 Proteomics. Applications in
Therapeutic and Diagnostic Development
	  	San Diego, CA	  	PROTEOMICS	  	Optional
	 JUNE 18-21
	  	Endocrine	  	Philadelphia, PA	  	Rodent Disease Models/Transgenic	  	Yes
	 JUNE 18-20
	  	LAMA Annual Meeting	  	San Juan, PR	  	Attendees ONLY	  	N/R
	 JUNE 19
	  	University of PA	  	Philadelphia, PA	  	Rodent/Transgenic	  	Yes
	 JUNE 21-25
	  	SNM 50th Annual Meeting	  	New Orleans, LA	  	LAL	  	N/R
	 JUNE 22-25
	  	BIO	  	Washington, DC	  	All Businesses	  	Yes
	 JUNE 25
	  	University of Wisconsin	  	Madison, WI	  	Rodent Consomic/Transgenic	  	Yes
	 JULY 12-14
	  	Raw Materials & Contract Services	  	Newport Beach, CA	  	BPS	  	N/R
	 JULY 17
	  	University of Michigan BioFaire	  	Ann Arbor, MI	  	Rodent/Transgenic	  	Yes
	 JULY 31
	  	University of Pittsburgh BioFaire	  	Pittsburg, PA	  	Rodent/Transgenic	  	Yes
	 AUG 6
	  	University of Minnesota	  	Minneapolis, MN	  	 Rodent
 LAL
	  	Optional
	 AUG 10-15
	  	IBC’s Drug Discovery Technology	  	Boston, MA	  	DDS	  	Optional
	 AUG 12
	  	University of Texas, San Antonio	  	San Antonio, TX	  	Rodent/Transgenic	  	Yes
	 AUG 14
	  	Texas Medical Center, Houston	  	Houston, TX	  	Rodent/Transgenic	  	Yes
	 AUG 28
	  	University of WA, Seattle	  	Seattle, WA	  	 Rodent/Transgenic
 LAL
	  	Yes
	 FALL 2003
	  	Co-Sponsor NESOT Meeting w/Novartis	  	TBD	  	DDS	  	N/R
	 SEPT ??
	  	Cal Tech	  	Pasadena, CA	  	Rodent/Transgenic	  	Yes
	 SEPT 22-25
	  	Cell & Tissue	  	Memphis, TN	  	BPS	  	N/R
	 SEPT ??
	  	NCAB AALAS	  	??	  	Rodent/Transgenic	  	Yes
	 SEPT 4
	  	University of CA, San Diego	  	San Diego, CA	  	 Rodent/Transgenic
 LAL
	  	Yes
	 SEPT 8-12
	  	PDA/FDA Joint Regulatory Cont.	  	Washington, DC	  	LAL/BPS	  	N/R
	 SEPT 14-17
	  	PBA	  	Orlando, FL	  	DDS	  	N/R
	 SEPT 17-18
	  	Harvard Research Festival	  	Boston, MA	  	 Rodent/Transgenic
 LAL
	  	Yes
	 SEPT 18
	  	Ohio State University BioFaire	  	Columbus, OH	  	Rodent/Transgenic	  	Yes
	 SEPT 21-24
	  	Heart Failure	  	Las Vegas, NV	  	Rodent Disease Models, DDS	  	Optional
	 SEPT 24
	  	University of Missouri BioFaire	  	Columbia, MO	  	Rodent/Transgenic	  	N/R
	 OCT 1-4
	  	Academy of Surgical Research	  	St. Louis, MO	  	Rodent Surg/DDS	  	N/R

  

 Confidential - Xenogen Corporation 

									
	 OCT 6-10
	  	Genomics on Target	  	Boston, MA	  	GTS, TG, Consomic Rats, DDS	  	Yes
	 OCT 11-15
	  	NAASO	  	Ft Lauderdale, FL	  	Rodent Disease Models	  	Optional
	 OCT 15
	  	University of CA, Irvine BioFaire	  	Irvine, CA	  	Rodent/Transge nic	  	Yes
	 OCT 12-16
	  	National AALAS	  	Seattle, WA	  	All Businesses	  	Yes
	 OCT 12-16
	  	ISSX	  	Providence, RI	  	MAP / BAC	  	N/R
	 OCT 16-17
	  	NIH Research Festival	  	Bethesda, MD	  	Rodent/Transge nic	  	Yes
	 OCT 26 –30
	  	AAPS	  	Salt Lake City, UT	  	MAP /BAC/ BPS	  	Optional
	 NOV ??
	  	Viral Vectors	  	Las Vegas, NV	  	BPS	  	N/R
	 NOV ??
	  	Viral Vectors Workshop	  	Las Vegas, NV	  	 	  	N/R
	 NOV ??
	  	Biopharmaceutical Production Wk Recovery & Purification Portion Only	  	West Coast	  	BPS	  	N/R
	 NOV 2-5
	  	ACT	  	Washington, DC	  	DDS	  	N/R
	 NOV 8-13
	  	Neuroscience	  	New Orleans, LA	  	Rodent/Transg/ DDS	  	Yes
	 NOV 9-12
	  	AHA	  	Orlando, FL	  	Rodent / DDS	  	Optional
	 NOV 10-12
	  	PDA	  	Atlanta, GA	  	LAL	  	N/R
	 NOV 12-17
	  	ASN	  	San Diego, CA	  	Rodent	  	Yes
	 NOV 20
	  	University of Alabama BioFaire	  	Birmingham, AL	  	 Rodent/Transge
 nic
	  	Yes
	 DEC 11
	  	LSU & Tulane University Health Sciences Centers	  	New Orleans, LA	  	Rodent/Transge nic	  	Yes

  

 Confidential - Xenogen Corporation 

	•	DISTRICT 8 AALAS WILL NOT BE HELD IN 2003 DUE TO NATIONAL AALAS LOCATION ON WEST COAST (Seattle, WA) 

  
 ~KEY~ 
  
 AACR ~ American Association for Cancer Research 
 AACC ~ Am
Association of Clinical Chemistry 
 AAMI ~ Assoc for the Advancement of Medical Instru. 
 AAPS ~ Am Association of Pharmaceutical Scientists 
 AALAS ~ Am Association for Lab Animal Science 

ACC ~ American College of Cardiology 
 ACS ~ American College of Surgeons 
 ACS ~ American Chemical Society 
 ACT ~ American College of Toxicology 
 ACVP ~ Am College of Vet
Pathologists 
 ADA ~ American Diabetes Association 
 AFSTAL ~ French Assoc for Lab Animal Science 
 AHA ~ American Heart Association 
 ARVO ~ Assoc for Rsch in Vision in Ophthalmology 
 ASCB ~
American Society for Cell Biology 
 ASGT ~ Am Society of Gene Therapy 
 ASHP ~ Am Soc of Health-System Pharmacists 
 ASM ~ American Society of Microbiology 
 ASMS ~ American Society for Mass Spectrometry 
 ASN ~ American
Society of Nephrology 
 ASBMB ~ Am.Society/Biochemistry/Molecular/Bio 
 AUA ~ American Urological Association 
 BGVV ~ (translation) Institution of healthy, consumer protection and
vet medicine 
 BIO ~ Biotechnology Industry Organization 
 CBI ~ Center for Business Intelligence 
 CHI ~ Cambridge Healthtech Institute 
 DIA ~ Drug Information Association 
 DSI ~ Data Sciences
International 
 ENDO ~ The Endocrine Society 
 ETS ~
European Teratology Society 
 HBM ~ Human Brain Mapping 
 IAT ~ Institute of Animal Technology Cong 
 IBC ~ International Business Communications 
 IRA ~ Inflammation Research Association 
 ISSX ~ Intn’l Soc
for the Study of Xenobiogen 
 LASA ~ Laboratory Animal Science Winter 
 MBC ~ Massachusetts Biotech Council 
 MDM ~ Medical Design & Manufacturing 
 NAASO ~ North Am Assoc for the Study of Obesity 
 NEDMDG ~ New
England Drug Metabolism Discussion Group 
 NIH ~ National Institutes of Health 
  
  
  

 Confidential - Xenogen Corporation 

 EXHIBIT C 
 ANNUAL FEE PAYMENT SCHEDULE 
  

					
	 Days after Effective Date or
 Anniversary of Effective Date*

	  	2003

	 	2004

	 90 days
	  	***	 	***
	 120 days
	  	***	 	***
	 270 days
	  	***	 	***
	 360 days
	  	***	 	***
	 December 31**
	  	Prorated amount of next
payment, next payment is less
December 31st payment	 	Prorated amount of next
payment, next payment is less
December 31st, payment

  

	*	Effective day is day one 

  

	**	*** 

  
 Confidential - Xenogen Corporation 
  

	***	Confidential treatment requested 

 EXHIBIT D 
 EXCLUSIONS FROM REVENUE 
  
 For
these third party customers, only revenue for Creation Services in calendar year 2003 that is above the amount stated below will be paid as described above. 
  
 *** 
  
 Confidential - Xenogen Corporation 
  

	***	Confidential treatment requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}]]